

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/42, C11D 3/386, D06M 16/00		A1	(11) International Publication Number: WO 96/29397 (43) International Publication Date: 26 September 1996 (26.09.96)
(21) International Application Number: PCT/DK96/00105 (22) International Filing Date: 18 March 1996 (18.03.96) (30) Priority Data: 0272/95 17 March 1995 (17.03.95) DK 0885/95 8 August 1995 (08.08.95) DK 0886/95 8 August 1995 (08.08.95) DK 0887/95 8 August 1995 (08.08.95) DK 0888/95 8 August 1995 (08.08.95) DK 0137/96 12 February 1996 (12.02.96) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHÜLEIN, Martin [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). ANDERSEN, Lene, Nonboc [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). LASSEN, Søren, Flensted [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). KAUPPINEN, Markus, Sakari [FI/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). LANGE, Lene [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK).		NIELSEN, Ruby, Ilum [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). IHARA, Michiko [JP/JP]; Novo Nordisk Bioindustry Ltd., Makuhari Techno Garden CB-6, 3, Nakase 1-chome, Chiba-shi 261-01 (JP). TAKAGI, Shinobu [JP/JP]; Novo Nordisk Bioindustry Ltd., Makuhari Techno Garden CB-6, 3, Nakase 1-chome, Chiba-shi 261-01 (JP). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: NOVEL ENDOGLUCANASES			
(57) Abstract <p>An enzyme preparation consisting essentially of an enzyme having cellulolytic activity and comprising a first amino acid sequence of 14 residues having the sequence Thr Arg X3 X4 Asp Cys Cys X8 X9 X10 Cys X12 Trp X14, in which X3 and X4 independently is Trp, Tyr or Phe; X8 is Arg, Lys or His; each of X9, X10, X12 and X13 is any of the 20 naturally occurring amino acid residues; and a second amino acid sequence of 5 residues having the sequence Trp Cys Cys XX4 Cys, in which XX4 is any of the 20 naturally occurring amino acid residues with the proviso that, in the first amino acid sequence, (i) when X12 is Ser, then X14 is not Ser, and (ii) when X12 is Gly, then X14 is not Ala; performs excellently in detergent, laundering, textile and papermaking pulp applications.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL ENDOGLUCANASES

5 The present invention relates to novel enzyme preparations comprising an enzyme exhibiting endoglucanase activity which performs very good in industrial applications such as laundry compositions, for biopolishing of newly manufactured textiles, for providing an abraded look of cellulosic fabric or garment, and for treatment of paper pulp. Further, the invention relates to DNA constructs encoding such enzymes, a method for providing a gene encoding for such enzymes, a method of producing the enzymes, enzyme preparations containing such enzymes, and the use of these enzymes for a number of industrial applications.

BACKGROUND OF THE INVENTION

20

Cellulases or cellulytic enzymes are enzymes involved in hydrolyses of cellulose. In the hydrolysis of native cellulose, it is known that there are three major types of cellulase enzymes involved, namely cellobiohydrolase (1,4- β -D-glucan cellobiohydrolase, EC 3.2.1.91), endo- β -1,4-glucanase (endo-1,4- β -D-glucan 4-glucanohydrolase, EC 3.2.1.4) and β -glucosidase (EC 3.2.1.21).

Cellulases are synthesized by a large number of microorganisms which include fungi, actinomycetes, myxobacteria and true bacteria but also by plants. Especially endoglucanases of a wide variety of specificities have been identified.

35 A very important industrial use of cellulytic enzymes is the use for treatment of cellulosic textile or fabric, e.g. as ingredients in detergent compositions or fabric

softener compositions, for bio-polishing of new fabric (garment finishing), and for obtaining a "stone-washed" look of cellulose-containing fabric, especially denim, and several methods for such treatment have been suggested, e.g. in GB-A-1 368 599, EP-A-0 307 564 and EP-A-0 435 876, WO 91/17243, WO 91/10732, WO 91/17244, PCT/DK95/000108 and PCT/DK95/00132.

Another important industrial use of cellulytic enzymes is the use for treatment of paper pulp, e.g. for improving the drainage or for deinking of recycled paper.

Especially the endoglucanases (EC No. 3.2.1.4) constitute an interesting group of hydrolases for the mentioned industrial uses. Endoglucanases catalyses endo hydrolysis of 1,4- β -D-glycosidic linkages in cellulose, cellulose derivatives (such as carboxy methyl cellulose and hydroxy ethyl cellulose), lichenin, β -1,4 bonds in mixed β -1,3 glucans such as cereal β -D-glucans or xyloglucans and other plant material containing cellulosic parts. The authorized name is endo-1,4- β -D-glucan 4-glucano hydrolase, but the abbreviated term endoglucanase is used in the present specification. Reference can be made to T.-M. Enveri, "Microbial Cellulases" in W.M. Fogarty, Microbial Enzymes and Biotechnology, Applied Science Publishers, p. 183-224 (1983); Methods in Enzymology, (1988) Vol. 160, p. 200-391 (edited by Wood, W.A. and Kellogg, S.T.); Béguin, P., "Molecular Biology of Cellulose Degradation", Annu. Rev. Microbiol. (1990), Vol. 44, pp. 219-248; Béguin, P. and Aubert, J-P., "The biological degradation of cellulose", FEMS Microbiology Reviews 13 (1994) p.25-58; Henrissat, B., "Cellulases and their interaction with cellulose", Cellulose (1994), Vol. 1, pp. 169-196.

Fungal endoglucanases have been described in numerous publications, especially those derived from species as e.g. *Fusarium oxysporum*, *Trichoderma reesei*, *Trichoderma*

longibrachiatum, *Aspergillus aculeatus*, *Neocallimastix patriciarum*, and e.g. from species of the genera *Piromyces*, *Humicola*, *Myceliophthora*, *Geotricum*, *Penicillium*, *Irpex*, *Coprinus*.

5

- For example, fungal endoglucanases have been described by Sheppard, P.O., et al., "The use of conserved cellulase family-specific sequences to clone Cellulase homologue cDNAs from *Fusarium oxysporum*", *Gene*, (1994), Vol. 15, pp. 163-167; Saloheimo, A., et al., "A novel, small endoglucanase gene, *egl5*, from *Trichoderma reesei* isolated by expression in yeast", *Molecular Microbiology* (1994), Vol. 13(2), pp. 219-228; van Arsdell, J.N. et al., (1987), Cloning, characterization, and expression in *Saccharomyces cerevisiae* of endoglucanase I from *Trichoderma reesei*, *Bio/Technology* 5: 60-64; Penttilä, M. et al., (1986), "Homology between cellulase genes of *Trichoderma reesei*: complete nucleotide sequence of the endoglucanase I gene", *Gene* 45:253-263; Saloheimo, M. et al., (1988), "EGIII, a new endoglucanase from *Trichoderma reesei*: the characterization of both gene and enzyme", *Gene* 63:11-21; Gonzáles, R., et al., "Cloning, sequence analysis and yeast expression of the *egl1* gene from *Trichoderma longibrachiatum*", *Appl. Microbiol. Biotechnol.*, (1992), Vol. 38, pp. 370-375; Ooi, T. et al. "Cloning and sequence analysis of a cDNA for cellulase (FI-CMCase) from *Aspergillus aculeatus*", *Curr. Genet.*, (1990), Vol. 18, pp. 217-222; Ooi, T. et al., "Complete nucleotide sequence of a gene coding for *Aspergillus aculeatus* cellulase (FI-CMCase)", *Nucleic Acids Research*, (1990), Vol. 18, No. 19, p. 5884; Xue, G. et al., "Cloning and expression of multiple cellulase cDNAs from the anaerobic rumen fungus *Neocallimastix patriciarum* in *E. coli*", *J. Gen. Microbiol.*, (1992), Vol. 138, pp. 1413-1420; Xue, G. et al., "A novel polysaccharide hydrolase cDNA (*celD*) from *Neocallimastix patriciarum* encoding three multi-functional catalytical domains with high

endoglucanase, cellobiohydrolase and xylanase activities", J. Gen. Microbiol., (1992), Vol. 138, pp. 2397-2403; Zhou, L. et al., "Intronless celB from the anaerobic fungus *Neocallimastix patriciarum* encodes a modular family A endoglucanase", Biochem. J., (1994), Vol. 297, pp. 359-364; Dalbøge, H. and Heldt-Hansen, H.P., "A novel method for efficient expression cloning of fungal enzyme genes", Mol. Gen. Genet., (1994), Vol. 243, pp. 253-260; Ali, B.R.S. et al., "Cellulases and hemicellulases of the anaerobic fungus *Piromyces* constitute a multiprotein cellulose-binding complex and are encoded by multigene families", FEMS Microbiol. Lett., (1995), Vol. 125, No. 1, pp. 15-21. Further, the DNA Data Bank of Japan (DDBJ database publicly available at Internet) comprises two DNA sequences cloned from *Penicillium janthinellum* encoding endoglucanases (cloned by A. Koch and G. Mernitz, respectively) and a DNA sequence cloned from *Humicola grisea* var. *thermoidea* encoding an endoglucanase (cloned by T. Uozumi). Two endoglucanases from *Macrophomina phaseolina* have been cloned and sequenced, see Wang, H.Y. and Jones, R.W.: "Cloning, characterization and functional expression of an endoglucanase-encoding gene from the phytopathogenic fungus *Macrophomina phaseolina*" in Gene, 158:125-128, 1995, and Wang, H.Y. and Jones, R.W.: "A unique endoglucanase-encoding gene cloned from the phytopathogenic fungus *Macrophomina phaseolina*" in Applied And Environmental Microbiology, 61:2004-2006, 1995. One of these endoglucanases shows high homology to the egl3 endoglucanase from the fungus *Trichoderma reesei*, the other shows homology to the egl1 from the microbial phytopathogen *Pseudomonas solanacearum* indicating that both endoglucanases belong to family 5 of glycosyl hydrolases (B. Henrissat, Biochem J 280:309-316 (1991)). Filament-specific expression of a cellulase gene in the dimorphic fungus *Ustilago maydis* is disclosed in Schauwecker, F. et al. (1995).

- WO 91/17243 (Novo Nordisk A/S) discloses a cellulase preparation consisting of a homogenous endoglucanase component immunoreactive with an antibody raised against a highly purified 43 kDa endoglucanase derived from
- 5 *Humicola insolens*, DSM 1800; WO 91/17244 (Novo Nordisk A/S) discloses a new (hemi)cellulose degrading enzyme, such as an endoglucanase, a cellobiohydrolase or a β -glucosidase, which may be derived from fungi other than *Trichoderma* and *Phanerochaete*; WO 93/20193 discloses an
- 10 endoglucanase derivable from *Aspergillus aculeatus*; WO 94/21801 (Genencor Inc.) concerns a cellulase system isolated from *Trichoderma longibrachiatum* exhibiting endoglucanase activity; WO 94/26880 (Gist Brocades N.V.) discloses an isolated mixture of cellulose degrading
- 15 enzymes, which preferable are obtained from *Trichoderma*, *Aspergillus* or *Disporotrichum*, comprising endoglucanase, cellobiohydrolase, and xyloglucanase activity; and WO 95/02043 (Novo Nordisk A/S) describes an enzyme with endoglucanase activity derived from *Trichoderma*
- 20 *harzianum*, which can be used for a number of purposes including e.g. degradation or modification of plant cell walls.

It is also known that cellulases may or may not have a

25 cellulose binding domain (a CBD). The CBD enhances the binding of the enzyme to a cellulose-containing fiber and increases the efficacy of the catalytic active part of the enzyme.

- 30 There is an ever existing need for providing novel cellulase enzyme preparations which may be used for applications where cellulase, preferably an endoglucanase, activity is desirable.
- 35 The object of the present invention is to provide novel enzyme preparations having substantial cellulytic activity at acid, neutral or alkaline conditions and improved

performance in paper pulp processing, textile treatment, laundry processes or in animal feed; preferably novel cellulases, more preferably well-performing endoglucanases, which are contemplated to be producible or produced by recombinant techniques.

SUMMARY OF THE INVENTION

Surprisingly, it has been found that a group of endoglucanases having certain unique characteristics perform very good in those industrial applications for which endoglucanases are conventionally used. These unique characteristics can be described in terms of conserved regions of the amino acid sequence of the enzyme protein and the inventors have found that cellulytic enzymes, i.e. enzymes exhibiting cellulytic activity, having certain conserved regions are very effective e.g. in the treatment of laundry, in the treatment of newly manufactured textile, in the treatment of papermaking pulp.

Accordingly, in its first aspect the present invention relates to an enzyme preparation consisting essentially of an enzyme having cellulytic activity and comprising a first amino acid sequence consisting of 14 amino acid residues having the following sequence

Thr	Arg	Xaa	Xaa	Asp	Cys	Cys	Xaa	Xaa	Xaa	Cys	Xaa	Trp	Xaa
1	2	3	4	5	6	7	8	9	10	11	12	13	14

30

and a second amino acid sequence consisting of 5 amino acid residues having the following sequence

Trp	Cys	Cys	Xaa	Cys
1	2	3	4	5

35

wherein,

- in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;
in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;
- 5 in position 8 of the first sequence, the amino acid is Arg, Lys or His;
in position 9, 10, 12 and 14, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino
- 10 acid residues with the provisos that, in the first amino acid sequence, (i) when the amino residue in position 12 is Ser, then the amino acid residue in position 14 is not Ser, and (ii) when the amino residue in position 12 is Gly, then the amino acid residue in position 14 is not
- 15 Ala.

This surprising finding of clearly recognisable conserved regions, in spite of rather prominent variations found within well-performing endoglucanase enzymes, is a result

20 of studies of a number of fungal DNA sequences encoding for specific amino acid sequences of enzymes having significant cellulytic, especially endoglucanase, activities.

- 25 Based on this finding, a novel molecular method taylorred to screen specifically for genomic DNA or cDNA characterised by encoding the enzymes of the invention has been developed. As tools for this three sets of degenerated primers were constructed. Accordingly, in its
- 30 second aspect, the invention relates to a method for providing a gene encoding for cellulytic enzymes having the above conserved regions.

By using this method, i.e. the set of primers for a PCR

35 screening on genomic DNA, it was surprisingly found that DNA encoding for said enzymes can be found from a broad range of fungi, belonging to taxonomically very different

organisms and inhabiting ecologically very different niches.

Further, by using this method it has been possible to
5 find DNA sequences encoding for the core regions (catalytically active regions or domains) of said enzymes without any attached cellulose binding domain (CBD) which core regions of enzymes would not have been selected by using conventional performance based screening
10 approaches. The inventors have verified experimentally that the linking of a CBD region to a core region enzyme (comprising the catalytically active region or domain of the enzyme) of the present invention results in a significantly improved performance, e.g. a fifty times
15 higher performance, of the multiple domain enzyme.

Accordingly, the present invention provides novel cellulases, especially endoglucanases, having improved performance in industrial applications, either in their
20 native form, or homo- or heterologously produced.

In further aspects, the present invention relates to novel cellulytic enzyme preparations which are derivable from taxonomically specific phyli, classes, orders,
25 families, genera, and species; e.g. from Basidiomycotous Hymenomycetes, Zygomycota, Chytridiomycota; or from the classes Discomycetes, Loculoascomycetes, Plectomycetes; Archaeascomycetes, Hemiascomycetes or from the orders Diaportales, Xylariales, Trichosphaeriales, Phyllachorales;
30 or from the families Nectriaceae, Sordariaceae, Chaetomiaceae, Ceratostomaceae, Lasiosphaeriaceae; or from the genera *Cylindrocarpon*, *Gliocladium*, *Volutella*, *Scytalidium*, *Acremonium*, or from the species *Fusarium lycopersici*, *Fusarium passiflora*, *Fusarium solani*,
35 *Fusarium anguioides*, *Fusarium poae*, *Humicola nigrescens*, *Humicola grisea*, especially such consisting essentially of an enzyme comprising an amino acid sequence selected

from the group consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa

1 2 3 4 5 6 7 ;

Xaa Thr Arg Xaa Tyr Asp Xaa

5 1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa

1 2 3 4 5 6 7

wherein, in position 4, Xaa is Trp, Tyr or Phe; and

10 in position 1 and 7, Xaa is any of the 20 naturally occurring amino acid residues.

More specifically, the enzyme preparation of the invention is preferably obtainable from the taxonomically specific phyla, classes, orders, families, genera, and species mentioned above which all produce endoglucanases comprising a first peptide consisting of 13 amino acid residues having the following sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp

20 1 2 3 4 5 6 7 8 9 10 11 12 13

and a second peptide consisting of 5 amino acid residues having the following sequence

Trp Cys Cys Xaa Cys

1 2 3 4 5

25 wherein, in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 8 of the first sequence, the amino acid is Arg, Lys or His; in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues.

In yet further aspects, the present invention provides DNA constructs comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises the DNA sequence shown in SEQ ID Nos.

1, 4, 6, 8, 10, 12, 16, and 19, respectively, or analogues thereof.

The present invention also relates to a recombinant expression vector comprising a DNA construct of the invention; to a cell comprising a DNA construct or a recombinant expression vector of the invention; to a method of producing an enzyme, e.g. a recombinant enzyme, of the invention; to a method of providing colour clarification of laundry by using the enzyme of the invention; to a laundry composition comprising the enzyme of the invention; to uses of the enzyme of the invention for degradation or modification of plant material, e.g. cell walls, for treatment of fabric, textile or garment, for treatment of paper pulp; and to an enzyme preparation which is enriched in an enzyme of the present invention.

THE DRAWINGS

20

Figure 1 is an alignment of the deduced encoded amino acid sequences of *Acremonium sp. (I)*, *Volutella colletotrichoides*, *Crinipellis scabellia*, *Acremonium sp. (II)*, *Myceliophthora thermophila*, *Thielavia terrestris*, *Macrophomina phaseolina*. The Pileup program (Feng and Doolittle, 1987) (GCG package, version 8.0) was used to create the best alignment. Identical residues in at least four sequences (boxed) are indicated around the corresponding amino acids.

30

Figure 2

Figure 2a,b,c illustrates the taxonomic classification within the Fungal Kingdom of all the microorganisms disclosed herein as being capable of producing said enzyme preparations and enzymes of the invention.

The taxonomic classification used herein builds primarily

on the system used in the :NIH Data Base (Entrez, version spring 1996) available on World Wide Web:

(<http://www3.ncbi.nlm.nih.gov/htbin/ef/entrezTAX>).

Regarding classification of organisms which are not

- 5 included in the Entrez data base the following generally available and world wide accepted reference books have been used:

For *Ascomycetes*: Eriksson, O.E. & Hawksworth, D.L.: *Systema Ascomycetum* vol 12 (1993).

- 10 For *Basidiomycetes*: Jülich, W.: *Higher Taxa of Basidiomycetes*, *Bibliotheca Mycologia* 85, 485pp (1981).

For *Zygomycetes*: O'Donnell, K.: *Zygomycetes in culture*, University of Georgia, US, 257pp (1979).

General mycological reference books:

- 15 Hawksworth, D.L., Kirk, P.M., Sutton, B.C. and Pegler, D.N.: *Dictionary of the fungi*, International Mycological Institute, 616pp (1995);

Von Arx, J.A.: *The genera of fungi sporulating in culture*, 424pp (1981).

20

The taxonomic implacement of the genus *Humicola* has untill recently remained unclear. However, studies of 18SRNA of a wide selection of Sordariales has given strong indications of referring *Humicola* to the order

- 25 Sordariales (Taylor, Clausen & Oxenbøll, unpublished).

Further these data suggests *Humicola* along with *Scytalidium* to be only rather distantly related to the families Sordariaceae, Chaetomiaceae, Ceratostomataceae, and Lasiosphaeriaceae. In accordance with the above *Humicola*

- 30 and *Scytalidium* are here placed within the order Sordariales, with unclassified Family.

Figure 3 is an alignment of the deduced partial amino acid sequences derived from a selection of 26 of the 46
35 microorganisms described in Example 5.

DETAILED DESCRIPTION OF THE INVENTION

In the present context, the term "the 20 naturally occurring amino acid residues" denotes the 20 amino acid residues usually found in proteins and conventionally known as alanine (Ala or A), valine (Val or V), leucine (Leu or L), isoleucine (Ile or I), proline (Pro or P), phenylalanine (Phe or F), tryptophan (Trp or W), methionine (Met or M), glycine (Gly or G), serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), glutamine (Gln or Q), aspartic acid (Asp or D), glutamic acid (Glu or E), lysine (Lys or K), arginine (Arg or R), and histidine (His or H).

15

According to the present invention there is provided novel well-performing endoglucanases comprising conserved amino acid sequence regions, especially a first amino acid sequence consisting of 14 amino acid residues having the following sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp Xaa
1 2 3 4 5 6 7 8 9 10 11 12 13 14

25 and a second amino acid sequence consisting of 5 amino acid residues having the following sequence

Trp Cys Cys Xaa Cys
1 2 3 4 5

30 wherein,

in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;

in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;

35 in position 8 of the first sequence, the amino acid is Arg, Lys or His;

in position 9, 10, 12 and 14, respectively, of the first

sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues with the provisos that, in the first amino acid sequence, (i) when the amino residue in position 12
5 is Ser, then the amino acid residue in position 14 is not Ser, and (ii) when the amino residue in position 12 is Gly, then the amino acid residue in position 14 is not Ala.

10 Preferably, the enzyme of the invention is of microbial origin, i.e. obtainable from a microorganism such as a fungus.

In a preferred embodiment, the amino acid residue in
15 position 9 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of
20 proline and threonine.

In another preferred embodiment, the amino acid residue in position 10 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine,
25 leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably serine.

In yet another preferred embodiment, the amino acid residue in position 12 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of alanine and glycine.
30
35

In yet another preferred embodiment, the amino acid resi-

- due in position 14 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine,
- 5 methionine, tryptophan, glutamic acid and aspartic acid, preferably from the group consisting of proline, threonine, serine, alanine, glutamic acid and aspartic acid.
- 10 Preferably, the amino acid residue in position 4 of the second sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine, tryptophan, glutamic acid
- 15 and aspartic acid, more preferably from the group consisting of alanine, glycine, and glutamine.

Examples of more preferred embodiments are such wherein, in the first sequence, the amino acid residue in position

20 3 is tyrosine; or the amino acid residue in position 4 is tryptophan; or the amino acid residue in position 8 is lysine.

In an especially preferred embodiment, the enzyme of the invention has a first sequence comprising the amino acid sequence

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ,

or the amino acid sequence

30 Thr Arg Tyr Trp Asp Cys Cys Lys Thr Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ,

or the amino acid sequence

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 .

35

In a second aspect, the present invention provides a method for finding and cloning of such an enzyme which

encoding such an enzyme which method comprises hybridization, e.g. PCR amplification, under standard conditions with an oligonucleotide derived from any of the conserved regions, illustrated in Fig.1.

5

A useful oligonucleotide comprises a nucleotide sequence encoding at least a pentapeptide comprised in a peptide selected from the group consisting of

a.

- 10 Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp Xaa
 1 2 3 4 5 6 7 8 9 10 11 12 13 14
 the amino acid in position 3 or 4 being Trp, Tyr or Phe;
 the amino acid in position 8 being Arg, Lys or His;
 the amino acid in position 9, 10, 12 and 14, respectively,
 15 being any of the 20 naturally occurring amino acid residues ; and

b.

Trp Cys Cys Xaa Cys Tyr
 1 2 3 4 5 6

- 20 the amino acid in position 4 being any of the 20 naturally occurring amino acid residues ; and

c.

Xaa Pro Gly Gly Gly Xaa Gly Xaa Phe
 1 2 3 4 5 6 7 8 9

- 25 the amino acid in position 1 being Met or Ile;
 the amino acid in position 6 and 8, respectively, being Leu, Ile or Val; and

d.

Gly Cys Xaa Xaa Arg Xaa Asp Trp Xaa

- 30 1 2 3 4 5 6 7 8 9
 the amino acid in position 3 being any of the 20 naturally occurring amino acid residues;
 the amino acid in position 4 and 6, respectively, being Trp, Tyr or Phe; and
 35 the amino acid in position 9 being Phe or Met;

The useful oligonucleotides also comprises nucleotide

sequences complementary to the sequences mentioned.

In a preferred embodiment of the method of the invention, the oligonucleotide corresponds to a PCR primer selected

5 from the PCR primers

sense:

5'-CCCCAAGCTTACI^A/_CGITA^C/_TTGGGA^C/_TTG^C/_TTG^C/_TAA^A/_G^A/_CC-3'

antisense 1:

5'- CTAGTCTAGATA^A/_GCAIGC^A/_GCA^A/_GCACC -3';

10 antisense 2:

CTAGTCTAGAAAIA^A/_G/_TICCIA^A/_C/_GICCICCICIGG -3'; and

antisense 3:

5'- CTAGTCTAGAIAACCA^A/_GTCA^A/_G/_TAIC^G/_TCC-3.

15 In a third aspect, the present invention provides an enzyme preparation which essentially consists of an enzyme having cellulytic activity and having the conserved regions found by the inventors, i.e. which comprises a peptide consisting of 7 amino acid residues having the following sequence

Xaa Thr Arg Xaa Phe Asp Xaa

1 2 3 4 5 6 7 ;

Xaa Thr Arg Xaa Tyr Asp Xaa

1 2 3 4 5 6 7 ; and

25 Xaa Thr Arg Xaa Trp Asp Xaa

1 2 3 4 5 6 7

wherein, in position 4, Xaa is Trp, Tyr or Phe; and in position 1 and 7, Xaa is any of the 20 naturally occurring amino acid residues.

30

This enzyme is obtainable from a strain belonging to Basidiomycotous *Hymenomycetes* (see Fig.2), more preferably to the group consisting of the orders Agaricales, Auriculariales, and Aphyllophorales, even more preferably to the group consisting of the families Exidiaceae, Tricholomataceae, Coprinaceae, Schizophyllaceae, Bjerkanderaceae and Polyporaceae,

35

especially to the group consisting of the genera *Exidia*, *Crinipellis*, *Fomes*, *Panaeolus*, *Trametes*, *Schizophyllum*, and *Spongipellis*.

- 5 Specific examples are endoglucanases obtainable from a strain belonging to the group consisting of the species *Exidia glandulosa*, *Crinipellis scabella*, *Fomes fomentarius*, and *Spongipellis* sp., more specific examples being *Exidia glandulosa*, CBS 277.96, *Crinipellis*
10 *scabella*, CBS 280.96, *Fomes fomentarius*, CBS 276.96, and *Spongipellis* sp., CBS 283.96.

- Exidia glandulosa* was deposited at Centraalbureau voor Schimmelcultures, Oosterstraat 1, Postbus 273, NL-3740 AG
15 Baarn, the Netherlands, on 12 March, 1996, under the deposition number CBS 277.96; *Crinipellis scabella* was deposited at Centraalbureau voor Schimmelcultures on 12 March, 1996, under the deposition number CBS 280.96, *Fomes fomentarius* was deposited at Centraalbureau voor
20 Schimmelcultures on 12 March, 1996, under the deposition number CBS 276.96, and *Spongipellis* sp. was deposited at Centraalbureau voor Schimmelcultures on 12 March, 1996, under the deposition number CBS 283.96; all deposited under the Budapest Treaty.

- 25 The enzyme preparation of the invention is also obtainable from a strain belonging to *Chytridiomycota*, preferably from a strain belonging to the class of *Chytridiomycetes*, more preferably belonging to the group
30 consisting of the order *Spizellomycetales*, even more preferably to the family *Spizellomycetaceae*, especially belonging to the genus *Rhizophlyctis*. A specific example is a strain belonging to the species *Rhizophlyctis rosea*, more specifically to *Rhizophlyctis rosea*, CBS 282.96.

- 35 *Rhizophlyctis rosea* was deposited at Centraalbureau voor Schimmelcultures on 12 March, 1996, under the deposition

number CBS 282.96; under the Budapest Treaty.

The enzyme preparation of the invention is also obtainable from a strain belonging to *Zygomycota*, preferably
5 belonging to the class *Zygomycetes*, more preferably to the order *Mucorales*, even more preferably to the group of families consisting of *Mucoraceae* and *Thamnidaceae*, especially belonging to the group consisting of the genera *Rhizomucor*, *Phycomyces* and *Chaetostylum*. Specific
10 examples are strains belonging to the genera *Rhizomucor pusillus*, *Phycomyces nitens*, and *Chaetostylum fresenii* more specifically to *Rhizomucor pusillus*, IFO 4578, and *Phycomyces nitens*, IFO 4814 and *Chaetostylum fresenii*, NRRL 2305.

15 Further, the enzyme preparation of the invention is also obtainable from a strain belonging to the group consisting of *Archaeascomycetes*, *Discomycetes*, *Hemiascomycetes*, *Loculoascomycetes*, and *Plectomycetes*, preferably
20 belonging to the group consisting of the orders *Pezizales*, *Rhytismatales*, *Dothideales*, and *Eurotiales*. Especially, the enzyme is obtainable from a strain belonging to the group consisting of the families *Cucurbitariaceae*, *Ascobolaceae*, *Rhytismataceae*, and
25 *Trichocomaceae*, preferably belonging to the group consisting of the genera *Diplodia*, *Microsphaeropsis*, *Ulospora*, *Macrophomina*, *Ascobolus*, *Saccobolus*, *Penicillium*, and *Thermomyces*. Specific examples are enzymes obtainable from a strain belonging to the group consist-
30 ing of the species *Diplodia gossypina*, *Microsphaeropsis* sp., *Ulospora bilgramii*, *Aureobasidium* sp., *Macrophomina phaseolina*, *Ascobolus stictoides*, *Saccobolus dilutellus*, *Peziza*, *Penicillium verruculosum*, *Penicillium chrysogenum*, and *Thermomyces verrucosus*; more
35 specifically *Diplodia gossypina*, CBS 274.96, *Ulospora bilgramii*, NKBC 1444, *Macrophomina phaseolina*, CBS 281.96, *Saccobolus dilutellus*, CBS 275.96, *Penicillium*

verruculosum, ATCC 62396, *Penicillium chrysogenum*, ATCC 9480, and *Thermomyces verrucosus*, CBS 285.96.

Diplodia gossypina was deposited at Centraalbureau voor
5 Schimmelcultures on 12 March, 1996, under the deposition
number CBS 274.96, *Macrophomina phaseolina* was deposited
at Centraalbureau voor Schimmelcultures on 12 March,
1996, under the deposition number CBS 281.96, *Saccobolus*
dilutellus was deposited at Centraalbureau voor
10 Schimmelcultures on 12 March, 1996, under the deposition
number CBS 275.96; *Thermomyces verrucosus* was deposited
at Centraalbureau voor Schimmelcultures on 12 March,
1996, under the deposition number CBS 285.96; all under
the Budapest Treaty.

15 Yet further, the enzyme is obtainable from a strain
belonging to the group consisting of the orders *Dia-*
portales, *Xylariales*, *Trichosphaeriales* and
Phyllachorales, preferably from a strain belonging to the
20 group consisting of the families *Xylariaceae*, *Valsaceae*,
and *Phyllachoraceae*, more preferably belonging to the ge-
nera *Diaporthe*, *Colletotrichum*, *Nigrospora*, *Xylaria*,
Nodulisporum and *Poronia*. Specific examples are the
species *Diaporthe syngenesia*, *Colletotrichum lagenarium*,
25 *Xylaria hypoxylon*, *Nigrospora* sp., *Nodulisporum* sp., and
Poronia punctata, more specifically *Diaporthe syngenesia*,
CBS 278.96, *Colletotrichum lagenarium*, ATCC 52609,
Nigrospora sp., CBS 272.96, *Xylaria hypoxylon*, CBS
284.96.

30 *Diaporthe syngenesia* was deposited at Centraalbureau voor
Schimmelcultures on 12 March, 1996, under the deposition
number CBS 278.96, *Nigrospora* sp. was deposited at
Centraalbureau voor Schimmelcultures on 12 March, 1996,
35 under the deposition number CBS 272.96, *Xylaria hypoxylon*
was deposited at Centraalbureau voor Schimmelcultures on
12 March, 1996, under the deposition number CBS 284.96;

all under the Budapest Treaty.

The enzyme is also obtainable from the unidentified fungal, mitosporic, coleomycetous deposited at
5 Centraalbureau voor Schimmelcultures on 12 March, 1996, under the deposition numbers CBS 270.96, CBS 271.96 and CBS 273.96, respectively, under the Budapest Treaty.

The enzyme is also obtainable from a strain belonging to
10 the group consisting of the genera *Cylindrocarpon*, *Gliocladium*, *Nectria*, *Volutella*, *Sordaria*, *Scytalidium*, *Thielavia*, *Syspastospora*, *Cladorrhinum*, *Chaetomium*, *Myceliophthora* and *Acremonium*, especially from a strain belonging to the group consisting of the species *Cylin-*
15 *drocarpon* sp., *Nectria pinea*, *Volutella colletotrichoides*, *Sordaria fimicola*, *Sordaria macrospora*, *Thielavia terrestris*, *Thielavia thermophila*, *Syspastospora boninensis*, *Cladorrhinum foecundissimum*, *Chaetomium murorum*, *Chaetomium virescens*, *Chaetomium*
20 *brasiliensis*, *Chaetomium cunicolorum*, *Myceliophthora thermophila*, *Gliocladium catenulatum*, *Scytalidium thermophila*, and *Acremonium* sp., more specifically from *Nectria pinea*, CBS 279.96, *Volutella colletotrichoides*, CBS 400.58, *Sordaria fimicola*, ATCC 52644, *Sordaria*
25 *macrospora*, ATCC 60255, *Thielavia terrestris*, NRRL 8126, *Thielavia thermophila*, CCBS 174.70, *Chaetomium murorum*, CBS 163.52, *Chaetomium virescens*, CBS 547.75, *Chaetomium brasiliensis*, CBS 122.65, *Chaetomium cunicolorum*, CBS 799.83, *Syspastospora boninensis*, NRBC 1515, *Cladorrhinum*
30 *foecundissimum*, ATCC 62373, *Myceliophthora thermophila*, CBS 117.65, *Scytalidium thermophila*, ATCC 28085, *Gliocladium catenulatum*, ATCC 10523, and *Acremonium* sp., CBS 478.94.

35 *Nectria pinea* was deposited at Centraalbureau voor Schimmelcultures on 12 March, 1996, under the deposition number CBS 279.96, and *Acremonium* sp. was deposited in

28 September 1994 under the deposition number CBS 478.94, both according to the Budapest Treaty.

The enzyme is also obtainable from a strain belonging to the group consisting of the species *Fusarium solani*, *Fusarium anguioides*, *Fusarium poae*, *Fusarium oxysporum* ssp. *lycopersici*, *Fusarium oxysporum* ssp. *passiflora*, *Humicola nigrescens* and *Humicola grisea*, especially *Fusarium oxysporum* ssp. *lycopersici*, CBS 645.78, *Fusarium oxysporum* ssp. *passiflora*, CBS 744.79, *Fusarium solani*, IMI 107.511, *Fusarium anguioides*, IFO 4467, *Fusarium poae*, ATCC 60883, *Humicola nigrescens*, CBS 819.73 and *Humicola grisea*, ATCC 22726. It is to be noted that *Humicola grisea* is different from *Humicola grisea* var. *thermoidea*.

In a preferred embodiment, the enzyme preparation of the invention is derived from the disclosed classes, orders, families, genera and species and essentially consists of an enzyme comprising a first peptide consisting of 13 amino acid residues having the following sequence

Thr	Arg	Xaa	Xaa	Asp	Cys	Cys	Xaa	Xaa	Xaa	Cys	Xaa	Trp
1	2	3	4	5	6	7	8	9	10	11	12	13

25

and a second peptide consisting of 5 amino acid residues having the following sequence

Trp	Cys	Cys	Xaa	Cys
1	2	3	4	5

30

wherein, in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 8 of the first sequence, the amino acid is Arg, Lys or His; in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence,

the amino acid is any of the 20 naturally occurring amino acid residues.

- 5 Preferably, the amino acid residue in position 9 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, more
- 10 preferably from the group consisting of proline and threonine; the amino acid residue in position 10 of the first sequence which is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine,
- 15 glutamine, tyrosine, serine, methionine and tryptophan, preferably serine; the amino acid residue in position 12 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine,
- 20 glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of alanine and glycine; and the amino acid residue in position 4 of the second sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine,
- 25 phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine, tryptophan, glutamic acid and aspartic acid, more preferably from the group consisting of alanine, glycine, and glutamine.
- 30 In further aspects, the present invention provides a DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises
- a) the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10,
- 35 12, 16, or 19, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia*

coli, DSM 10512, DSM 10511, DSM 10571, DSM 10576, respectively; or

- b) an analogue of the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16, or 19, respectively, or the DNA
5 sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571, DSM 10576, respectively, which
- i) is homologous with the DNA sequence shown in SEQ
10 ID No. 1, 4, 6, 8, 10, 12, 16, or 19, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571, DSM 10576, respectively,
- 15 ii) hybridizes with the same oligonucleotide probe as the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16, or 19, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM
20 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571, DSM 10576, respectively,
- iii) encodes a polypeptide which is homologous with the polypeptide encoded by a DNA sequence comprising
25 the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16, or 19, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM
30 10571, DSM 10576, respectively,
- iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence
35 shown in SEQ ID No 1, 4, 6, 8, 10, 12, 16, or 19, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Esch richia coli*,

DSM 10512, DSM 10511, DSM 10571, DSM 10576,
respectively.

5 *Escherichia coli* DSM 10512 was deposited under the Buda-
pest Treaty on 2 February, 1996, at DSM (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH,
Mascheroder Weg 16, D-38124 Braunschweig, Germany).

10 *Escherichia coli* DSM 10511 was deposited under the Buda-
pest Treaty on 2 February, 1996, at DSM (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH,
Mascheroder Weg 16, D-38124 Braunschweig, Germany).

15 *Escherichia coli* DSM 10571 was deposited under the Buda-
pest Treaty on 6 March, 1996, at DSM (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 16, D-38124 Braunschweig, Germany).

20 *Escherichia coli* DSM 10576 was deposited under the Buda-
pest Treaty on 12 March, 1996, at DSM (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 16, D-38124 Braunschweig, Germany).

25 *Escherichia coli* DSM 10583 was deposited under the Buda-
pest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 16, D-38124 Braunschweig, Germany).

30 *Escherichia coli* DSM 10584 was deposited under the Buda-
pest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 16, D-38124 Braunschweig, Germany).

35 *Escherichia coli* DSM 10585 was deposited under the Buda-
pest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Mascheroder
Weg 16, D-38124 Braunschweig, Germany).

Escherichia coli DSM 10586 was deposited under the Budapest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

5

Escherichia coli DSM 10587 was deposited under the Budapest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

10

Escherichia coli DSM 10588 was deposited under the Budapest Treaty on 13 March, 1996, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

15

Saccharomyces cerevisiae DSM 9770 was deposited under the Budapest Treaty on 24 February, 1995, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

20

Saccharomyces cerevisiae DSM 10082 was deposited under the Budapest Treaty on 30 June, 1995, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

25

Saccharomyces cerevisiae DSM 10080 was deposited under the Budapest Treaty on 30 June, 1995, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

30

Saccharomyces cerevisiae DSM 10081 was deposited under the Budapest Treaty on 30 June, 1995, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany).

35

The DNA construct of the invention relating to SEQ ID No. 1 can be isolated from or produced on the basis of a DNA

library of a strain of *Myceliophthora*, in particular a strain of *M. thermophila*, especially *M. thermophila*, CBS 117.65.

5 The DNA constructs of the invention relating to SEQ ID Nos. 4 and 6 can be isolated from or produced on the basis of a DNA library of a strain of *Acremonium*, especially *Acremonium* sp., CBS 478.94.

10 The DNA construct of the invention relating to SEQ ID No. 8 can be isolated from or produced on the basis of a DNA library of a strain of *Thielavia* in particular a strain of *Thielavia terrestris*, especially *Thielavia terrestris*, NRRL 8126.

15 The DNA construct of the invention relating to SEQ ID No. 10 can be isolated from or produced on the basis of a DNA library of a strain of *Macrophomina*, in particular a strain of *M. phaseolina*, especially *M. phaseolina*, CBS
20 281.96.

The DNA construct of the invention relating to SEQ ID No. 12 can be isolated from or produced on the basis of a DNA library of a strain of *Crinipellis*, in particular a
25 strain of *C. scabella*, especially *C. scabella*, CBS 280.96.

The DNA construct of the invention relating to SEQ ID No. 19 can be isolated from or produced on the basis of a DNA
30 library of a strain of *Sordaria*, in particular a strain of *Sordaria fimicola*.

In the present context, the "analogue" of the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16 or
35 19, respectively, is intended to indicate any DNA sequence encoding an enzyme exhibiting endoglucanase activity, which has any or all of the properties i)-iv).

The analogous DNA sequence

- a) may be isolated from another or related (e.g. the same) organism producing the enzyme with endoglucanase activity on the basis of the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16 or 19, respectively, e.g. using the procedures described herein; the homologue may be an allelic variant of the DNA sequence comprising the DNA sequences shown herein, i.e. an alternative form of a gene that arises through mutation; mutations can be silent (no change in the encoded enzyme) or may encode enzymes having altered amino acid sequence; the homologue of the present DNA sequence may also be a genus or species homologue, i.e. encoding an enzyme with a similar activity derived from another species,
- b) may be constructed on the basis of the DNA sequences shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16 or 19, respectively, e.g. by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the endoglucanase encoded by the DNA sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. However, in the latter case amino acid changes are preferably of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding or activity of the protein, small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain. See in general Ford et al., Protein Expression and Purification 2: 95-107, 1991. Examples of conservative substitutions are within the

group of basic amino acids (such as arginine, lysine, histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, valine), aromatic amino acids (such as phenylalanine, tryptophan, tyrosine) and small amino acids (such as glycine, alanine, serine, threonine, methionine).

10 It will be apparent to persons skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acids essential to the activity of the polypeptide encoded by the DNA construct
15 of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-1085, 1989). In the latter technique
20 mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological (i.e. endoglucanase) activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can
25 also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255: 306-312, 1992; Smith et al., J. Mol. Biol. 224: 899-904, 1992; Wlodaver et
30 al., FEBS Lett. 309: 59-64, 1992.

The endoglucanase encoded by the DNA sequence of the DNA construct of the invention may comprise a cellulose binding domain (CBD) existing as an integral part of the
35 encoded enzyme, or a CBD from another origin may be introduced into the endoglucanase enzyme thus creating an enzyme hybride. In this context, the term "cellulose-

binding domain" is intended to be understood as defined by Peter Tomme et al. "Cellulose-Binding Domains: Classification and Properties" in "Enzymatic Degradation of Insoluble Carbohydrates", John N. Saddler and Michael H. Penner (Eds.), ACS Symposium Series, No. 618, 1996. This definition classifies more than 120 cellulose-binding domains (CBDs) into 10 families (I-X), and it demonstrates that CBDs are found in various enzymes such as cellulases, xylanases, mannanases, arabinofuranosidases, acetyl esterases and chitinases. CBDs have also been found in algae, e.g., the red alga Porphyra purpurea as a non-hydrolytic polysaccharide-binding protein, for reference see Peter Tomme et al., supra. However, most of the CBDs are from cellulases and xylanases. CBDs are found at the N or C termini of proteins or are internal. Enzyme hybrids are known in the art, see e.g. WO 90/00609 and WO 95/16782, and may be prepared by transforming into a host cell a DNA construct comprising at least a fragment of DNA encoding the cellulose-binding domain ligated, with or without a linker, to a DNA sequence encoding the enzyme of interest and growing the host cell to express the fused gene. Enzyme hybrids may be described by the following formula:

CBD - MR - X,

wherein CBD is the N-terminal or the C-terminal region of an amino acid sequence corresponding to at least the cellulose-binding domain; MR is the middle region (the linker), and may be a bond, or a short linking group preferably of from about 2 to about 100 carbon atoms, more preferably of from 2 to 40 carbon atoms; or is preferably from about 2 to about 100 amino acids, more preferably of from 2 to 40 amino acids; and X is an N-terminal or C-terminal region of a polypeptide encoded by the DNA sequence of the invention.

The homology referred to in i) above is determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman, S.B. and Wunsch, C.D., *Journal of Molecular Biology*, 48: 443-453, 1970). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the DNA sequence exhibits a degree of identity preferably of at least 60%, more preferably at least 65%, more preferably at least 70%, even more preferably at least 80%, especially at least 90%, with the coding region of the DNA sequence shown in SEQ ID No.1, 4, 6, 8, 10, 12, or 16, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571, or DSM 10576, respectively.

20

The hybridization referred to in ii) above is intended to indicate that the analogous DNA sequence hybridizes to the same probe as the DNA sequence encoding the endoglucanase enzyme under certain specified conditions which are described in detail in the Materials and Methods section hereinafter. The oligonucleotide probe to be used is the DNA sequence corresponding to the endoglucanase encoding part of the DNA sequence shown in SEQ ID NO 1, 4, 6, 8, 10, 12, or 16 respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively.

35 The homology referred to in iii) above is determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second.

The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman, S.B. and Wunsch, C.D., *Journal of Molecular Biology*, 48: 443-453, 1970).

- 5 Using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1, the polypeptide encoded by an analogous DNA sequence exhibits a degree of identity preferably of at least 55%, more preferably at least 60%,
10 more preferably at least 65%, even more preferably at least 70%, more preferably at least 80%, especially at least 90%, with the enzyme encoded by a DNA construct comprising the DNA sequence shown in SEQ ID No.1, 4, 6, 8, 10, 12, 16 or 19, respectively, or the DNA sequence
15 obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively.
- 20 In connection with property iv) above it is intended to indicate an endoglucanase encoded by a DNA sequence isolated from strain *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively, and
25 produced in a host organism transformed with said DNA sequence or the corresponding endoglucanase naturally produced by *Myceliophthora thermophila*, *Acremonium sp.*, *Thielavia terrestris*, *Macrophomina phaseolina*, *Crinipellis scabellia*, *Volutella colletotrichoides*, or
30 *Sordaria fimicola*, respectively. The immunological reactivity may be determined by the method described in the Materials and Methods section below.

- In further aspects the invention relates to an expression
35 vector harbouring a DNA construct of the invention, a cell comprising the DNA construct or expression vector and a method of producing an enzyme exhibiting

endoglucanase activity which method comprises culturing said cell under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

- 5 In a still further aspect the invention relates to an enzyme exhibiting endoglucanase activity, which enzyme
- a) is encoded by a DNA construct of the invention
 - b) produced by the method of the invention, and/or
 - c) is immunologically reactive with an antibody raised
- 10 against a purified endoglucanase encoded by the DNA sequence shown in SEQ ID No.1, 4, 6, 8, 10, 12, or 16, respectively, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *Escherichia coli*, DSM 10512, DSM
- 15 10511, DSM 10571 or DSM 10576, respectively.

The endoglucanase mentioned in c) above may be encoded by the DNA sequence isolated from the strain *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081,

20 *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively, and produced in a host organism transformed with said DNA sequence or the corresponding endoglucanase naturally produced by *Myceliophthora thermophila*, *Acremonium sp.*, *Thielavia terrestris*,

25 *Macrophomina phaseolina*, *Crinipellis scabellia*, *Volutella colletotrichoides* or *Sordaria fimicola*, respectively.

Generally, in the present context the term "enzyme" is understood to include a mature protein or a precursor

30 form thereof as well to a functional fragment thereof which essentially has the activity of the full-length enzyme. Furthermore, the term "enzyme" is intended to include homologues of said enzyme.

- 35 Homologues of the present enzyme may have one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conser-

vative amino acid substitutions that do not significantly affect the folding or activity of the protein, small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain. See in general Ford et al. , Protein Expression and Purification 2: 95-107, 1991. Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine, histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, valine), aromatic amino acids (such as phenylalanine, tryptophan, tyrosine) and small amino acids (such as glycine, alanine, serine, threonine, methionine).

It will be apparent to persons skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active enzyme. Amino acids essential to the activity of the enzyme of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham, 1989). In the latter technique mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for cellulytic activity to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labelling. See, for example, de Vos et al., 1992; Smith et al., 1992, Wlodaver et al., 1992.

The homologue may be an allelic variant, i.e. an alternative form of a gene that arises through mutation, or an altered enzyme encoded by the mutated gene, but having substantially the same activity as the enzyme of the invention. Hence mutations can be silent (no change in the encoded enzyme) or may encode enzymes having altered amino acid sequence.

The homologue of the present enzyme may also be a genus or species homologue, i.e. an enzyme with a similar activity derived from another species.

A homologue of the enzyme may be isolated by using the procedures described herein.

Molecular screening and cloning by polymerase chain reaction (PCR)

Molecular screening for DNA sequences of the invention may be carried out by polymerase chain reaction (PCR) using genomic DNA or double-stranded cDNA isolated from a suitable source, such as any of the herein mentioned organisms, and synthetic oligonucleotide primers prepared on the basis of the DNA sequences or the amino acid sequences disclosed herein. For instance, suitable oligonucleotide primers may be the primers described in the Materials and Methods section.

In accordance with well-known procedures, the PCR fragment generated in the molecular screening may be isolated and subcloned into a suitable vector. The PCR fragment may be used for screening DNA libraries by e.g. colony or plaque hybridization.

Expression cloning in yeast

The DNA sequence of the invention encoding an enzyme exhibiting endoglucanase activity may be isolated by a

5 general method involving

- cloning, in suitable vectors, a DNA library from a suitable source, such as any of the herein mentioned organisms
- transforming suitable yeast host cells with said
10 vectors,
- culturing the host cells under suitable conditions to express any enzyme of interest encoded by a clone in the DNA library,
- screening for positive clones by determining any
15 endoglucanase activity of the enzyme produced by such clones, and
- isolating the enzyme encoding DNA from such clones.

20 The general method is further disclosed in WO 94/14953 the contents of which are hereby incorporated by reference. A more detailed description of the screening method is given in Example 1 below.

25 The DNA sequence coding for the enzyme may for instance be isolated by screening a cDNA library of *Macrophomina phaseolina*, *Crinipellis scabella*, *Sordaria fimicola* or *Volutella colletotrichoides*, and selecting for clones expressing the appropriate enzyme activity (i.e.

30 endoglucanase activity) or from *Escherichia coli* DSM 10512 deposited under the Budapest Treaty on 2 February, 1996, at DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany), or from *Escherichia coli* DSM
35 10511 deposited under the Budapest Treaty on 2 February, 1996, at DSM, or from *Escherichia coli* DSM 10576, deposited under the Budapest Treaty on 12 March, 1996, at

DSM; or from *Escherichia coli* DSM 10571 deposited under the Budapest Treaty on 6 March, 1996, at DSM; or by screening a cDNA library of *Myceliphthora thermophila*, CBS 117.65, *Acremonium* sp., CBS 478.94, or *Thielavia*
5 *terrestris*, NRRL 8126, and selecting for clones expressing the appropriate enzyme activity (i.e. endoglucanase activity) or from *Saccharomyces cerevisiae* DSM 9770 deposited under the Budapest Treaty on 24 February, 1995, at DSM (Deutsche Sammlung von Mikroorganismen und
10 Zellkulturen GmbH, Mascheroder Weg 16, D-38124 Braunschweig, Germany), or from *Saccharomyces cerevisiae* DSM 10082 deposited under the Budapest Treaty on 30 June, 1995, at DSM, from *Saccharomyces cerevisiae* DSM 10080 deposited under the Budapest Treaty on 30 June, 1995, or
15 from *Saccharomyces cerevisiae* DSM 10081 deposited under the Budapest Treaty on 30 June, 1995, at DSM. The appropriate DNA sequence may then be isolated from the clone by standard procedures, e.g. as described in Example 1.

20

Nucleic acid construct

As used herein the term "nucleic acid construct" is
25 intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is intended to indicate a nucleic acid segment which may be single- or double-stranded, and which may be based on a complete or partial naturally
30 occurring nucleotide sequence encoding an enzyme of interest. The construct may optionally contain other nucleic acid segments.

The nucleic acid construct encoding the enzyme of the
35 invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of

the enzyme by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., 1989).

- 5 The nucleic acid construct encoding the enzyme may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, (1981), or the method described by Matthes et al., (1984). According to the phospho-
10 amidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

- Furthermore, the nucleic acid construct may be of mixed
15 synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid construct, in accordance with standard tech-
20 niques.

- The nucleic acid construct may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al.,
25 (1988).

- The nucleic acid construct is preferably a DNA construct which term will be used exclusively in this specification and claims.
30

Recombinant vector

- A recombinant vector comprising a DNA construct encoding
35 the enzyme of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host

cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal
5 replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

10

The vector is preferably an expression vector in which the DNA sequence encoding the enzyme of the invention is operably linked to additional segments required for transcription of the DNA. In general, the expression
15 vector is derived from plasmid or viral DNA, or may contain elements of both. The term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds
20 through the DNA sequence coding for the enzyme.

The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either
25 homologous or heterologous to the host cell.

Examples of suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 -
30 12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al.,
35 Nature 304 (1983), 652 - 654) promoters.

Examples of suitable promoters for use in filamentous

fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4 (1985), 2093 - 2099) or the tpiA promoter. Examples of other useful promoters are those derived from the gene encoding *A. oryzae* TAKA
5 amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral α -amylase, *A. niger* acid stable α -amylase, *A. niger* or *A. awamori* glucoamylase (gluA), *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.
10 Preferred are the TAKA-amylase and gluA promoters.

Examples of suitable promoters for use in bacterial host cells include the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus*
15 *licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* BAN amylase gene, the *Bacillus subtilis* alkaline protease gen, or the *Bacillus pumilus* xylosidase gene, or by the phage Lambda P_2 or P_1 promoters or the *E. coli* lac, trp or tac promoters.

20

The DNA sequence encoding the enzyme of the invention may also, if necessary, be operably connected to a suitable terminator.

25 The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

The vector may also comprise a selectable marker, e.g. a
30 gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or the *Schizosaccharomyces pombe* TPI gene (described by P.R. Russell, *Gene* 40, 1985, pp. 125-130). For filamentous fungi, selectable markers include
35 amdS, pyrG, argB, niaD, sc.

To direct an enzyme of the present invention into the

secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is
5 joined to the DNA sequence encoding the enzyme in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the enzyme. The secretory signal sequence may be that normally associated with the enzyme or may be from a gene
10 encoding another secreted protein.

For secretion from yeast cells, the secretory signal sequence may encode any signal peptide which ensures efficient direction of the expressed enzyme into the
15 secretory pathway of the cell. The signal peptide may be naturally occurring signal peptide, or a functional part thereof, or it may be a synthetic peptide. Suitable signal peptides have been found to be the α -factor signal peptide (cf. US 4,870,008), the signal peptide of mouse
20 salivary amylase (cf. O. Hagenbuchle et al., Nature **289**, 1981, pp. 643-646), a modified carboxypeptidase signal peptide (cf. L.A. Valls et al., Cell **48**, 1987, pp. 887-897), the yeast BAR1 signal peptide (cf. WO 87/02670), or the yeast aspartic protease 3 (YAP3) signal peptide (cf.
25 M. Egel-Mitani et al., Yeast **6**, 1990, pp. 127-137).

For efficient secretion in yeast, a sequence encoding a leader peptide may also be inserted downstream of the signal sequence and upstream of the DNA sequence encoding
30 the enzyme. The function of the leader peptide is to allow the expressed enzyme to be directed from the endoplasmic reticulum to the Golgi apparatus and further to a secretory vesicle for secretion into the culture medium (i.e. exportation of the enzyme across the cell
35 wall or at least through the cellular membrane into the periplasmic space of the yeast cell). The leader peptide may be the yeast α -factor leader (the use of which is

described in e.g. US 4,546,082, EP 16 201, EP 123 294, EP 123 544 and EP 163 529). Alternatively, the leader peptide may be a synthetic leader peptide, which is to say a leader peptide not found in nature. Synthetic
5 leader peptides may, for instance, be constructed as described in WO 89/02463 or WO 92/11378.

For use in filamentous fungi, the signal peptide may conveniently be derived from a gene encoding an
10 *Aspergillus* sp. amylase or glucoamylase, a gene encoding a *Rhizomucor miehei* lipase or protease, a *Humicola lanuginosa* lipase. The signal peptide is preferably derived from a gene encoding *A. oryzae* TAKA amylase, *A. niger* neutral α -amylase, *A. niger* acid-stable amylase, or
15 *A. niger* glucoamylase.

The procedures used to ligate the DNA sequences coding for the present enzyme, the promoter and optionally the terminator and/or secretory signal sequence,
20 respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

25

Host cells

The DNA sequence encoding the present enzyme introduced into the host cell may be either homologous or
30 heterologous to the host in question. If homologous to the host cell, i.e. produced by the host cell in nature, it will typically be operably connected to another promoter sequence or, if applicable, another secretory signal sequence and/or terminator sequence than in its
35 natural environment. The term "homologous" is intended to include a cDNA sequence encoding an enzyme native to the host organism in question. The term "heterologous" is

intended to include a DNA sequence not expressed by the host cell in nature. Thus, the DNA sequence may be from another organism, or it may be a synthetic sequence.

5 The host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell which is capable of producing the present enzyme and includes bacteria, yeast, fungi and higher eukaryotic cells.

10

Examples of bacterial host cells which, on cultivation, are capable of producing the enzyme of the invention are gram-positive bacteria such as strains of *Bacillus*, such as strains of *B. subtilis*, *B. licheniformis*, *B. lentus*,
15 *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. megatherium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or gram-negative bacteria such as *Echerichia coli*. The
20 transformation of the bacteria may be effected by protoplast transformation or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

When expressing the enzyme in bacteria such as *E. coli*,
25 the enzyme may be retained in the cytoplasm, typically as insoluble granules (known as inclusion bodies), or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed and the granules are recovered and denatured after
30 which the enzyme is refolded by diluting the denaturing agent. In the latter case, the enzyme may be recovered from the periplasmic space by disrupting the cells, e.g. by sonication or osmotic shock, to release the contents of the periplasmic space and recovering the enzyme.

35

Examples of suitable yeasts cells include cells of *Saccharomyces* spp. or *Schizosaccharomyces* spp., in

- particular strains of *Saccharomyces cerevisiae* or *Saccharomyces kluyveri*. Methods for transforming yeast cells with heterologous DNA and producing heterologous enzymes therefrom are described, e.g. in US 4,599,311, US 4,931,373, US 4,870,008, 5,037,743, and US 4,845,075, all of which are hereby incorporated by reference. Transformed cells are selected by a phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient, e.g. leucine. A preferred vector for use in yeast is the POT1 vector disclosed in US 4,931,373. The DNA sequence encoding the enzyme of the invention may be preceded by a signal sequence and optionally a leader sequence, e.g. as described above. Further examples of suitable yeast cells are strains of *Kluyveromyces*, such as *K. lactis*, *Hansenula*, e.g. *H. polymorpha*, or *Pichia*, e.g. *P. pastoris* (cf. Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465; US 4,882,279).
- 20 Examples of other fungal cells are cells of filamentous fungi, e.g. *Aspergillus* spp., *Neurospora* spp., *Fusarium* spp. or *Trichoderma* spp., in particular strains of *A. oryzae*, *A. nidulans*, *A. niger*, or *Fusarium graminearum*. The use of *Aspergillus* spp. for the expression of proteins is described in, e.g., EP 272 277, EP 230 023. The transformation of *F. oxysporum* may, for instance, be carried out as described by Malardier et al., 1989, Gene 78: 147-156.
- 30 When a filamentous fungus is used as the host cell, it may be transformed with the DNA construct of the invention, conveniently by integrating the DNA construct in the host chromosome to obtain a recombinant host cell. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed

according to conventional methods, e.g. by homologous or heterologous recombination.

5 The transformed or transfected host cell described above is then cultured in a suitable nutrient medium under conditions permitting the expression of the present enzyme, after which the resulting enzyme is recovered from the culture.

10 The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture
15 Collection). The enzyme produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate
20 by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of enzyme in question.

25

In a still further aspect, the present invention relates to a method of producing an enzyme according to the invention, wherein a suitable host cell transformed with a DNA sequence encoding the enzyme is cultured under
30 conditions permitting the production of the enzyme, and the resulting enzyme is recovered from the culture.

Enzyme Screening driven by taxonomy as well as ecology:

35

A powerful tool like the molecular screening disclosed herein, designed to detect and select said type of

- interesting enzymes, can still not stand on its own. In order to maximize the chances of making interesting discoveries the molecular screening approach was in the present investigation combined with careful selection of which fungi to screen. The selection was done through a thorough insight in the identification of fungi, in taxonomical classification and in phylogenetic relationships.
- 10 A taxonomic hot spot for production of cellulytic enzymes can further only be fully explored if also the ecological approach is included. Thorough knowledge about the adaptation to various substrates (especially saprotrophic, necrotrophic or biotrophic degradation of plant materials) are prerequisites for designing an intelligent screening and for managing a successful selection of strains and ecological niches to be searched.
- 20 Both the taxonomy and the ecological approach disclosed herein aim at maximizing discovery of said enzymes in the molecular screening program. However, still several hundreds (or if all preliminary work is included) several thousand fungi have been brought in culture in order to detect the 53 hits of said type of cellulytic enzyme here reported.

The screening and cloning may be carried out using the following:

MATERIALS AND METHODS

List of organisms:

- 35 *Saccharomyces cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, or *Escherichia coli*, DSM 10512, DSM 10511, DSM 10571, DSM 10576, respectively, containing the plasmid

comprising the full length DNA sequence, coding for the endoglucanase of the invention, in the shuttle vector pYES 2.0.

- 5 *Escherichia coli* DSM 10583, 10584, 10585, 10586, 10587, and 10588.

Diplodia gossypina Cooke

Deposit of Strain, Acc No: CBS 274.96

- 10 Classification: Ascomycota, Loculoascomycetes, Dothideales, Cucurbitariaceae

Ulospora bilgramii (Hawksw. et al.) Hawksw. et al.

Acc No of strain: NKBC 1444, Nippon University, (Prof.

- 15 Tubaki collection)

Classification: Ascomycota, Loculoascomycetes, Dothideales, (family unclassified)

Microsphaeropsis sp.

- 20 Isolated from: Leaf of *Camellia japonica* (Theaceae, Guttiferales), grown in Kunming Botanical garden, Yunnan Province, China

Classification: Ascomycota, Loculoascomycetes, Dothideales, (family unclassified)

25

Macrophomina phaseolina (Tassi) Goidannich

Syn: *Rhizoctonia bataticola*

Deposit of Strain, Acc No.: CBS 281.96

Isolated from seed of *Glycine max* (Leguminosa), cv CMM

- 30 60, grown in Thailand, 1990

Classification: Ascomycota, Discomycetes, Rhytismatales, Rhytismataceae

Ascobolus stictoides Speg.

- 35 Isolated from goose dung, Svalbard, Norway

Classification: Ascomycota, Discomycetes, Pezizales, Asc bolaceae

Saccobolus dilutellus (Fuck.) Sacc.

Deposit of strain: Acc No CBS 275.96

Classification: Ascomycota, Discomycetes, Pezizales,
Ascobolaceae

5

Penicillium verruculosum Peyronel

Ex on Acc No of species: ATCC 62396

Classification: Ascomycota, Plectomycetes, Eurotiales,
Trichocomaceae

10

Penicillium chrysogenum Thom

Acc No of Strain: ATCC 9480

Classification: Ascomycota, Plectomycetes, Eurotiales,
Trichocomaceae

15

Thermomyces verrucosus Pugh et al

Deposit of Strain, Acc No.: CBS 285.96

Classification: Ascomycota, Plectomycetes, Eurotiales,
(family unclassified; affiliation based on 18S RNA,

20 sequencing and homologies)

Xylaria hypoxylon L. ex Greville

Deposit of Strain, Acc No: CBS 284.96

Classification: Ascomycota, Pyrenomycetes, Xylariales,
25 Xylariaceae

Poronia punctata (Fr.ex L.) Fr.

Classification: Ascomycota, Pyrenomycetes, Xylariales,
Xylariaceae

30

Nodulisporum sp

Isolated from leaf of *Camellia reticulata* (Theaceae,
Guttiferales), grown in Kunming Botanical Garden, Yunnan
Province, China

35 Classification: Ascomycota, Pyrenomycetes, Xylariales,
Xylariaceae

Cylindrocarpon sp

Isolated from marine sample, the Bahamas

Classification: Ascomycota, Pyrenomycetes, Hypocreales
(unclassified)

5

Acremonium sp

Deposit of Strain, Acc. No.: CBS 478.94

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

10

Fusarium anguioides Sherbakoff

Acc No of strain: IFO 4467

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

15

Fusarium poae (Peck) Wr.

Ex on Acc No of species: ATCC 60883

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

20

Fusarium solani (Mart.) Sacc. emend. Snyder & Hans.

Acc No of strain: IMI 107.511

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

25

Fusarium oxysporum ssp lycopersici (Sacc.) Snyder & Hans.

Acc No of strain: CBS 645.78

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

30

Fusarium oxysporum ssp passiflora

Acc No of strain: CBS 744.79

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

35

Gliocladium catenulatum Gillman & Abbott

Acc. No. of strain: CBS 227.48

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Hypocreaceae

Nectria pinea Dingley

- 5 Deposit of Strain, Acc. No. CBS 279.96

Classification: Ascomycota, Pyrenomycetes, Hypocreales,
Nectriaceae

Volutella colletotrichoides

- 10 Acc No of Strain: CBS 400.58

Classification: Ascomycota, Pyrenomycetes, Hypocreales
(unclassified)

Sordaria macrospora Auerswald

- 15 Ex on Acc No of species: ATCC 60255

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Sordariaceae

Sordaria fimicola (Roberge) Cesati et De Notaris

- 20 Ex on Acc. No. for the species: ATCC 52644

Isolated from dung by H.Dissing, ISP, KU, Denmark

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Sordariaceae

- 25 *Humicola grisea* Traeen

ex on Acc No for the species: ATCC 22726

Source: Hatfield Polytechnic

Classification: Ascomycota, Pyrenomycetes, Sordariales,
(fam. unclassified)

- 30

Humicola nigrescens Omvik

Acc No of strain: CBS 819.73

Classification: Ascomycota, Pyrenomycetes, Sordariales,
(fam. unclassified)

- 35

Scytalidium thermophilum (Cooney et Emerson) Austwick

Acc No of strain: ATCC 28085

Classification: Ascomycota, Pyrenomycetes, Sordariales,
(fam. unclassified)

Thielavia thermophila Fergus et Sinden

5 (syn *Corynascus thermophilus*)

Acc No of strain: CBS 174.70, IMI 145.136

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

Isolated from Mushroom compost

10

Thielavia terrestris (Appinis) Malloch et Cain

Acc No of strain: NRRL8126

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

15

Cladorrhinum foecundissimum Saccardo et Marchal

Ex on Acc No of species: ATCC 62373

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Lasiosphaeriaceae

20 Isolated from leaf of *Selandin* sp. (Compositaceae,
Asterales), Dallas Mountain, Jamaica

Syspastospora boninensis

Acc No of strain: NKBC 1515 (Nippon University, profe
25 Tubaki Collection)

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Cerastomataceae

Chaetomium cuniculorum Fuckel

30 Acc. No. of strain: CBS 799.83

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

Chaetomium brasiliense Batista et Potual

35 Acc No of strain: CBS 122.65

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

Chaetomium murorum Corda

Acc No of strain: CBS 163.52

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

5

Chaetomium virescens (von Arx) Udagawa

Acc.No. of strain: CBS 547.75

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

10

Myceliophthora thermophila (Apinis) Oorschot

Deposit of Strain, Acc No: CBS 117.65

Classification: Ascomycota, Pyrenomycetes, Sordariales,
Chaetomiaceae

15

Nigrospora sp

Deposit of strain, Acc No: CBS 272.96

Isolated from leaf of *Artocarpus altilis*, Moraceae,
Urticales grown in Christiana, Jamaica

20 Classification: Ascomycota, Pyrenomycetes,
Trichosphaeriales, (family unclassified)

Nigrospora sp

Isolated from leaf of *Pinus yuannanensis*, Botanical

25 Garden, Kuning, Yunnan.

Classification: Ascomycota, Pyrenomycetes,
Trichosphaeriales, Abietaceae, Pinales.

Diaporthe syngenesia

30 Deposit of strain, Acc No: CBS 278.96

Classification: Ascomycota, Pyrenomycetes, Diaporthales,
Valsaceae

Colletotrichum lagenarium (Passerini) Ellis et Halsted

35 syn *Glomerella cingulata* var *orbiculare* Jenkins et
Winstead

Ex on acc No of species: ATCC 52609

Classification: Ascomycota, Pyrenomycetes, Phyllachorales

Exidia glandulosa Fr.

Deposit of Strain, Acc No: CBS 277.96

- 5 Classification: Basidiomycota, Hymenomycetes,
Auriculariales, Exidiaceae

Crinipellis scabella (Alb.&Schw.:Fr.)Murr

Deposit of strain: Acc No CBS 280.96

- 10 Classification: Basidiomycota, Hymenomycetes, Agaricales,

Panaeolus retirugis (Fr.) Gill.

Acc.No. of strain: CBS 275.47

- 15 Classification: Basidiomycota, Hymenomycetes, Agaricales,
Coprinnaceae

Fomes fomentarius (L.) Fr.

Deposit of strain: Acc No. CBS 276.96

- 20 Classification: Basidiomycota, Hymenomycetes,
Aphyllophorales,
Fomitaceae

Spongipellis sp.

Deposit of Strain: Acc No CBS 283.96

- 25 Classification: Basidiomycota, Hymenomycetes,
Aphyllophorales,
Bjerkanderaceae (identified and affiliated taxonomically
by 18S sequence and homology)

- 30 *Trametes sanguinea* (Fr.) Lloyd

syn: *Polyporus sanguineus*; *Pycnoporus sanguineus* (L.:Fr.)
Murrill

Acc No of strain: AKU 5062 (Kyoto University Culture
Collection)

- 35 Classification: Basidiomycota, Aphyllophorales,
Polyporaceae

Schizophyllum commune Fr

Acc. No. of species: ATCC 38548

Classification: Basidiomycota, Aphyllorphales,
Schizophyllaceae

5

Rhizophlyctis rosea (de Bary & Wor) Fischer

Deposit of Strain: Acc No.: CBS 282.96

Classification: Chytridiomycota, Chytridiomycetes,
Spizellomycetales, Spizellomycetaceae

10

Rhizomucor pusillus (Lindt) Schipper

syn: *Mucor pusillus*

Acc No of strain: IFO 4578

Ex on Acc No of species: ATCC 46883

15 Classification: Zygomycota, Zygomycetes, Mucorales,
Mucoraceae

Phycomyces nitens (Kunze) van Tieghem & Le Monnier

Acc No of strain: IFO 4814

20 Ex on Acc No of species: ATCC 16327

Classification: Zygomycota, Zygomycetes, Mucorales,
Mucoraceae

Chaetostylum fresenii van Tieghem & Le Monnier

25 syn. *Helicostylum fresenii*

Acc No of strain NRRL 2305

Classification: Zygomycota, Zygomycetes, Mucorales,
Thamnidaceae

30

Unclassified:

Trichothecium roseum

Acc No of strain: IFO 5372

35

Coniothecium sp

Endophyte, isolated from leaf of unidentified higher

plant, growing in Kunming, Yunnan, China

Unclassified and Un-identified:

5

Deposit of strain, Acc No.: CBS 271.96

Isolated from leaf of *Artocarpus altilis* (Moraceae, Urticales), grown in Christiana, Jamaica

10 Deposit of strain, Acc No.: CBS 273.96

Isolated from leaf of *Pimenta dioica* (Myrtaceae, Myrtales) grown in Dallas Mountain, Jamaica

Deposit of strain: CBS 270.96

15 Isolated from leaf of *Pseudocalymma alliaceum* (Bignoniaceae, Solanales) growing in Dallas Mountain, Jamaica

Other strains:

20 *Escherichia coli* MC1061 and DH10B.

Yeast strain: The *Saccharomyces cerevisiae* strain used was W3124 (MAT α ; ura 3-52; leu 2-3, 112; his 3-D200; pep 4-1137; prc1::HIS3; prb1::LEU2; cir+).

25

Plasmids:

The *Aspergillus* expression vector pHD414 is a derivative of the plasmid p775 (described in EP 238 023). The construction of pHD414 is further described in WO

30 93/11249.

pYES 2.0 (Invitrogen)

pA2C477, pA2C193, pA2C357, pA2C371, pA2C385, pA2C475,

35 pA2C488, pA2C502 (See example 1, 2, 3 and 4).

Isolation of the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16, or 19 respectively:

The full length DNA sequence, comprising the cDNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, 16 or
5 19, respectively, coding for the endoglucanase of the invention, can be obtained from the deposited organism *S. cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *E. coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively, by extraction of plasmid DNA by methods
10 known in the art (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY).

PCR primers for molecular screening of cellulases of the
15 present invention:

The four degenerate, deoxyinosine-containing oligonucleotide primers (sense; s and antisense; as1, as2 and as3) corresponding to four highly conserved amino
20 acid regions found in the deduced amino acid sequences of *Thielavia terrestris* cellulase, *Myceliophthora thermophilum* cellulase, and two cellulases from *Acremonium sp.* The residues are numbered according to the *Myceliophthora thermophilum* sequence. The deoxyinosines
25 are depicted by an I in the primer sequences, and the restriction sites are underlined.

27 35

NH ₂	-Thr	Arg	Tyr	Trp	Asp	Cys	Cys	Lys	Pro/Thr-	COOH
s 5'-CCCCA	<u>AGCTT</u>	ACI	AGI	TAC	TGG	GAC	TGC	TGC	AAA	AC -3'
	HindIII		C	T		T	T	T	G	C

106 111

NH ₂	-Trp	Cys	Cys	Ala	Cys	Tyr-	COOH
as1 3'-	CC	ACA	ACA	CGI	ACA	AT	<u>AGATCTGATC</u> -5'
		G	G		G		XbaI

145 152

NH ₂	-Pro	Gly	Gly	Gly	Leu/Val	Gly	Ile/Leu	Phe-	COOH
as2 3'-	GGI	CCI	CCI	CCI	AAI	CCI	AAI	AA	<u>AGATCTGATC</u> -5'
					C		G		XbaI
					G		T		

193 198

NH ₂	-Trp	Arg	Phe/Tyr	Asp	Trp	Phe-	COOH
as3 3'-	CC	GCI	AAA	CTA	ACC	AAA	<u>AGATCTGATC</u> -5'
		T	TG	G		G	XbaI

Molecular screening by polymerase chain reaction (PCR):

In vitro amplification of genomic DNA and double-stranded cDNA.

- 5 Directional, double-stranded cDNA was synthesized from 5 μ g of poly(A)⁺RNA as described below. Genomic DNA was isolated according to Yelton et al.

- Approximately 10 to 20 ng of double-stranded,
10 cellulase-induced cDNA or 100 to 200 ng of genomic DNA from a selection of fungal strains was PCR amplified in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % (w/v) gelatin) containing 200 μ M of each dNTP and 100 pmol of each degenerate primer in three
15 combinations:

1)

sense,

5'-CCCCAAGCTTACI^A/C^GITA^C/T^TGGGA^C/T^TGC^C/T^TGC^C/T^TAA^A/G^A/C-3'

antisense 1,

- 20 5'-CTAGTCTAGATA^A/G^AIGC^A/G^ACA^A/CACC-3'; or

2)

sense,

5'-CCCCAAGCTTACI^A/C^GITA^C/T^TGGGA^C/T^TGC^C/T^TGC^C/T^TAA^A/G^A/C-3'

- 25 antisense 2,

CTAGTCTAGAAAIA^A/G^AT^TICCA^A/C^GIC^CIC^CIC^CIGG-3'; or

3)

sense,

- 30 5'-CCCCAAGCTTACI^A/C^GITA^C/T^TGGGA^C/T^TGC^C/T^TGC^C/T^TAA^A/G^A/C-3'

antisense 3,

5'-CTAGTCTAGAAIAACCA^A/G^ATCA^A/G^A/T^TAIC^G/T^TCC-3;

- a DNA thermal cycler (Landgraf, Germany) and 2.5 units of
35 Taq polymerase (Perkin-Elmer, Cetus, USA). Thirty cycles of PCR were performed using a cycle profile of denaturation at 94 °C for 1 min, annealing at 64 °C for 2

min, and extension at 72 °C for 3 min. Ten-μl aliquots of the amplification products were analyzed by electrophoresis in 3 % agarose gels (NuSieve, FMC) with HaeIII-digested φX174 RF DNA as a size marker.

5

Direct sequencing of the PCR products. Eighty-μl aliquots of the PCR products were purified using the QIAquick PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The nucleotide sequences of the amplified PCR fragments were determined directly on the purified PCR products by the dideoxy chain-termination method, using 50-150 ng template, the Taq deoxy-terminal cycle sequencing kit (Perkin-Elmer, USA), fluorescent labeled terminators and 5 pmol of the sense primer: 5'- CCCCAGCTTACI^A/C^GITA^C/T^TG^GGA^C/T^T-G^C/T^TG^C/T^TAA^A/O^A/C^C-3'. Analysis of the sequence data were performed according to Devereux et al.

Cloning by polymerase chain reaction (PCR):
20 Subcloning of PCR fragments.

Twentyfive-μl aliquots of the PCR products generated as described above were electrophoresed in 0.8 % low gelling temperature agarose (SeaPlaque GTG, FMC) gels, the relevant fragments were excised from the gels, and recovered by agarase treatment by adding 0.1 vol of 10 x agarase buffer (New England Biolabs) and 2 units per 100 μl molten agarose to the sample, followed by incubation at 45 °C for 1.5 h. The sample was phenol and chloroform extracted, and precipitated by addition of 2 vols of 96 % EtOH and 0.1 of 3 M NaAc, pH 5.2. The PCR fragments were recovered by centrifugation, washed in 70 % EtOH, dried and resuspended in 20 μl of restriction enzyme buffer (10 mM Tris-HCl, 10 mM MgCl₂, 50 mM NaCl, 1 mM DTT). The fragments were digested with HindIII and XbaI, phenol and chloroform extracted, recovered by precipitation with 2 vols of 96 % EtOH and 0.1 of 3 M

NaAc, pH 5.2, and subcloned into *Hind*III/*Xba*I-cleaved pYES 2.0 vector.

Screening of cDNA libraries and characterization of the positive clones. cDNA libraries in *S. cerevisiae* or *E. coli*, constructed as described below, were screened by colony hybridization (Sambrook, 1989) using the corresponding random-primed (Feinberg and Vogelstein) ³²P-labeled (>1 x 10⁹ cpm/μg) PCR products as probes. The hybridizations were carried out in 2 x SSC (Sambrook, 1989), 5 x Denhardt's solution (Sambrook, 1989), 0.5 % (w/v) SDS, 100 μg/ml denatured salmon sperm DNA for 20 h at 65°C followed by washes in 5 x SSC at 25°C (2 x 15 min), 2 x SSC, 0.5 % SDS at 65°C (30 min), 0.2 x SSC, 0.5 % SDS at 65°C (30 min) and finally in 5 x SSC (2 x 15 min) at 25°C. The positive cDNA clones were characterized by sequencing the ends of the cDNA inserts with pYES 2.0 polylinker primers (Invitrogen, USA), and by determining the nucleotide sequence of the longest cDNA from both strands by the dideoxy chain termination method (Sanger et al.) using fluorescent labeled terminators. Qiagen purified plasmid DNA (Qiagen, USA) was sequenced with the Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) and either pYES 2.0 polylinker primers (Invitrogen, USA) or synthetic oligonucleotide primers using an Applied Biosystems 373A automated sequencer according to the manufacturers instructions. Analysis of the sequence data was performed according to Devereux et al.

Extraction of total RNA was performed with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M CsCl cushion, and isolation of poly(A)⁺RNA was carried out by oligo(dT)-cellulose affinity chromatography using the procedures described in WO 94/14953.

35

cDNA synthesis: Double-stranded cDNA was synthesized from 5 μg poly(A)⁺ RNA by the RNase H method (Gubler and

Hoffman (1983) Gene 25:263-269, Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY) using the hair-pin modification developed by F. S. Hagen (pers. comm.). The
5 poly(A)⁺ RNA (5 µg in 5 µl of DEPC-treated water) was heated at 70°C for 8 min. in a pre-siliconized, RNase-free Eppendorph tube, quenched on ice and combined in a final volume of 50 µl with reverse transcriptase buffer (50 mM Tris-Cl, pH 8.3, 75 mM KCl, 3 mM MgCl₂, 10 mM DTT,
10 Bethesda Research Laboratories) containing 1 mM of dATP, dGTP and dTTP and 0.5 mM 5-methyl-dCTP (Pharmacia), 40 units human placental ribonuclease inhibitor (RNasin, Promega), 1.45 µg of oligo(dT)₁₈-Not I primer (Pharmacia) and 1000 units SuperScript II RNase H reverse
15 transcriptase (Bethesda Research Laboratories). First-strand cDNA was synthesized by incubating the reaction mixture at 45°C for 1 hour. After synthesis, the mRNA:cDNA hybrid mixture was gelfiltrated through a MicroSpin S-400 HR (Pharmacia) spin column according to
20 the manufacturer's instructions.

After the gelfiltration, the hybrids were diluted in 250 µl second strand buffer (20 mM Tris-Cl, pH 7.4, 90 mM KCl, 4.6 mM MgCl₂, 10 mM (NH₄)₂SO₄, 0.16 mM βNAD⁺)
25 containing 200 µM of each dNTP, 60 units *E. coli* DNA polymerase I (Pharmacia), 5.25 units RNase H (Promega) and 15 units *E. coli* DNA ligase (Boehringer Mannheim). Second strand cDNA synthesis was performed by incubating the reaction tube at 16°C for 2 hours and additional 15
30 min. at 25°C. The reaction was stopped by addition of EDTA to a final concentration of 20 mM followed by phenol and chloroform extractions.

Mung bean nuclease treatment: The double-stranded cDNA
35 was precipitated at -20°C for 12 hours by addition of 2 vols 96% EtOH, 0.2 vol 10 M NH₄Ac, recovered by centrifugation, washed in 70% EtOH, dried and resuspended

- in 30 μ l Mung bean nuclease buffer (30 mM NaAc, pH 4.6, 300 mM NaCl, 1 mM ZnSO₄, 0.35 mM DTT, 2% glycerol) containing 25 units Mung bean nuclease (Pharmacia). The single-stranded hair-pin DNA was clipped by incubating the reaction at 30°C for 30 min., followed by addition of 70 μ l 10 mM Tris-Cl, pH 7.5, 1 mM EDTA, phenol extraction and precipitation with 2 vols of 96% EtOH and 0.1 vol 3 M NaAc, pH 5.2 on ice for 30 min.
- 10 **Blunt-ending with T4 DNA polymerase:** The double-stranded cDNAs were recovered by centrifugation and blunt-ended in 30 μ l T4 DNA polymerase buffer (20 mM Tris-acetate, pH 7.9, 10 mM MgAc, 50 mM KAc, 1 mM DTT) containing 0.5 mM of each dNTP and 5 units T4 DNA polymerase (New England Biolabs) by incubating the reaction mixture at 16°C for 1 hour. The reaction was stopped by addition of EDTA to a final concentration of 20 mM, followed by phenol and chloroform extractions, and precipitation for 12 hours at -20°C by adding 2 vols 96% EtOH and 0.1 vol 3 M NaAc pH 5.2.
- 25 **Adaptor ligation, Not I digestion and size selection:** After the fill-in reaction the cDNAs were recovered by centrifugation, washed in 70% EtOH and dried. The cDNA pellet was resuspended in 25 μ l ligation buffer (30 mM Tris-Cl, pH 7.8, 10 mM MgCl₂, 10 mM DTT, 0.5 mM ATP) containing 2.5 μ g non-palindromic BstXI adaptors (Invitrogen) and 30 units T4 ligase (Promega) and incubated at 16°C for 12 hours. The reaction was stopped by heating at 65°C for 20 min. and then cooling on ice for 5 min. The adapted cDNA was digested with Not I restriction enzyme by addition of 20 μ l water, 5 μ l 10x Not I restriction enzyme buffer (New England Biolabs) and 50 units Not I (New England Biolabs), followed by incubation for 2.5 hours at 37°C. The reaction was stopped by heating at 65°C for 10 min. The cDNAs were size-fractionated by gel electrophoresis on a 0.8%
- 30
- 35

SeaPlaque GTG low melting temperature agarose gel (FMC) in 1x TBE to separate unligated adaptors and small cDNAs. The cDNA was size-selected with a cut-off at 0.7 kb and rescued from the gel by use of β -Agarase (New England Biolabs) according to the manufacturer's instructions and precipitated for 12 hours at -20°C by adding 2 vols 96% EtOH and 0.1 vol 3 M NaAc pH 5.2.

Construction of libraries: The directional, size-selected cDNA was recovered by centrifugation, washed in 70% EtOH, dried and resuspended in 30 μl 10 mM Tris-Cl, pH 7.5, 1 mM EDTA. The cDNAs were desalted by gelfiltration through a MicroSpin S-300 HR (Pharmacia) spin column according to the manufacturer's instructions. Three test ligations were carried out in 10 μl ligation buffer (30 mM Tris-Cl, pH 7.8, 10 mM MgCl_2 , 10 mM DTT, 0.5 mM ATP) containing 5 μl double-stranded cDNA (reaction tubes #1 and #2), 15 units T4 ligase (Promega) and 30 ng (tube #1), 40 ng (tube #2) and 40 ng (tube #3, the vector background control) of BstXI-NotI cleaved pYES 2.0 vector. The ligation reactions were performed by incubation at 16°C for 12 hours, heating at 70°C for 20 min. and addition of 10 μl water to each tube. 1 μl of each ligation mixture was electroporated into 40 μl electrocompetent *E. coli* DH10B cells (Bethesda research Laboratories) as described (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY). Using the optimal conditions a library was established in *E. coli* consisting of pools. Each pool was made by spreading transformed *E. coli* on LB+ampicillin agar plates giving 15.000-30.000 colonies/plate after incubation at 37°C for 24 hours. 20 ml LB+ampicillin was added to the plate and the cells were suspended herein. The cell suspension was shaken in a 50 ml tube for 1 hour at 37°C . Plasmid DNA was isolated from the cells according to the manufacturer's instructions using QIAGEN plasmid kit and stored at -20°C .

1 μ l aliquots of purified plasmid DNA (100 ng/ μ l) from individual pools were transformed into *S. cerevisiae* W3124 by electroporation (Becker and Guarante (1991) Methods Enzymol. 194:182-187) and the transformants were
5 plated on SC agar containing 2% glucose and incubated at 30°C.

Identification of positive colonies: After 3-5 days of growth, the agar plates were replica plated onto a set of
10 SC + galactose-uracil agar plates containing 0.1% AZCL HE cellulose. These plates were incubated for 3-7 days at 30°C. Endoglucanase positive colonies were identified as colonies surrounded by a blue halo.

15 Cells from enzyme-positive colonies were spread for single colony isolation on agar, and an enzyme-producing single colony was selected for each of the endoglucanase-producing colonies identified.

20 **Characterization of positive clones:** The positive clones were obtained as single colonies, the cDNA inserts were amplified directly from the yeast colony using biotinylated polylinker primers, purified by magnetic beads (Dynabead M-280, Dynal) system and characterized
25 individually by sequencing the 5'-end of each cDNA clone using the chain-termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467) and the Sequenase system (United States Biochemical).

30 The nucleotide sequence was determined of the longest cDNA from both strands by the dideoxy chain termination method (Sanger et al.) using fluorescent labeled terminators. Plasmid DNA was rescued by transformation into *E. coli* as described below. Qiagen purified plasmid
35 DNA (Qiagen, USA) was sequenced with the Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) and either pYES 2.0 polylinker primers (Invitrogen, USA) or

synthetic oligonucleotide primers using an Applied Biosystems 373A automated sequencer according to the manufacturers instructions. Analysis of the sequence data was performed according to Devereux et al.

5

Isolation of a cDNA gene for expression in *Aspergillus*:

An endoglucanase-producing yeast colony was inoculated into 20 ml YPD broth in a 50 ml glass test tube. The tube was shaken for 2 days at 30°C. The cells were harvested
10 by centrifugation for 10 min. at 3000 rpm.

DNA was isolated according to WO 94/14953 and dissolved in 50 µl water. The DNA was transformed into *E. coli* by standard procedures. Plasmid DNA was isolated from *E.*
15 *coli* using standard procedures, and analyzed by restriction enzyme analysis. The cDNA insert was excised using appropriate restriction enzymes and ligated into an *Aspergillus* expression vector.

20 Transformation of *Aspergillus oryzae* or *Aspergillus niger*

Protoplasts may be prepared as described in WO 95/02043, p. 16, line 21 - page 17, line 12, which is hereby incorporated by reference.

25

100 µl of protoplast suspension is mixed with 5-25 µg of the appropriate DNA in 10 µl of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH = 7.5, 10 mM CaCl₂). Protoplasts are mixed with p3SR2 (an *A. nidulans* amdS gene carrying
30 plasmid). The mixture is left at room temperature for 25 minutes. 0.2 ml of 60% PEG 4000 (BDH 29576), 10 mM CaCl₂ and 10 mM Tris-HCl, pH 7.5 is added and carefully mixed (twice) and finally 0.85 ml of the same solution is added and carefully mixed. The mixture is left at room
35 temperature for 25 minutes, spun at 2500 g for 15 minutes and the pellet is resuspended in 2 ml of 1.2 M sorbitol. After one more sedimentation the protoplasts are spread

on minimal plates (Cove, Biochem. Biophys. Acta 113
(1966) 51-56) containing 1.0 M sucrose, pH 7.0, 10 mM
acetamide as nitrogen source and 20 mM CsCl to inhibit
background growth. After incubation for 4-7 days at 37°C
5 spores are picked and spread for single colonies. This
procedure is repeated and spores of a single colony after
the second reisolation is stored as a defined
transformant.

10 **Test of *A. oryzae* transformants**

Each of the transformants were inoculated in 10 ml YPM
and propagated. After 2-5 days of incubation at 37°C, 10
ml supernatant was removed. The endoglucanase activity
was identified by AZCL HE cellulose as described above.

15

Hybridization conditions (to be used in evaluating
property ii) of the DNA construct of the invention):
Suitable conditions for determining hybridization between
a nucleotide probe and a homologous DNA or RNA sequence

- 20 involves presoaking of the filter containing the DNA
fragments or RNA to hybridize in 5 x SSC (standard saline
citrate) for 10 min, and prehybridization of the filter
in a solution of 5 x SSC (Sambrook et al. 1989), 5 x
Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and
25 100 µg/ml of denatured sonicated salmon sperm DNA
(Sambrook et al. 1989), followed by hybridization in the
same solution containing a random-primed (Feinberg, A. P.
and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13), ³²P-
dCTP-labeled (specific activity > 1 x 10⁹ cpm/µg) probe
30 for 12 hours at ca. 45°C. The filter is then washed two
times for 30 minutes in 2 x SSC, 0.5 % SDS at preferably
not higher than 50°C, more preferably not higher than
55°C, more preferably not higher than 60°C, more
preferably not higher than 65°C, even more preferably not
35 higher than 70°C, especially not higher than 75°C.
The nucleotide probe to be used in the hybridization is
the DNA sequence corresponding to the endoglucanase

encoding part of the DNA sequence shown in SEQ ID No. 1, 4, 6, 8, 10, 12, or 16, respectively, and/or the DNA sequence obtainable from the plasmid in *S. cerevisiae*, DSM 9770, DSM 10082, DSM 10080, DSM 10081, *E. coli*, DSM 10512, DSM 10511, DSM 10571 or DSM 10576, respectively.

Immunological cross-reactivity: Antibodies to be used in determining immunological cross-reactivity may be prepared by use of a purified cellulase. More specifically, antiserum against the cellulase of the invention may be raised by immunizing rabbits (or other rodents) according to the procedure described by N. Axelsen *et al.* in: A Manual of Quantitative Immuno-electrophoresis, Blackwell Scientific Publications, 1973, Chapter 23, or A. Johnstone and R. Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, 1982 (more specifically pp. 27-31). Purified immunoglobulins may be obtained from the antisera, for example by salt precipitation ((NH₄)₂ SO₄), followed by dialysis and ion exchange chromatography, e.g. on DEAE-Sephadex. Immunochemical characterization of proteins may be done either by Outcherlony double-diffusion analysis (O. Ouchterlony in: Handbook of Experimental Immunology (D.M. Weir, Ed.), Blackwell Scientific Publications, 1967, pp. 655-706), by crossed immunoelectrophoresis (N. Axelsen *et al.*, *supra*, Chapters 3 and 4), or by rocket immunoelectrophoresis (N. Axelsen *et al.*, Chapter 2).

Media

YPD: 10 g yeast extract, 20 g peptone, H₂O to 900 ml.
Autoclaved, 100 ml 20% glucose (sterile filtered) added.

YPM: 10 g yeast extract, 20 g peptone, H₂O to 900 ml.
Autoclaved, 100 ml 20% maltodextrin (sterile filtered) added.

10 x Basal salt: 75 g yeast nitrogen base, 113 g succinic acid, 68 g NaOH, H₂O ad 1000 ml, sterile filtered.

5 SC-URA: 100 ml 10 x Basal salt, 28 ml 20% casamino acids without vitamins, 10 ml 1% tryptophan, H₂O ad 900 ml, autoclaved, 3.6 ml 5% threonine and 100 ml 20% glucose or 20% galactose added.

SC-URA agar: SC-URA, 20 g/l agar added.

10

PD agar: 39g potato dextrose agar, DIFCO 0013; add deionized water up to 1000ml; autoclave (121°C for 15-20 min).

15 PC agar: Potatoes and carrots (grinded, 20 g of each) and water, added up to 1000ml, are boiled for 1 hr; agar (20g/l of Merck 1614); autoclave (121°C for 20 min)

PC liquid broth: as PC agar but without the Agar

20

PD liquid broth: 24g potato dextrose broth, Difco 0549, deionized water up to 1000ml; autoclave (121°C for 15-20 min)

25 PC and PD liquid broth with cellulose: add 30 g Solcafloc (Dicacel available from Dicalite-Europe-Nord, 9000 Gent, Belgium) per 1000ml

30 PB-9 liquid broth: 12 g Rofec (Roquette 101-0441) and 24 g glucose are added to 1000ml water; pH is adjusted to 5.5; 5ml mineral oil and 5 g CaCO₃ are added per 1000ml. autoclave (121°C for 40 min)

35 YPG liquid broth: 4g yeast extract (Difco 0127), 1g KH₂PO₄ (Merck 4873), 0.5g MgSO₄·7H₂O Merck 5886, 15g Dextrose, Roquette 101-0441, 0.1ml Pluronic (101-3088); deionized water up to 1000ml; autoclave (20min at 121°C)

Dilute salt solution (DS): Make up two stock solutions:

P-stock: 13.61g KH_2PO_4 ; 13.21g $(\text{NH}_4)_2\text{PO}_4$, 17.42g KH_2PO_4 ;
deionized water up to 100ml

Ca/Mg stock: 7.35g CaCl_2 , $2\text{H}_2\text{O}$, 10.17g MgCl_2 , $6\text{H}_2\text{O}$,

- 5 deionized water up to 100ml; pH adjusted to 7.0;
autoclaving (121°C ; 20min)

Mix 0.5ml P-stock with 0.1ml Ca/Mg stock

add deionized water up to 1000ml

- 10 AZCL HE cellulose (Megazyme, Australia).

Uses

- 15 During washing and wearing, dyestuff from dyed fabrics or
garment will conventionally bleed from the fabric which
then looks faded and worn. Removal of surface fibers from
the fabric will partly restore the original colours and
looks of the fabric. By the term "colour clarification",
20 as used herein, is meant the partly restoration of the
initial colours of fabric or garment throughout multiple
washing cycles.

- The term "de-pilling" denotes removing of pills from the
25 fabric surface.

- The term "soaking liquor" denotes an aqueous liquor in
which laundry may be immersed prior to being subjected to
a conventional washing process. The soaking liquor may
30 contain one or more ingredients conventionally used in a
washing or laundering process.

- The term "washing liquor" denotes an aqueous liquor in
which laundry is subjected to a washing process, i.e.
35 usually a combined chemical and mechanical action either
manually or in a washing machine. Conventionally, the

washing liquor is an aqueous solution of a powder or liquid detergent composition.

The term "rinsing liquor" denotes an aqueous liquor in which laundry is immersed and treated, conventionally immediately after being subjected to a washing process, in order to rinse the laundry, i.e. essentially remove the detergent solution from the laundry. The rinsing liquor may contain a fabric conditioning or softening composition.

The laundry subjected to the method of the present invention may be conventional washable laundry. Preferably, the major part of the laundry is sewn or unsewn fabrics, including knits, wovens, denims, yarns, and toweling, made from cotton, cotton blends or natural or manmade cellulosics (e.g. originating from xylan-containing cellulose fibers such as from wood pulp) or blends thereof. Examples of blends are blends of cotton or rayon/viscose with one or more companion material such as wool, synthetic fibers (e.g. polyamide fibers, acrylic fibers, polyester fibers, polyvinyl alcohol fibers, polyvinyl chloride fibers, polyvinylidene chloride fibers, polyurethane fibers, polyurea fibers, aramid fibers), and cellulose-containing fibers (e.g. rayon/viscose, ramie, flax/linen, jute, cellulose acetate fibers, lyocell).

Detergent Compositions

According to one aspect of the present invention, the present endoglucanases may typically be components of a detergent composition. As such, they may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or protected enzymes. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo

- Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated
5 nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples
10 of film-forming coating materials suitable for application by fluid bed techniques are given in patent GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric
15 acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238,216.
- 20 The detergent composition of the invention may be in any convenient form, e.g. as powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or nonaqueous.
- 25 The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0-50% of anionic surfactant such as linear
30 alkylbenzenesulfonate (LAS), alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. It may also contain 0-40%
35 of nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamine oxide,

ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

- 5 The detergent composition may additionally comprise one or more other enzymes such as amylase, lipase, cutinase, protease, peroxidase, and oxidase, e.g. laccase.

The detergent may contain 1-65% of a detergent builder or
10 complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered
15 silicates (e.g. SKS-6 from Hoechst). The detergent may also be unbuilt, i.e. essentially free of detergent builder.

The detergent may comprise one or more polymers. Examples
20 are carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

25 The detergent may contain a bleaching system which may comprise a H_2O_2 source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylenediamine (TAED) or
30 nonanoyloxybenzenesulfonate (NOBS). Alternatively, the bleaching system may comprise peroxyacids of, e.g., the amide, imide, or sulfone type.

The enzymes of the detergent composition of the invention
35 may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a

boric acid derivative such as, e.g., an aromatic borate ester, and the composition may be formulated as described in, e.g., WO 92/19709 and WO 92/19708.

- 5 The detergent may also contain other conventional detergent ingredients such as, e.g., fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil-redeposition agents, dyes, bactericides, optical
10 brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11.

15

Particular forms of detergent compositions within the scope of the invention include:

- 1) A detergent composition formulated as a granulate
20 having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	7	-	12%
5	Alcohol ethoxysulfate (e.g. C ₁₂₋₁₈ alcohol, 1-2 EO) or alkyl sulfate (e.g. C ₁₆₋₁₈)	1	-	4%
	Alcohol ethoxylate (e.g. C ₁₄₋₁₅ alcohol, 7 EO)	5	-	9%
	Sodium carbonate (as Na ₂ CO ₃)	14	-	20%
	Soluble silicate (as Na ₂ O, 2SiO ₂)	2	-	6%
10	Zeolite (as NaAlSiO ₄)	15	-	22%
	Sodium sulfate (as Na ₂ SO ₄)	0	-	6%
	Sodium citrate/citric acid (as C ₆ H ₅ Na ₃ O ₇ /C ₆ H ₈ O ₇)	0	-	15%
	Sodium perborate (as NaBO ₃ ·H ₂ O)	11	-	18%
15	TAED	2	-	6%
	Carboxymethylcellulose	0	-	2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0	-	3%
20	Enzymes (calculated as pure enzyme protein)	0.0001	-	0.1%
	Minor ingredients (e.g. suds suppressors, perfume, optical brightener, photobleach)	0	-	5%

2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	6 - 11%
	Alcohol ethoxysulfate (e.g. C ₁₂₋₁₈ alcohol, 1-2 EO or alkyl sulfate (e.g. C ₆₋₁₈))	1 - 3%
10	Alcohol ethoxylate (e.g. C ₁₄₋₁₅ alcohol, 7 EO)	5 - 9%
	Sodium carbonate (as Na ₂ CO ₃)	15 - 21%
	Soluble silicate (as Na ₂ O, 2SiO ₂)	1 - 4%
	Zeolite (as NaAlSiO ₄)	24 - 34%
	Sodium sulfate (as Na ₂ SO ₄)	4 - 10%
15	Sodium citrate/citric acid (as C ₆ H ₅ Na ₃ O ₇ /C ₆ H ₈ O ₇)	0 - 15%
	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 6%
20	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
25	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	5	-	9%
5	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO)	7	-	14%
	Soap as fatty acid (e.g. C ₁₆₋₂₂ fatty acid)	1	-	3%
	Sodium carbonate (as Na ₂ CO ₃)	10	-	17%
10	Soluble silicate (as Na ₂ O, 2SiO ₂)	3	-	9%
	Zeolite (as NaAlSiO ₄)	23	-	33%
	Sodium sulfate (as Na ₂ SO ₄)	0	-	4%
	Sodium perborate (as NaBO ₃ ·H ₂ O)	8	-	16%
	TAED	2	-	8%
15	Phosphonate (e.g. EDTMPA)	0	-	1%
	Carboxymethylcellulose	0	-	2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0	-	3%
20	Enzymes (calculated as pure enzyme protein)	0.0001	-	0.1%
25	Minor ingredients (e.g. suds suppressors, perfume, optical brightener)	0	-	5%

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	8	- 12%
	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO)	10	- 25%
	Sodium carbonate (as Na ₂ CO ₃)	14	- 22%
	Soluble silicate (as Na ₂ O, 2SiO ₂)	1	- 5%
10	Zeolite (as NaAlSiO ₄)	25	- 35%
	Sodium sulfate (as Na ₂ SO ₄)	0	- 10%
	Carboxymethylcellulose	0	- 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1	- 3%
15	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. suds suppressors, perfume)	0	- 5%

5) An aqueous liquid detergent composition comprising

	Linear alkylbenzenesulfonate (calculated as acid)	15	- 21%
5	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO or C ₁₂₋₁₅ alcohol, 5 EO)	12	- 18%
	Soap as fatty acid (e.g. oleic acid)	3	- 13%
	Alkenylsuccinic acid (C ₁₂₋₁₄)	0	- 13%
10	Aminoethanol	8	- 18%
	Citric acid	2	- 8%
	Phosphonate	0	- 3%
	Polymers (e.g. PVP, PEG)	0	- 3%
	Borate (as B ₄ O ₇)	0	- 2%
15	Ethanol	0	- 3%
	Propylene glycol	8	- 14%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brightener)	0	- 5%

6) An aqueous structured liquid detergent composition comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	15	- 21%
	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO, or C ₁₂₋₁₅ alcohol, 5 EO)	3	- 9%
	Soap as fatty acid (e.g. oleic acid)	3	- 10%
10	Zeolite (as NaAlSiO ₄)	14	- 22%
	Potassium citrate	9	- 18%
	Borate (as B ₄ O ₇)	0	- 2%
	Carboxymethylcellulose	0	- 2%
	Polymers (e.g. PEG, PVP)	0	- 3%
15	Anchoring polymers such as, e.g., lauryl methacrylate/acrylic acid copolymer; molar ratio 25:1; MW 3800	0	- 3%
	Glycerol	0	- 5%
20	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
25	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brighteners)	0	- 5%

7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Fatty alcohol sulfate	5	- 10%
5	Ethoxylated fatty acid monoethanol- amide	3	- 9%
	Soap as fatty acid	0	- 3%
	Sodium carbonate (as Na_2CO_3)	5	- 10%
	Soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$)	1	- 4%
10	Zeolite (as NaAlSiO_4)	20	- 40%
	Sodium sulfate (as Na_2SO_4)	2	- 8%
	Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$)	12	- 18%
	TAED	2	- 7%
15	Polymers (e.g. maleic/acrylic acid copolymer, PEG)	1	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. optical brightener, suds suppressors, per- fume)	0	- 5%

8) A detergent composition formulated as a granulate comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	8	- 14%
	Ethoxylated fatty acid monoethano- lamide	5	- 11%
	Soap as fatty acid	0	- 3%
	Sodium carbonate (as Na_2CO_3)	4	- 10%
10	Soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$)	1	- 4%
	Zeolite (as NaAlSiO_4)	30	- 50%
	Sodium sulfate (as Na_2SO_4)	3	- 11%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$)	5	- 12%
15	Polymers (e.g. PVP, maleic/acrylic acid copolymer, PEG)	1	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. suds suppressors, perfume)	0	- 5%

9) A detergent composition formulated as a granulate comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	6	- 12%
	Nonionic surfactant	1	- 4%
	Soap as fatty acid	2	- 6%
	Sodium carbonate (as Na_2CO_3)	14	- 22%
	Zeolite (as NaAlSiO_4)	18	- 32%
10	Sodium sulfate (as Na_2SO_4)	5	- 20%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$)	3	- 8%
	Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$)	4	- 9%
	Bleach activator (e.g. NOBS or TAED)	1	- 5%
15	Carboxymethylcellulose	0	- 2%
	Polymers (e.g. polycarboxylate or PEG)	1	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. optical brightener, perfume)	0	- 5%

10) An aqueous liquid detergent composition comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	15	- 23%
	Alcohol ethoxysulfate (e.g. C ₁₂₋₁₅ alcohol, 2-3 EO)	8	- 15%
	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ al- cohol, 7 EO, or C ₁₂₋₁₅ alcohol, 5 EO)	3	- 9%
10	Soap as fatty acid (e.g. lauric acid)	0	- 3%
15	Aminoethanol	1	- 5%
	Sodium citrate	5	- 10%
	Hydrotrope (e.g. sodium toluensulfonate)	2	- 6%
	Borate (as B ₄ O ₇)	0	- 2%
	Carboxymethylcellulose	0	- 1%
	Ethanol	1	- 3%
	Propylene glycol	2	- 5%
20	Enzymes (calculated as pure en- zyme protein)	0.0001 - 0.1%	
	Minor ingredients (e.g. polymers, dispersants, perfume, optical brighteners)	0	- 5%

11) An aqueous liquid detergent composition comprising

	Linear alkylbenzenesulfonate (calculated as acid)	20	- 32%
5	Alcohol ethoxylate (e.g. C ₁₂₋₁₅ alcohol, 7 EO, or C ₁₂₋₁₅ alcohol, 5 EO)	6	- 12%
	Aminoethanol	2	- 6%
	Citric acid	8	- 14%
	Borate (as B ₄ O ₇)	1	- 3%
10	Polymer (e.g. maleic/acrylic acid copolymer, anchoring polymer such as, e.g., lauryl methacrylate-/acrylic acid copolymer)	0	- 3%
	Glycerol	3	- 8%
15	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. hydrotropes, dispersants, perfume, optical brighteners)	0	- 5%

12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

5	Anionic surfactant (linear alkylbenzenesulfonate, alkyl sulfate, alpha-olefinsulfonate, alpha-sulfo fatty acid methyl esters, alkanesulfonates, soap)	25	- 40%
10	Nonionic surfactant (e.g. alcohol ethoxylate)	1	- 10%
	Sodium carbonate (as Na_2CO_3)	8	- 25%
	Soluble silicates (as Na_2O , 2SiO_2)	5	- 15%
	Sodium sulfate (as Na_2SO_4)	0	- 5%
	Zeolite (as NaAlSiO_4)	15	- 28%
15	Sodium perborate (as $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$)	0	- 20%
	Bleach activator (TAED or NOBS)	0	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. perfume, optical brighteners)	0	- 3%

13) Detergent formulations as described in 1) - 12)
 25 wherein all or part of the linear alkylbenzenesulfonate is replaced by (C_{12} - C_{18}) alkyl sulfate.

14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	(C ₁₂ -C ₁₈) alkyl sulfate	9	- 15%
5	Alcohol ethoxylate	3	- 6%
	Polyhydroxy alkyl fatty acid amide	1	- 5%
	Zeolite (as NaAlSiO ₄)	10	- 20%
	Layered disilicate (e.g. SK56 from Hoechst)	10	- 20%
10	Sodium carbonate (as Na ₂ CO ₃)	3	- 12%
	Soluble silicate (as Na ₂ O, 2SiO ₂)	0	- 6%
	Sodium citrate	4	- 8%
	Sodium percarbonate	13	- 22%
	TAED	3	- 8%
15	Polymers (e.g. polycarboxylates and PVP=	0	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
20	Minor ingredients (e.g. optical brightener, photo bleach, perfume, suds suppressors)	0	- 5%

15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

5	(C ₁₂ -C ₁₈) alkyl sulfate	4	- 8%
	Alcohol ethoxylate	11	- 15%
	Soap	1	- 4%
	Zeolite MAP or zeolite A	35	- 45%
	Sodium carbonate (as Na ₂ CO ₃)	2	- 8%
10	Soluble silicate (as Na ₂ O, 2SiO ₂)	0	- 4%
	Sodium percarbonate	13	- 22%
	TAED	1	- 8%
	Carboxymethyl cellulose	0	- 3%
	Polymers (e.g. polycarboxylates and PVP)	0	- 3%
15	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
	Minor ingredients (e.g. optical brightener, phosphonate, perfume)	0	- 3%

20

16) Detergent formulations as described in 1) - 15) which contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for already specified bleach systems.

25

17) Detergent compositions as described in 1), 3), 7), 9) and 12) wherein perborate is replaced by percarbonate.

18) Detergent compositions as described in 1), 3), 7), 9), 12), 14) and 15) which additionally contain a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", Nature 369, 1994, pp. 637-639.

35

19) Detergent composition formulated as a nonaqueous

detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxyated primary alcohol, a builder system (e.g. phosphate), enzyme and alkali. The detergent may also comprise anionic surfactant and/or a
5 bleach system.

The endoglucanase may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the laundry composition of the in-
10 vention, the cellulase may be added in an amount corresponding to 0.0001-10 mg (calculated as pure enzyme protein) of cellulase per liter of wash liquor.

According to yet another aspect of the present invention,
15 endoglucanase may typically be a component of a fabric conditioning or softener composition. Examples of conventional softener compositions are disclosed in e.g. EP 0 233 910.

20

Textile applications

In another embodiment, the present invention relates to use of the endoglucanase of the invention in the bio-
25 polishing process. Bio-Polishing is a specific treatment of the yarn surface which improves fabric quality with respect to handle and appearance without loss of fabric wettability. The most important effects of Bio-Polishing can be characterized by less fuzz and pilling, increased
30 gloss/luster, improved fabric handle, increased durable softness and altered water absorbency. Bio-Polishing usually takes place in the wet processing of the manufacture of knitted and woven fabrics. Wet processing comprises such steps as e.g. desizing, scouring,
35 bleaching, washing, dyeing/printing and finishing. During each of these steps, the fabric is more or less subjected to mechanical action. In general, after the textiles have

been knitted or woven, the fabric proceeds to a desizing stage, followed by a scouring stage, etc. Desizing is the act of removing size from textiles. Prior to weaving on mechanical looms, warp yarns are often coated with size starch or starch derivatives in order to increase their tensile strength. After weaving, the size coating must be removed before further processing the fabric in order to ensure a homogeneous and wash-proof result. It is known that in order to achieve the effects of Bio-Polishing, a combination of cellulytic and mechanical action is required. It is also known that "super-softness" is achievable when the treatment with a cellulase is combined with a conventional treatment with softening agents. It is contemplated that use of the endoglucanase of the invention for bio-polishing of cellulosic fabrics is advantageous, e.g. a more thorough polishing can be achieved. Bio-polishing may be obtained by applying the method described e.g. in WO 93/20278.

20 Stone-washing

It is known to provide a "stone-washed" look (localized abrasion of the colour) in dyed fabric, especially in denim fabric or jeans, either by washing the denim or jeans made from such fabric in the presence of pumice stones to provide the desired localized lightening of the colour of the fabric or by treating the fabric enzymatically, in particular with cellulytic enzymes. The treatment with an endoglucanase of the present invention may be carried out either alone such as disclosed in US 4,832,864, together with a smaller amount of pumice than required in the traditional process, or together with perlite such as disclosed in WO 95/09225.

Pulp and paper applications

In the papermaking pulp industry, the endoglucanase of the present invention may be applied advantageously e.g. as follows:

- 5 - For debarking: pretreatment with the endoglucanase may degrade the cambium layer prior to debarking in mechanical drums resulting in advantageous energy
10 savings.
- 15 - For defibration: treatment of a material containing cellulosic fibers with the endoglucanase prior to refining or beating may result in reduction of the energy
consumption due to the hydrolysing effect of the
cellulase on the interfibre surfaces. Use of the
endoglucanase may result in improved energy savings as
compared to the use of known enzymes, since it is
believed that the enzyme composition of the invention may
20 possess a higher ability to penetrate fibre walls.
- 25 - For fibre modification, i.e. improvement of fibre properties where partial hydrolysis across the fibre wall is needed which requires deeper penetrating enzymes (e.g.
in order to make coarse fibers more flexible). Deep
treatment of fibers has so far not been possible for high
yield pulps e.g. mechanical pulps or mixtures of recycled
pulps. This has been ascribed to the nature of the fibre
wall structure that prevents the passage of enzyme
30 molecules due to physical restriction of the pore matrix of the fibre wall. It is contemplated that the present
endoglucanase is capable of penetrating into the fibre
wall.
- 35 - For drainage improvement. The drainability of papermaking pulps may be improved by treatment of the pulp with hydrolysing enzymes, e.g. cellulases. Use of

The treatment of lignocellulosic pulp may, e.g., be performed as described in WO 91/14819, WO 91/14822, WO 92/17573 and WO 92/18688.

5

Degradation of plant material

In yet another embodiment, the present invention relates to use of the endoglucanase and/or enzyme preparation
10 according to the invention for degradation of plant material e.g. cell walls.

It is contemplated that the novel endoglucanase and/or enzyme preparation of the invention is useful in the pre-
15 paration of wine, fruit or vegetable juice in order to increase yield. Endoglucanases according to the invention may also be applied for enzymatic hydrolysis of various plant cell-wall derived materials or waste materials, e.g. agricultural residues such as wheat-straw, corn
20 cobs, whole corn plants, nut shells, grass, vegetable hulls, bean hulls, spent grains, sugar beet pulp, and the like. The plant material may be degraded in order to improve different kinds of processing, facilitate purification or extraction of other components like
25 purification of beta-glucan or beta-glucan oligomers from cereals, improve the feed value, decrease the water binding capacity, improve the degradability in waste water plants, improve the conversion of e.g. grass and corn to ensilage, etc.

30

The following examples illustrate the invention.

EXAMPLE 1

Cellulytic enzymes from 4 fungi, belonging to 3 families under two orders within the Ascomycetes were detected by
5 expression cloning; corresponding DNA sequences were determined; the enzymes heterologously expressed, and produced by liquid fermentation, characterized and demonstrated to give good performance in colour clarification assays.

10

Isolate CBS 117.65, CBS 478.94, NRRL 8126, and ATCC 10523 were grown in shake flask cultures on cellulose enriched potato dextrose broth, incubated for 5 days at 26°C (shaking conditions, 150 rpm).

15

A. Cloning and expression of an endoglucanase from *Myceliophthora thermophila*, *Acremonium sp.*, and *Thielavia terrestris* and *Volutella colletotrichoides*

20 mRNA was isolated from *Myceliophthora thermophila*, *Acremonium sp.*, *Thielavia terrestris* and *Volutella colletotrichoides*, respectively, grown in a cellulose-containing fermentation medium with agitation to ensure sufficient aeration. Mycelia were harvested after 3-5
25 days' growth, immediately frozen in liquid nitrogen and stored at -80°C. Libraries from *Myceliophthora thermophila*, *Acremonium sp.*, *Thielavia terrestris* and *Volutella colletotrichoides*, respectively, each consisting of approx. 10⁶ individual clones were
30 constructed in *E. coli* as described with a vector background of 1%.

Plasmid DNA from some of the pools from each library was transformed into yeast, and 50-100 plates containing 250-
35 400 yeast colonies were obtained from each pool.

Endoglucanase-positive colonies were identified and

isolated on SC-agar plates with the AZCL HE cellulose assay. cDNA inserts were amplified directly from the yeast colonies and characterized as described in the Materials and Methods section above.

5

The DNA sequence of the cDNA encoding the endoglucanase from *Myceliophthora thermophila* is shown in SEQ ID No. 1 and the corresponding amino acid sequence is also shown in SEQ ID No. 1. The cDNA is obtainable from the plasmid
10 in DSM 9770.

The DNA sequence of the cDNA encoding the endoglucanase from *Acremonium sp.* is shown in SEQ ID No. 4 and the corresponding amino acid sequence is shown in SEQ ID No.
15 5. The cDNA is obtainable from the plasmid in DSM 10082.

The DNA sequence of the cDNA encoding the endoglucanase from *Thielavia terrestris* is shown in SEQ ID No. 8 and the corresponding amino acid sequence is shown in SEQ ID
20 No. 9. The cDNA is obtainable from the plasmid in DSM 10081.

The DNA sequence of the cDNA encoding the endoglucanase from *Volutella colletotrichoides* is shown in SEQ ID No.
25 16 and the corresponding amino acid sequence is shown in SEQ ID No. 17. The cDNA is obtainable from the plasmid in DSM 10571.

Total DNA was isolated from a yeast colony and plasmid
30 DNA was rescued by transformation of *E. coli* as described above. In order to express the endoglucanases in *Aspergillus*, the DNA was digested with appropriate restriction enzymes, size fractionated on gel, and a fragment corresponding to the endoglucanase gene from
35 *Myceliophthora thermophila*, *Acremonium sp.*, *Thielavia terrestris* and *Volutella colletotrichoides*, respectively, was purified. The genes were subsequently ligated to

PHD414, digested with appropriate restriction enzymes, resulting in the plasmids pA2C193, pA2C357, pA2C385 and pA2C488, respectively.

- 5 After amplification of the DNA in *E. coli* the plasmids were transformed into *Aspergillus oryzae* as described above.

Test of *A. oryzae* transformants

- 10 Each of the transformants were tested for endoglucanase activity as described above. Some of the transformants had endoglucanase activity which was significantly larger than the *Aspergillus oryzae* background. This demonstrates efficient expression of the endoglucanases in *Aspergillus*
15 *oryzae*. The transformants with the highest endoglucanase activity were selected and inoculated in a 500 ml shake flask with YPM media. After 3-5 days of fermentation with sufficient agitation to ensure good aeration, the culture broth was centrifuged for 10 minutes at 2000 g and the
20 supernatant recovered.

B. Determination of endoglucanase activity

- The cellulytic activity of the endoglucanase may be
25 determined relative to an analytical standard and expressed in the unit S-CEVU.

- Cellulytic enzymes hydrolyse CMC, thereby decreasing the viscosity of the incubation mixture. The resulting
30 reduction in viscosity may be determined by a vibration viscosimeter (e.g. MIVI 3000 from Sofraser, France).

- Determination of the cellulytic activity, measured in terms of S-CEVU, may be determined according to the
35 analysis method AF 301.1 which is available from the Applicant upon request.

The S-CEVU assay quantifies the amount of catalytic activity present in the sample by measuring the ability of the sample to reduce the viscosity of a solution of carboxy-methylcellulose (CMC). The assay is carried out
5 at 40°C, pH 7.5 using a relative enzyme standard for reducing the viscosity of the CMC substrate.

Assay for determination of endoglucanase activity in terms of SAVI units using phosphoric-acid swollen cellulose (PASC):
10 lose (PASC):

Definition:

1 SAVI-U is the amount of enzyme which forms an amount of reducing carbohydrates equivalent to 1 μ mol of glucose
15 per minute.

Assay condition:

Enzyme solution: 0,5 ml
4 g/l PASC in 0,1 M Buffer: 2.0 ml
20 20 min, 40 °C

Sensitivity:

Max 0.1 SAVIU/ml = approx. 1 S-CEVU/ml (CMC viscosity)
Min 0.01 SAVIU/ml = approx. 0.1 S-CEVU/ml
25

Determination of formation of reducing sugars:

The reducing groups assay was performed according to Lever, M. A new reaction for colormetric determination of
30 carbohydrates. Anal. Biochem. 1972. Vol 47 (273-279).
Reagent mixture was prepared by mixing 1,5 gram p-hydroxybenzoic-acide hydracide (PHBAH) with 5 gram sodium tartrate in 100 ml 2 % sodium hydroxide.

35 Substrate:

PASC stock solution was prepared the following way using

ice cold acetone and phosphoric acid. 5 gram of cellulose (Avicel[®]) was moistened with water, and 150 ml ice cold 85% ortho-phosphoric acid was added. The mixture was placed in ice bath under slow stirring for 1 hr. Then 100
5 ml ice cold acetone was added with stirring. The slurry was transferred to a Buchner filter with pyrex sintered disc number 3 and then washed three times with 100 ml ice cold acetone, and sucked as dry as possible after each wash. Finally, the filter cake was washed twice with 500
10 ml water, sucked as dry as possible after each wash. The PASC was mixed with deionized water to a total volume of 300 ml, blended to homogeneity (using the Ultra Turrax Homogenizer) and stored in refrigerator (up to one month).

15 Substrate equilibration with buffer: 20 gram phosphoric acid swollen cellulose PASC stock solution was centrifuged for 20 min at 5000 rpm., the supernatant was poured of; the sediment was resuspended in 30 ml of buffer and
20 centrifuged for 20 min. at 5000 rpm., the supernatant was poured of, and the sediment was resuspended in buffer to a total of 60 g corresponding to a substrate concentration of 5 g cellulose/litre.

25 Buffer for pH 8,5 determination: 0.1 M Barbital.
Buffer for pH 10 determination: 0.1 M Glycine.

Procedure:

1. Dilution of enzyme samples

30 The enzyme solution is diluted in the same buffer as the substrate.

2. Enzyme reaction

The substrate in buffer solution is preheated for 5 min.
35 at 40°C (2 ml).

Then the enzyme solution (diluted to between 0.2 and 1 S-CEVU/ml) 0,5 ml is added and mixed for 5 sec. Enzymes

blanks are obtained by adding the stop reagent before enzyme solution. Incubate for 20 min. at 40 °C. The reaction is stopped by adding 0.5 ml 2% NaOH solution and mixing for 5 sec.

5

The samples are centrifuged for 20 min. at 5000 rpm. 1 ml supernatant is mixed with 0.5 ml PHBAH reagent and boiled for 10 min. The test tubes are cooled in a ice water bath.

10

3. Determination of reducing end groups:

The absorbancy at 410 nm is measured using a spectrophotometer. Blanks are prepared by adding sodium hydroxide before adding enzyme solution.

15

A standard glucose curve was obtained by using glucose concentrations of 5, 10, 15 and 25 mg/l in the same buffer and adding PHBAH reagent before boiling. The release of reducing glucose equivalent is calculated using this standard curve.

20

4. Calculation of catalytic activity:

Measure absorbance at 410 nm

25

1) Standard curve

(Glucose) - (H₂O) vs concentration of glucose

30 2) Enzyme sample

(Sample) - (Blank)

Calculate glucose concentration according to a standard curve

35

Activity (SAVIU/ml):

$$X \text{ (mg glucose/l)} * \text{Dilution}$$

5
$$180.16 \text{ (MW of glucose)} * 20 \text{ (min)}$$

C. Purification and characterisation of the endoglucanase from *M. thermophila*

10

Aspergillus oryzae transformed with pA2C193 was grown on YPM medium for 4 days. The liquid was then centrifuged and sterile filtered.

- 15 The sample was concentrated by ultrafiltration on AMICON cells using a DOW membrane GR61PP with cut-off 20 kD. The Uf-concentrate was analyzed for S-CEVU/ml and SaviU/ml with the following result:

20

UF-concentrate	S- CEVU/ml	SaviU/ml
9.25 ml	570	41

Purification:

- 2 ml of the UF-concentrate was diluted 5 times to lower
25 the ionic strength and filtered through 0.22 μ m disk filter. This sample was applied to a Mono Q⁺ HR5/5 Pharmacia column, equilibrated with 50 mM Tris/HCl buffer, pH 7.5, (buffer A) and a flow of 1 ml/min. After wash to baseline, with buffer A, the column was eluted with a
30 Tris/HCl buffer, pH 7.5, containing 1 M NaCl (buffer B), the elution gradient was 0-50% buffer B in 1 hour.

- After 36 min. a peak complex showed up, 1 ml fractions
were picked up and the first 10 fractions showed
35 cellulase activity on CMC/Agarose/congo-red plates.

These fractions were pooled and concentrated, by ultrafiltration on AMICON cells using a DOW membrane GR61PP with cut-off 20 kD, to 3 ml.

- 5 This sample was applied to a HiLoad 26/60 Superdex 75™ prep grade Pharmacia column, equilibrated with 100 mM Na-Acetate buffer, pH 6.35, and a 1 ml/min flow.

- After 82 min. a peak showed up, 1 ml fractions were
10 picked up and the first 10 fractions showed cellulase activity on CMC/Agarose/congo-red plates.

These fractions were pooled and the following results were obtained:

- 15 $A_{280}=0.15$
 $A_{280}/A_{260}=1.62$
 $Mw(SDS)=22 \text{ kD}$
 $pI=3.5 - 5$
Purity on SDS-PAGE =100%
20 $S\text{-CEVU/ml}=28.5$
 $S\text{-CEVU}/A_{280}=188$
 $S\text{-CEVU/mg}=436$
Extinction coefficient=54880 (calculated)
 $Mw(\text{calculated})=22 \text{ kD}$

25

The Extinction coefficient is based on the content of tyrosine, tryptophane and cystein calculated from the sequence of the enclosed SEQ ID No. 1 (the amino acid sequence). SDS-Page was performed on NOVEX Pre-Cast Gels

- 30 4-20% Tris-Glycine Gel 1.0 mm x 10 Well

IEF was performed on Pharmacia PAGplate pH 3.5 - 9.5, the activity was visualized by CMC-Congored overlaying.

- 35 Determination of K_M & k_{cat} :

k_m and k_{cat} was determined in the same manner as the determination of SAVI Units at pH 8.5 with a substrate

concentration up to 8 g/l.

The following results were obtained:

5 k_{cat} 38 per .sec.

k_m 5 g/l,

phosphoric acid swollen cellulose, pH 8.5.

Specific activity on CMC at pH 7.5:

10 436 S-CEVU per mg protein.

**D. Determination of pH and temperature profile of the
endoglucanase from *M. thermophila***

15

The pH profile was determined at the following
conditions:

20 Buffers of pH values between 2.5 and 10.0 were made by
mixing 0.1M Tri-sodium phosphate with 0.1M citric acid.
Purified endoglucanase was diluted to ensure the assay
response to be within the linear range of the assay. The
substrate was a 0.4% suspension of AZCL-HE-cellulose
(MegaZyme) mixed 1:1 with the citrate/phosphate buffer to
25 a final substrate concentration of 0.2% AZCL-HE-
cellulose. 1 ml substrate in Eppendorf® 1.5ml
polypropylene tubes were added 10 μ l of enzyme solution
and incubated for 15 minutes in Eppendorf® temperature
controlled Thermomixers before heat-inactivation of
30 enzymes for 20 minutes at 95°C in a separate Thermomixer.
The tubes were centrifuged and 200 μ l of each supernatant
was transferred to a well in a 96 well microtiter plate
and OD was measured at 620nm in an ELISA reader
(Labsystems Multiskan® MCC/340).

35

For the pH optimum incubations took place at 30°C. For
each pH value, three tubes were added enzyme and

incubated before heat-inactivation, whereas one tube (the blank) was added enzyme and heat-inactivated immediately. The mean value of the three incubated samples was calculated and the blank value was subtracted.

5

The following pH profile was determined:

	pH	Relative Activity
	2.5	<10%
10	3	<10%
	3.5	22%
	4	87%
	4.5	89%
	5	100%
15	6	94%
	6.5	86%
	7	78%
	7.5	73%
	8	68%
20	8.5	54%
	9	31%
	10	18%

25 It is seen that the endoglucanase has more than 60% activity between pH 4.0 and 8.0 and optimal activity at pH 5.0-6.0.

Temperature profile:

The temperature optimum was determined in the same manner at pH 5.5. The temperatures ranged from 30°C to 80°C. For each temperature three incubations were carried out and the mean calculated. Three blanks were produced by
5 immediate heat-inactivation of enzyme and the mean was subtracted from the incubated sample values.

It is seen that the endoglucanase has optimal activity at 50-70°C.

10

Temp. (°C)	30	40	50	60	70	80
Relative Activity	74%	77%	99%	100%	93%	62%

15 The temperature stability was determined in the same manner at pH 5.5 and 30°C, and, further, the enzyme solutions were preheated for 1 hour at the actual temperature and cooled on ice. The residual activity is shown below in % of the activity of a non-preheated enzyme sample:

20

Temp. (°C)	40	50	60	70	80
Relative Activity	95%	84%	92%	86%	24%

25

E. Color clarification of Myceliophthora cellulase (SEQ ID No. 1) measured as removal of surface fibrils and fibers protruding from the yarn of a textile containing cellulosic fibers

5

Apparatus : Terg-o-tometer
 Liquid volume : 100 ml
 Agitation : 150 movements/min with vertical stirrer

10

Rinse time : 5 min in tapwater
 Washing temp : 40°
 Washing liquor : 0.05 M phosphate buffer
 pH : 7.0
 Washing time : 30 min

15

Repetitions : 2
 Enzymes : Myceliophthora SEQ ID No. 1B
 Dosage : 500 and 2500 S-CEVU/l
 Textile : 2 swatches of aged black 100% cotton 5x6 cm (0.9 gram)

20

Drying : Tumble dry
 Evaluation : The light remission is measured by a Datacolor Elrepho Remission spectrophotometer. Remission is calculated as delta L (Hunter Lab-values). When the surface fibrils and fibers protruding from the yarn are removed by the cellulase, the surface of the black fabric appears darker, and lower L values are obtained.

25

30

The sample is compared with a blind sample, i.e. washed without enzyme:

No cellulase 500 ECU/l 2500 ECU/l

35 0.00 -1.41 -1.91

Delta L-values compared to blind sample.

The data shows that Myceliophthora cellulase without CBD gives good color clarification under the conditions tested.

5

F. Construction of the gene fusions between the endoglucanase from Myceliophthora thermophila and the 43kD endoglucanase from Humicola insolens

- 10 The purpose of the two constructions was to make derivatives of the endoglucanase from *M. thermophila* with the linker and CBD from the 43kD endoglucanase from *H. insolens* (disclosed in WO 91/17243). The native endoglucanase from *M. thermophila* do not have a linker
15 and/or a cellulose binding domain, CBD.

CM1: Construction 1 consist of the endoglucanase from *M. thermophila* (225 amino acids) and the 72 C-terminal amino acids from the *H. insolens* 43kD endoglucanase.

20

CM2: Construction 2 consist of the endoglucanase from *M. thermophila* (225 amino acids) and the 83 C-terminal amino acids from the *H. insolens* 43kD endoglucanase.

- 25 The 43kD endoglucanase cDNA from *H. insolens* was cloned into pHD414 in such a way that the endoglucanase gene was transcribed from the Taka-promoter. The resulting plasmid was named pCaHj418.

- 30 In a similar way the cDNA encoding the endoglucanase from *M. thermophila* was cloned into pHD414 and the resulting plasmid was named pA2C193.

Primers:

primer 1: 5'-

CGGAGCTCACGTCCAAGAGCGGCTGCTCCCGTCCCTCCAGCAGCACCAGCTCTCCGG

5 -3'

primer 2: 5'

CCGGAGAGCTGGTGCTGCTGGAGGGACGGGAGCAGCCGCTCTTGGACGTGAGCTCCG

-3'

primer 3: 5'-

10 CGGAGCTCACGTCCAAGAGCGGCTGCTCCCGTAACGACGACGGCAACTTCCCTGCCG

-3'

primer 4: 5'-

CGGCAGGGAAGTTGCCGTCGTCGTTACGGGAGCAGCCGCTCTTGGACGTGAGCTCCG

-3'

15 Taka-pro. primer: 5' CAACATCACATCAAGCTCTCC -3'

AMG-term. primer: 5' CCCCATCCTTTAACTATAGCG -3'

The endoglucanase fusions were constructed by the PCR overlap-extension method as described by Higuchi et al.

20 1988.

Construction 1:

Reaction A: The Polymerase Chain Reaction (PCR) was used to amplify the fragment of pCaHj418 between primer 1 and AMG-term. primer (the linker and CBD from the 43kD endoglucanase from H.insolens).

Reaction B: PCR amplification of the fragment between Taka-pro. primer and primer 2 in pA2C193, the endoglucanase gene from M.thermophila.

Reaction C: The two purified fragments were used in a third PCR in the presence of the primers flanking the total region, i.e. Taka-pro. primer and AMG-term. primer.

35 Construction 2:

The same procedure was used where primer 3 and primer 4

had replaced respectively primer 1 and primer 2.

The fragment amplified in reaction C was purified,
digested with restriction enzymes Xba I and BstE II. The
5 purified digested fragment was ligated into pA2C193
digested with restriction enzymes Xba I and BstE II.

Competent cells from E. coli strain DH5 α F' (New England
Biolabs.) were transformed with the ligated plasmid and
10 colonies containing the gene fusion were isolated. The
sequence of the cloned part was verified by DNA
sequencing.

The sequence of the gene in the two constructs are shown
15 in SEQ ID No. 2A and SEQ ID No. 3A.

Polymerase Chain Reactions were carried out under
standard conditions, as recommended by Perkin-Elmer.

20 Reaction A and B started with 2 min. at 94°C followed by
20 cycles of (30 sec. at 94°C, 30 sec. at 50°C and 1 min.
at 72°C) and end with 4 min. at 72 °C.

Reaction C started with (2 min. at 94°C, 1 min. at 52°C
25 and 2 min. at 72°C), followed by 15 cycles of (30 sec. at
94°C, 30 sec. at 52°C and 90 sec. at 72°C) and end with 4
min. at 72°C.

The two constructs were transformed into Aspergillus ory-
30 zae as described above.

G. Purification and characterisation of cloned cellulases with cellulose binding domains:

35

The cloned product is recovered after fermentation by
separation of the extracellular fluid from the production

organism.

About one gram of cellulase is then highly purified by affinity chromatography using 150 gram of Avicel in a slurry with 20 mm Sodium- phosphate pH 7.5.

5

The Avicel is mixed with the crude fermentation broth which contain total about 1 gram of cellulase. After mixing at 4 C for 20 min the Avicel enzyme is packed into a column with a dimension of 50 times 200 mm about 400 ml total.

10

The column is washed with the 200 ml buffer, then washed with 0.5 M NaCl in the same buffer until no more protein elutes. Then washed with 500 ml 20 mm Tris pH 8.5.

15

Finally the pure full length enzyme is eluted with 1% triethylamine pH 11.8.

The eluted enzyme solution is adjusted to pH 8 and concentrated using a Amicon cell unit with a membrane DOW GR61PP (polypropylene with a cut off of 20 KD) to above 5 mg protein per ml.

20

The purified cellulases were characterised as follow:

	Mw	pI	Molar E.280	S-CEVU per
25	SDS-PAGE			A.280
Myceliophthora				
(SEQ ID No.2)	43 kD	4	74.950	135
Acremonium				
30 (SEQ ID No.5)	40 kD	5	68.020	185
Thielavia				
(SEQ ID No.9)	35 kD	4.3	52.470	75

	pH Activity above 50%	N-terminal	Termo- stability DSC	
5				
	Myceliophthora			
	(SEQ ID No.2)	5.0-9.0	Blocked.	80°C
	Acremonium			
	(SEQ ID No.5)	6.0-9.5	Blocked.	61°C
10	Thielavia			
	(SEQ ID No.9)	5.0-9.0	ASGSG---	83°C

The purified cellulases was analysed for MW by SDS-PAGE
15 and using standard LMW protein marker kit from Pharmacia
the MW was calculated for the cellulases. The MW is
apparently higher than the MW of the composition of the
coding amin acids and is due to the fact the linker
region are O-glycosylated resulting in this higher MW.
20 The pI was determined using a Pharmacia Ampholine PAG
plates pH 3.5 to 9.5 and again using a Pharmacia kit with
known pI proteins.

The molar extinction coefficient was calculated based on
25 the amin acids composition using the known absorbance of
Tryptophan, Tyrosine and Cystein.

pH activity profile was obtained using CMC substrate,
incubation for 20 min at 40° C at a 0.5 pH interval and
30 measuring the formation of reducing sugars. The relative
activity at the different pH was calculated and the table
contain the interval with more than 50% relative activity
has been measured.

35 The N-terminal was determined for the purified cellulase
using a Applied Biosystems model 473A sequencer. The
protein sequenceer was run according to the manufacturer

instructions.

Two of the cellulases were blocked, this is due to the N-terminal glutamine which form a pyroglutamate which can
5 not be detected and which block for further sequencing. DSC Differential scanning calorimetry was done at neutral pH (7.0) using a MicroCalc Inc. MC calorimeter with a constant scan rate and raising the temperature from 20 to 90° at a rate of 90° per hour.

10

Raising antibody. The cellulases from Myceliophthora, Acremonium and Thielavia were used for raising antibody in rabbits. 0.1 mg of the purified cellulase in 0.9 % NaCl solution mixed with Freund's adjuvant immediately prior to
15 injection. The rabbits were immunized 10 times with one week interval. The immunoglobulin G fraction (IgG) was purified by ammonium sulfate precipitation (25% saturation). the precipitate was solubilized in water and then dialyzed extensively against sodium acetate buffer
20 (pH 5.0, 50 mM) altering with deionized water. After filtration, the IgG fraction was stabilized with sodium azide (0.01%).

Using immunodiffusion in agar plates all three cellulases
25 form a single immunoprecipitate with its homologous antiserum and no precipitate was seen between the 3 cloned cellulases and the sera raised against the other two cellulases.

30

H-I. Performance of endoglucanase of construction 1 (SEQ ID No. 2) measured in buffer as removal of surface fibrils and fibers protruding from the yarn of a textile containing cellulosic fibers

- 5
- Apparatus : Terg-o-tometer
- Liquid volume : 100 ml
- Agitation : 150 movements/min (rpm)
- Rinse time : 5 min in tap water
- 10 Washing temp : 40°C
- Water Hardness : 1 mM CaCl₂
- Washing liquor : 0.05 M phosphate buffer
- pH : 7.0
- Washing time : 30 min
- 15 Repetitions : 2
- Textile : 2 swatches of aged black,
100% cotton 5x6 cm
- Drying : Tumble dry

20 **Evaluation:**

The light remission was measured by a Macbeth Color Eye 7000 Remission spectrophotometer. Remission is calculated as delta L (Hunter Lab-values). When the surface fibrils and fibers protruding from the yarn were removed by the

25 cellulase, the surface appeared more bright, and lower L values were obtained.

Results:

30

S-CEVU/1	0	250	1000
Inventive enzyme	0	-1.4	-1.6

The data show that the enzyme of the invention gives very good color clarification under the conditions tested.

H-II. Performance of cloned endoglucanase from *Thielavia terrestris* (SEQ ID No.9) in buffer measured as removal of surface fibrils and fibers protruding from the yarn of a textile containing cellulosic fibers

5

- Apparatus : Terg-o-tometer
Liquid volume : 100 ml
Agitation : 150 movements/min with vertical stirrer
10 Rinse time : 10 min in tapwater
Washing temp : 40°
Washing liquor : 0.05 M phosphate buffer.
pH : 7.0
Washing time : 30 min
15 Repetitions : 2
Textile : 2 swatches of aged black cotton 5x6 cm (app. 150 g/m²)
Drying : Tumble dry
Evaluation :
20 The light remission was measured by a Datacolor Elrepho Remission spectrophotometer. Remission is calculated as delta L (Hunter Lab-values). When the surface fibrils and fibers protruding from the yarn are removed by the cellulase, the surface of the black fabric appears darker
25 and nicer, and lower L values are obtained.

Results:

30	S-CEVU/1	0	50	200
	Inventive enzyme	0	-0.66±0.10	-1.32±0.06

The data show that the cellulase gives good color clarification under the conditions tested.

35

H-III. Performance of endoglucanase of *Volutella collettrichoides* (SEQ ID No. 17) measured in buffer as removal of surface fibrils and fibers protruding from the yarn of a textile containing cellulosic fibers

5

Apparatus : Terg-o-tometer
Liquid volume : 100 ml
Agitation : 150 movements/min with vertical stirrer

10 Rinse time : 5 min in tapwater

Washing temp : 40°

Washing liquor : 0.05 M phosphate buffer

pH : 7.0

Washing time : 30 min

15 Repetitions : 2

Dosage : 2.5 S-CEVU/ml

Textile : 2 swatches of aged black 100% cotton
5x6 cm (0.9 gram)

Drying : Tumble dry

20 Evaluation:

The light remission is measured by a Datacolor Elrepho Remission spectrophotometer. Remission is calculated as delta L (Hunter Lab-values). When the surface fibrils and fibers protruding from the yarn are removed by the cellulase, the surface of the black fabric appears darker, and lower L values are obtained.

25

The sample is compared with a blind sample, i.e. washed without enzyme:

30

No cellulase	With cellulase
0.00	-0.57

Delta L remission values compared to blind sample.

35 The data shows that the *Volutella collettrichoides* cellulase gives good color clarification under the conditions tested.

H-IV. Performance of cloned cellulases from *Thielavia terrestris* and *Acremonium* sp. CBS 478.94 in high pH heavy duty detergent measured as removal of surface fibrils and fibers protruding from the yarn of a textile containing
5 cellulosic fibers

	Apparatus	:	Terg-o-tometer
	Liquid volume	:	150 ml
10	Agitation	:	150 movements/min with vertical stirrer
	Rinse time	:	10 min in tapwater
	Washing temp	:	35°C
	Washing liquor	:	1.0 g/l US type HDG (zeolite/soda built, anionic/nonionic weight ratio > 2.5)
15	pH	:	10.0
	Hardness	:	1.0 mM CaCl ₂ 0.34 mM MgCl ₂
	Washing time	:	12 min
20	Repetitions	:	6
	Textile	:	2 swatches of aged black cotton 5x6 cm (app. 150 g/m ²) 2 swatches of heavy knitted cotton 5x6 cm (app. 600 g/m ²)
25	Drying	:	Tumble dry

Evaluation :

The light remission is measured by a Datacolor Elrepho Remission spectrophotometer. Remission is calculated as delta L (Hunter Lab-values). When the surface fibrils and
30 fibers protruding from the yarn are removed by the cellulase, the surface of the black fabric appears darker and nicer, and lower L values are obtained. Different dosages of cloned cellulases from *Thielavia terrestris* (SEQ ID No. 9) and *Acremonium* sp. CBS 478.94 (SEQ ID
35 No.5), respectively, (denoted A and B, respectively) were tested.

Results:

S-CEVU/l	0	500	2000
A	0	-2.09 ±0.22	-2.86 ±0.19
B	0	-0.60 ±0.36	-1.96 ±0.23

5

The data show that both cellulases gives good color clarification under the conditions tested.

- 10 H-V. Performance of cellulases cloned from *Thielavia terrestris* and *Acremonium* sp. CBS 478.94, and construction 1 (SEQ ID No.2) measured as removal of surface fibrils and fibers protruding from the yarn of a textile containing cellulosic fibers

15

Apparatus : Terg-o-tometer
 Liquid volume : 150 ml
 Agitation : 150 movements/min with vertical stirrer
 20 Rinse time : 10 min in tapwater
 Washing temp : 35°C
 Hardness : 1.0 mM CaCl₂
 0.34 mM MgCl₂
 Washing liqour : 2.0 g/l HDL (neutral, citrate built
 25 HDL, with nonionic/anionic weight ratio > 0.5)
 pH : 7.5
 Washing time : 30 min
 Repetitions : 2
 30 Textile : 2 swatches of aged black cotton 5x6 cm (app. 150 g/m²)
 2 swatches of heavy knitted cotton 4x7 cm (app. 600 g/m²)

Drying : Tumble dry

Evaluation :

The light remission is measured by a Datacolor Elrepho
Remission spectrophotometer. Remission is calculated as
5 delta L (CIE Lab-values). When the surface fibrils and
fibers protruding from the yarn are removed by the
cellulase, the surface of the black fabric appears darker
and nicer, and lower L values are obtained. Three
different dosages Different dosages of cloned cellulases
10 from *Thielavia terrestris* (SEQ ID No. 9) and *Acremonium*
sp. CBS 478.94 (SEQ ID No.5) and the construction 1 (SEQ
ID No.2), respectively, (denoted A and B and C,
respectively) were tested.

Results:

15	S- CEVU/1	0	100	200	400
	A	0	-3.06 ±0.24	-3.15 ±0.27	-3.92 ±0.26
	B	0	-1.75 ±0.27	-3.08 ±0.32	-3.51 ±0.44
	C	0	-1.84 ±0.39	-1.70 ±0.47	-2.30 ±0.61

20

The data show that all cellulases gives very good color
clarification under the conditions tested.

25 I. Application of endoglucanases from *Thielavia terre-*
stris, *Acremonium sp.* and construction 1 (SEQ ID No. 2)
in denim finishing

Experimental

30 Apparatus: Washing machine Wascator FL 120
Liquid volume: 20 L
Fabric: 1.1 kg denim fabric, 14½ oz 100 %

- cotton
- Desizing: 10 min, 55°C, pH 7
50 ml Aquazyme 120L
2.5 g/l Phosphate buffer
- 5 Abrasion: 2 hours;

pH and temperature varied according to the following table:

10	<u>Enzyme</u>	<u>Activity</u>	<u>pH/temp</u>	<u>Buffer system</u>
	SEQ ID			
	No. 2	1400 S-CEVU/g	6/55°C	2.5 g/l phosphate buffer
	No. 9	292 S-CEVU/g	5/65°C	1 g/l citrate buffer
15	No. 5	782 S-CEVU/g	7/45°C	2.5 g/l phosphate buffer

Inactivation: 15 min, 80°C
1 g/l sodium carbonate

- 20 Rinses: Three rinse cycles of 5 min in cold
tap water

Evaluation:

- Abrasion: The remission from the fabric was determined at
25 420 nm using a Texflash 2000 as a measure of the abrasion
level.

- The results from the treatment of the denim fabric with
different endoglucanases of the invention is shown in the
30 following table:

	Enzyme	Dosage	Trial conditions	Abrasion 420 nm
	Blank	0 S-CEVU/g textile	pH 6, 55°C	9.96
	SEQ ID No. 2	10 S-CEVU/g textile	pH 6, 55°C	14.37
5	Blank	0 S-CEVU/g textile	pH 5, 65°C	9.26
	SEQ ID No. 9	10 S-CEVU/g textile	pH 5, 65°C	16.86
	Blank	0 S-CEVU/g textile	pH 7, 45°C	9.47
10	SEQ ID No. 5	10 S-CEVU/g textile	pH 7, 45°C	14.08

All tested cellulases show excellent performance in denim finishing, although each enzyme is unique in its own way. When applying the enzyme corresponding to SEQ ID No. 2 for denim finishing it is possible to reach a high abrasion level with a minimum of strength loss. When treating denim with the enzyme corresponding to SEQ ID No. 9, a very high wash down can be reached which leaves the fabric with an almost bleached appearance. Denim finishing with the enzyme corresponding to SEQ ID No. 5 gives a high abrasion level at a low temperature optimum which makes it possible to reduce the processing temperature and save energy.

25

J. Use of cloned cellulases from *Acremonium* sp. and *Thielavia terrestris* for Biopolishing of lyocell fibers

Lyocell fibers which are sold under the trade name Tencel

are spun from wood pulp cellulose in a more environmentally friendly waterbased solvent than is the case for normal viscose production). However, the fibers have a tendency to fibrillate when they are processed
5 into textiles which is seen on the surface and denoted "fuzz". By using cellulases it is possible to permanently remove the exposed and fuzzy fibers and significantly improve the look of the finished fabric, the treatment generally known as Biopolishing. The endoglucanases of
10 the present invention are especially suited for the removal of Lyocell surface fibers.

MATERIALS AND METHODS

The textile substrate was either 100 % woven or different
15 kinds of jersey knitted dark blue Tencel. The dark colour and jersey knit was preferred in order to enhance the visual effects which simplified the evaluation. A woven 70/30 Tencel/Rayon blend was also used to a lesser extent.

20 The assays were either performed in 200 ml scale using a Launder-o-meter or in the 20 l scale using a Wascator. The treatment time was 60min at 55° C in Wascator and 60-90 min in LOM. The buffer was 2 g/l sodium acetate adjusted to pH 5 with acetic acid. The fabric to liquid
25 ratio was 1:10 but in the Launder-o-meter 20 steel balls with a diameter of 14 mm (11 g each) was used to obtain sufficient mechanical abrasion. The biopolishing was immediately followed by inactivation using 2 g/lit sodium carbonate at 80° C for 15 min followed by rinsing in cold
30 water.

The results were evaluated using a fuzz note scale from 1 - 5 where 1 is the fibrillated look of the starting material and 5 is a high quality look with no visible fibers on the surface. Since the performance of
35 endocellulases is specific towards a surface treatment the weightloss is below 2 % and is therefore not included in the evaluation. Two cellulases were evaluated: the

cellulases cloned from *Acremonium sp.* (SEQ ID No. 5) and from *Thielavia terrestris* (SEQ ID No. 9).

The two cellulases are able to defibrillate both Tencel
5 and Tencel blended fabrics. By using an endoglucanase of the invention, only small fibrils are removed rather than whole fibers such as is the case when using acid
cellulase mixtures from *Trichoderma*. The strength loss of the treated fabric is therefore kept at a minimum when
10 using endoglucanases of the present invention.

The following dosages gave a superior defibrillation, i.e. fuzz note 4 or above:

15 15 S-CEVU/g fabric of cellulase from *Acremonium sp* (SEQ ID No. 5); and
10 S-CEVU/g fabric of cellulase from *Thelavia terrestris* (SEQ ID No.9).

20

EXAMPLE 2

A new cellulytic enzyme was by expression cloning as well as by PCR cloning detected to be produced by a plant pathogen, isolated from soy bean seeds and identified as *Macrophomina phaseolina*.
25

Production of biomass for PCR and expression cloning procedures:

Isolate CBS 281.96 was grown in shake flask cultures on
30 cellulose enriched potato dextrose broth, incubated for 5 days at 26°C (shaking conditions: 150 rpm).

A. Cloning and expression of an endoglucanase from *Macrophomina phaseolina*

35

mRNA was isolated from *Macrophomina phaseolina*, grown in a cellulose-containing fermentation medium with agitation

to ensure sufficient aeration. Mycelia were harvested after 3-5 days' growth, immediately frozen in liquid nitrogen and stored at -80°C. A library from *Macrophomina phaseolina*, consisting of approx. 10⁶ individual clones
5 was constructed in *E. coli* as described with a vector background of 14.

Plasmid DNA from some of the pools was transformed into yeast, and 50-100 plates containing 250-400 yeast
10 colonies were obtained from each pool.

Endoglucanase-positive colonies were identified and isolated on SC-agar plates with the AZCL HE cellulose assay. cDNA inserts were amplified directly from the
15 yeast colonies and characterized as described in the Materials and Methods section above. The DNA sequence of the cDNA encoding the endoglucanase is shown in SEQ ID No. 10 and the corresponding amino acid sequence is shown in SEQ ID No. 11.

20

The cDNA is obtainable from the plasmid in DSM 10512.

Total DNA was isolated from a yeast colony and plasmid DNA was rescued by transformation of *E. coli* as described
25 above. In order to express the endoglucanase in *Aspergillus*, the DNA was digested with appropriate restriction enzymes, size fractionated on gel, and a fragment corresponding to the endoglucanase gene was purified. The gene was subsequently ligated to pHD414,
30 digested with appropriate restriction enzymes, resulting in the plasmid pA2C477.

After amplification of the DNA in *E. coli* the plasmid was transformed into *Aspergillus oryzae* as described above.
35

Screening of the cDNA library by hybridization and characterization of the positive clones. Approximately

6000 colony forming units (c.f.u.) from the *Macrophomina phaseolina* cDNA library in *E. coli* was screened by colony hybridization using a random-primed ³²P-labeled PCR product from *M. phaseolina* as probe. The PCR product was
5 generated as described in the Materials and methods section. The positive cDNA clones were characterized by sequencing the ends of the cDNA inserts, and by determining the nucleotide sequence of the longest cDNA from both strands. The DNA sequence of the cDNA encoding
10 the endoglucanase is shown in SEQ ID No. 10 and the corresponding amino acid sequence is shown in SEQ ID No. 11.

15 **B. Construction of gene fusion between the endoglucanase from *Macrophomina phaseolina* and the 43 kD endoglucanase from *Hemicella insolens***

One construction was prepared in order to make a
20 derivative of the endoglucanase from *M. phaseolina* with the linker and CBD from the 43 kD endoglucanase from *H. insolens* (disclosed in WO 91/17243). The native endoglucanase from *M. phaseolina* does not have a linker and/or a cellulose binding domain, CBD.

25 The construction consists of the endoglucanase from *M. phaseolina* (223 amino acids) and the 72 C-terminal amino acids from the *H. insolens* 43 kD endoglucanase.

30 The 43 kD endoglucanase cDNA from *H. insolens* is cloned into pHD414 in such a way that the endoglucanase gene is transcribed from the Taka-promoter. The resulting plasmid is named pCaHj418.

35 The cDNA encoding the endoglucanase from *M. phaseolina* is cloned into pYES2.0 as a BstX I/Not I fragment and the resulting plasmid is named pC1C477.

Primers:

primer 1: 5'-

GGTCGCCCCGGACTGGCTGTTCCCGTACCCCTCCAGCAGCACCAGCTCTCCGG -3'

5 primer 2: 5'

CCGGAGAGCTGGTGCTGCTGGAGGGGGTACGGGAACAGCCAGTCCGGGCGACC -3'

pYES2.0 F.HT primer: 5' CGGACTACTAGCAGCTGTAATACG -3'

AMG-term. primer: 5' CCCCATCCTTTAACTATAGCG -3'

- 10 The endoglucanase fusion is constructed by the PCR overlap-extension method as described by Higuchi et al. 1988.

Reaction A: The Polymerase Chain Reaction (PCR) is used
15 to amplify the fragment of pCaHj418 between primer 1 and AMG-term. primer (the linker and CBD from the 43 kD endoglucanase from *H.insolens*).

Reaction B: PCR amplification of the fragment between
pYES2.0 F.HT primer and primer 2 in pC1C477, the
20 endoglucanase gene from *M. phaseolina*.

Reaction C: The two purified fragments are used in a third PCR in the presence of the primers flanking the total region, i.e. pYES2.0 F.HT primer and AMG-term. primer.

25 The fragment amplified in reaction C is purified, digested with restriction enzymes, e.g. Xba I and BamH I. The purified digested fragment is ligated into pHD414 digested with restriction enzymes, e.g. Xba I and BamH I.

30 Competent cells from *E. coli* strain DH5 α F' (New England Biolabs) are transformed with the ligated plasmid and colonies containing the gene fusion are isolated. The sequence of the cloned part was verified by DNA sequencing.
35

Polymerase Chain Reactions are carried out under standard

conditions, as recommended by Perkin-Elmer.

Reaction A and B start with 2 min. at 94°C followed by 20 cycles of (30 sec. at 94°C, 30 sec. at 52°C and 1 min. at 72°C) and ends with 4 min. at 72 °C.

Reaction C starts with (2 min. at 94°C, 1 min. at 52°C and 2 min. at 72°C), followed by 20 cycles of (30 sec. at 94°C, 30 sec. at 52°C and 90 sec. at 72°C) and ends with 4 min. at 72°C.

The construct may be transformed into *Aspergillus oryzae* as described above.

15

EXAMPLE 3

Cloning and expression of an endoglucanase from *Acremonium sp.* and *Sordaria fimicola*

20

Production of biomass for expression cloning procedures: Isolates CBS 478.94 and ATCC 52644, respectively, were grown in shake flask cultures on cellulose enriched potato dextrose broth, incubated for 5 days at 260C (shaking conditions: 150 rpm).

mRNA was isolated from *Acremonium sp.*, CBS 478.94, and *Sordaria fimicola*, ATCC 52644, respectively, grown in a cellulose-containing fermentation medium with agitation to ensure sufficient aeration. Mycelia were harvested after 3-5 days' growth, immediately frozen in liquid nitrogen and stored at -80°C. Libraries from *Acremonium sp.*, and *Sordaria fimicola*, respectively, each consisting of approx. 10⁶ individual clones were constructed in *E. coli* as described with a vector background of 1%.

Plasmid DNA from s m of the pools from each library was

transformed into yeast, and 50-100 plates containing 250-400 yeast colonies were obtained from each pool.

Endoglucanase-positive colonies were identified and
5 isolated on SC-agar plates with the AZCL HE cellulose assay. cDNA inserts were amplified directly from the yeast colonies and characterized as described in the Materials and Methods section above.

10 The DNA sequence of the cDNA encoding the endoglucanase from *Acremonium sp.* is shown in SEQ ID No. 6 and the corresponding amino acid sequence is shown in SEQ ID No. 7. The cDNA is obtainable from the plasmid in DSM 10080.

15

The partial DNA sequence of the cDNA encoding the endoglucanase from *Sordaria fimicola* is shown in SEQ ID No. 19 (Nucleotide sequence of the 5'-end of the cDNA) and the corresponding amino acid sequence is shown in SEQ
20 ID No. 20. The cDNA is obtainable from the plasmid in DSM 10576.

Total DNA was isolated from a yeast colony and plasmid DNA was rescued by transformation of *E. coli* as described
25 above. In order to express the endoglucanase in *Aspergillus*, the DNA was digested with appropriate restriction enzymes, size fractionated on gel, and a fragment corresponding to the endoglucanase gene from *Acremonium sp.* and *Sordaria fimicola*, respectively, was
30 purified. The genes were subsequently ligated to pHD414, digested with appropriate restriction enzymes, resulting in the plasmids pA2C371 and pA2C502, respectively.

After amplification of the DNA in *E. coli* the plasmids
35 were transformed into *Aspergillus oryzae* as described above.

EXAMPLE 4**A. Cloning by PCR an endoglucanase from *Crinipellis scabell*
bella, CBS 280.96**

5

Isolate CBS 280.96 was grown in static flask cultures, holding wheat bran medium (per flask: 300g wheat bran added 450 ml salt solution), incubated for 6 days at 26C. After incubation the wheat bran was extracted with
10 distilled water (300ml per flask) and the extract tested for endoglucanase activity (0.1% AZCL-HE-Cellulose (megazyme) in 1% agarose (Litex agarose, Medinova). Activity was observed on the plates holding pH of 3.0, 7.0 and 9.5.

15

mRNA was isolated from *Crinipellis scabell*
bella grown as describe above. Mycelia were harvested after 3-5 days' growth, immediately frozen in liquid nitrogen and stored at -80°C. A library from *Crinipellis scabell*
bella, consisting
20 of approx. 10⁶ individual clones was constructed in *E. coli* as described with a vector background of 1%.

Approximately 10 000 colony forming units (c.f.u.) from the *Crinipellis scabell*
bella cDNA library in *E. coli* was
25 screened by colony hybridization using a random-primed ³²P-labeled PCR product from *C. scabell*
bella as probe. The PCR product was generated as described in the Materials and methods section. The positive cDNA clones were
30 characterized by sequencing the ends of the cDNA inserts, and by determining the nucleotide seuenue of the longest cDNA from both strands.

The DNA sequence of the cDNA encoding the endoglucanase is shown in SEQ ID No. 12 and the corresponding amino
35 acid sequence is shown in SEQ ID No. 13.

The cDNA is obtainable from the plasmid in DSM 10511.

Total DNA was isolated from a yeast colony and plasmid DNA was rescued by transformation of *E. coli* as described above. In order to express the endoglucanase in *Aspergillus*, the DNA was digested with appropriate
5 restriction enzymes, size fractionated on gel, and a fragment corresponding to the endoglucanase gene was purified. The gene was subsequently ligated to pHD414, digested with appropriate restriction enzymes, resulting in the plasmid pA2C475.

10

After amplification of the DNA in *E. coli* the plasmid was transformed into *Aspergillus oryzae* as described above.

15 Construction of two gene fusions between the endoglucanase from *Crinipellis scabella* and the linker/CBD region of the 43 kDa endoglucanase from *Humicola insolens*.

20 The native endoglucanase from *Crinipellis scabella* neither has a linker nor a cellulose binding domain (CBD). In addition, the full-length cDNA contains an ATG start codon upstream from the endoglucanase encoding open
25 translation initiation upon heterologous expression of the cDNA, such as in the yeast *Saccharomyces cerevisiae* and the filamentous fungus *Aspergillus oryzae*. Thus, two gene fusions between the endoglucanase from *Crinipellis scabella* and the linker/CBD region of the 43kD
30 endoglucanase from *Humicola insolens* (disclosed in WO 91/17243) has been constructed using splicing by overlap extension (SOE) (Horton et al, 1989).

Construction 1 consists of the cDNA encoding the 226-residue endoglucanase from *C. scabella* fused by PCR with
35 the 3'-end cDNA of *H. insolens* coding for the linker and CBD region (72 amino acids) at the COOH-terminus of the

H. insolens 43kD endoglucanase. The second hybrid construct is identical to the abovementioned gene fusion, except that the first five residues from the putative signal peptide have been deleted by PCR resulting in a shorter signal, which starts with the second in-frame ATG start codon.

Plasmid constructs

10

The plasmid pC1C475 contains the full-length cDNA from *C. scabellia*, cloned into BstXI/NotI-cut yeast expression vector pYES 2.0, the plasmid pC1C144 contains the full-length cDNA from *H. insolens*, cloned into the BstXI site of pYES 2.0.

Splicing by overlap extension

Two PCR fragments encoding the core region of the endoglucanase from *C. scabellia* were generated in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % gelatin; containing 200 µM each dNTP), using 50-100 ng of pC1C475 as template, and 250 pmol of the reverse primer (5'-GACCGGAGAGCTGGTGCTGCTGGAGGGTTTACGAACACAGCCCGAGATATTAG TG- 3') in two combinations with 300-350 pmol of each forward primer (forward no. 1 5'-CCCCAAGCTTGACTTGGAACCAATGGTCCATCC-3', forward no. 2 5'-CCCCAAGCTTCCATCCAAACATGCTTAAAACGCTCG- 3'), a DNA thermal cycler (Landgraf, Germany) and 2.5 units of Taq polymerase (Perkin-Elmer, Cetus, USA). Thirty cycles of PCR were performed using a cycle profile of denaturation at 94 °C for 1 min, annealing at 55 °C for 2 min, and extension at 72 °C for 3 min. The PCR fragment coding for the linker and CBD of the endoglucanase of *H. insolens* was generated in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % gelatin; containing 200 µM each dNTP) using 100 ng of the pC1C144 template, 250 pmol

forward primer (5'-CACTAATATCTCGGGC-TGTGTTTCGTAAACCCTCCAGCAGCACCA-GCTCTCCGGTC-3'), 250 pmol of the pYES 2.0 reverse primer (5'-GGGCGTGAATGTAAGCGTGACATA-3') a DNA thermal cycler (Landgraf, Germany) and 2.5 units of Taq polymerase (Perkin-Elmer, USA). Thirty cycles of PCR were performed as above. The PCR products were electrophoresed in 0.7 % low gelling temperature agarose gels (SeaPlaque, FMC), the fragments of interest were excised from the gel and recovered by treatment with agarase (New England Biolabs, USA) according to the manufacturer's instructions, followed by phenol extraction and ethanol precipitation at - 20 °C for 12 h by adding 2 vols of 96 % EtOH and 0.1 vol of 3M NaAc.

The recombinant hybrid genes between the endoglucanase from *Crinipellis scabellia* and the linker/CBD region of the 43 kD endoglucanase from *Humicola insolens* were generated by combining the overlapping PCR fragments from above (ca. 50 ng of each template) in two combinations in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % gelatin; containing 200 µM each dNTP). The SOE reaction was carried out using the DNA thermal cycler (Landgraf, Germany) and 2.5 units of Taq polymerase (Perkin-Elmer, Cetus, USA). Two cycles of PCR were performed using a cycle profile of denaturation at 94 °C for 1 min, annealing at 55 °C for 2 min, and extension at 72 °C for 3 min, the reaction was stopped, 250 pmol of each end-primer (forward no. 1 5'-CCCCAAGCTTGACTTGGAACCAATGGTCCATCC-3', forward no. 2 5'-CCCCAAGCTTCCATCCAAACATGCTTAAAACGCTCG-3', reverse primer 5'-GGGCGTGAATGTAAGCGTGACATA-3') was added to the reaction mixture, and an additional 30 cycles of PCR were performed using a cycle profile of denaturation at 94 °C for 1 min, annealing at 55 °C for 2 min, and extension at 72 °C for 3 min.

Construction of the expression cassettes for heterologous expression in *Aspergillus oryzae*

The PCR-generated, recombinant fragments were
5 electrophoresed in a 0.7 % low gelling temperature
agarose gel (SeaPlaque, FMC), the fragments of interest
were excised from the gel and recovered by treatment with
agarase (New England Biolabs, USA) according to the
manufacturer's instructions, followed by phenol
10 extraction and ethanol precipitation at - 20 °C for 12 h.
The DNA fragments were digested to completion with
HindIII and XbaI, and ligated into *HindIII/XbaI*-cleaved
pHD414 vector followed by electroporation of the
constructs into *E. coli* DH10B cells according to the
15 manufacturer's instructions (Life Technologies, USA).

The nucleotide sequence of the resulting gene fusions
were determined from both strands as described in the
Materials and methods section, SEQ ID no. 14A and 15A.
20 The constructs may be transformed into *A. oryzae* as
described.

EXAMPLE 5

25 PCR facilitated detection of said type of cellulytic en-
zyme from 46 filamentous and monocentric fungi,
representing 32 genera, from 23 families, belonging to 15
orders of 7 classes, covering all in all all four groups
of the true Fungi: Ascomycetous, Basidiomycetous, Chytri-
30 diomycetous and Zygomycetous fungi

5.1 Materials

1. *Diplodia gossypina* Cooke

Deposit of Strain, Acc No: CBS 274.96

35

2. *Ulospora bilgramii* (Hawksw. et al.) Hawksw. et al.
Acc No of strain: NKBC 1444,

3. *Microsphaeropsis* sp4. *Ascobolus stictoides* Speg.

Acc No of strain: Q026 (Novo Nordisk collection)

5 Isolated from goose dung, Svalbard, Norway

5. *Saccobolus dilutellus* (Fuck) Sacc.

Deposit of strain: Acc No CBS 275.96

10 6. *Penicillium verruculosum* Peyronel

Ex on Acc No of species: ATCC 62396

7. *Penicillium chrysogenum* Thom

Acc No of Strain: ATCC 9480

15

8. *Thermomyces verrucosus* Pugh et al

Deposit of Strain, Acc No.: CBS 285.96

9. *Xylaria hypoxylon* L. ex Greville

20 Deposit of Strain, Acc No: CBS 284.96

10. *Poronia punctata* (Fr.ex L.) Fr.

Ref:A.Munk: Danish Pyrenomycetes,

Dansk Botanisk Arkiv, Vol17,1 1957

25

11. *Nodulisporum* spIsolated from leaf of *Camellia reticulata* (Theaceae,
Guttiferales),

Kunming Botanical Garden, Yunnan Province, China

30

12. *Cylindrocarpon* sp

Isolated from marine sample, the Bahamas

13. *Fusarium anguioides* Sherbakoff

35 Acc No of strain: IFO 4467

14. *Fusarium poae* (Peck) Wr.
Ex on Acc No of species: ATCC 60883
15. *Fusarium solani* (Mart.) Sacc. emnd. Snyd & Hans.
5 Acc No of strain: IMI 107.511
16. *Fusarium oxysporum* ssp *lycopersici* (Sacc.) Snyd. & Hans.
Acc No of strain: CBS 645.78
- 10 17. *Fusarium oxysporum* ssp *passiflora*
Acc No of strain: CBS 744.79
18. *Gliocladium catenulatum* Gillman & Abbott
15 Acc. No. of strain: ATCC 10523
19. *Nectria pinea* Dingley
Deposit of Strain, Acc. No. CBS 279.96
- 20 20. *Sordaria macrospora* Auerswald
Ex on Acc No of species: ATCC 60255
21. *Humicola grisea* Traeen
ex on Acc No for the species: ATCC 22726
- 25 22. *Humicola nigrescens* Omvik
Acc No of strain: CBS 819.73
23. *Scytalidium thermophilum* (Cooney et Emerson) Austwick
30 Acc No of strain: ATCC 28085
24. *Thielavia thermophila* Fergus et Sinden
(syn *Corynascus thermophilus*)
Acc No of strain: CBS 174.70, IMI 145.136
- 35 25. *Cladorrhinum foecundissimum* Saccardo et Marchal
Ex on Acc No of species: ATCC 62373

26. *Syspastospora boninensis*
Acc No of strain: NKBC 1515 (Nippon University, profe
Tubaki Collection)
- 5 27. *Chaetomium cuniculorum* Fuckel
Acc. No. of strain: CBS 799.83
28. *Chaetomium brasiliense* Batista et Potual
Acc No of strain: CBS 122.65
- 10 29. *Chaetomium murorum* Corda
Acc No of strain: CBS 163.52
30. *Chaetomium virescens* (von Arx) Udagawa
15 Acc.No. of strain: CBS 547.75
31. *Nigrospora* sp
Deposit of strain, Acc No: CBS 272.96
- 20 32. *Nigrospora* sp
Isolated from:
33. *Diaporthe syngenesia*
Deposit of strain, Acc No: CBS 278.96
- 25 34. *Colletotrichum lagenarium* (Passerini) Ellis et
Halsted
syn *Glomerella cingulata* var *orbiculare* Jenkins et
Winstead
- 30 Ex on acc No of species: ATCC 52609
35. *Exidia glandulosa* Fr.
Deposit of Strain, Acc No: CBS 277.96
- 35 36. *Fomes fomentarius* (L.) Fr.
Deposit of strain: Acc No. CBS 276.96

37. *Spongipellis* (?)

Deposit of Strain: Acc No CBS 283.96

38. *Rhizophlyctis rosea* (de Bary & Wor) Fischer

5 Deposit of Strain: Acc No.: CBS 282.96

39. *Rhizomucor pusillus* (Lindt) Schippersyn: *Mucor pusillus*

Acc No of strain: IFO 4578

10

40. *Phycomyces nitens* (Kunze) van Tieghem & Le Monnier

Acc No of strain: IFO 4814

41 *Chaetostylum fresenii* van Tieghem & Le Monnier15 syn. *Helicostylum fresenii*

Acc No of strain NRRL 2305

42. *Trichothecium roseum*, Acc No of strain: IFO 537220 43. *Coniothecium* spEndophyte, isolated from leaf of flowering plant,
Kunming , Yunnan, China

44. Deposit of strain, Acc No.: CBS 271.96

25 Coelomycete, Isolated from leaf of *Artocarpus altilis*
(Moraceae, Urticales), Christiana, Jamaica

45. Deposit of strain, Acc No.: CBS 273.96

30 Coelomycete, isolated from leaf of *Pimenta dioica*
(Myrtaceae, Myrtales), Dallas Mountain, Jamaica

46. Deposit of strain: CBS 270.96

35 Coelomycete, isolated from leaf of *Pseudocalymma*
alliaceum (Bignoniaceae, Solanales) growing in Dallas
Mountain, Jamaica

5.2 Procedure

Maintenance of strains and production of biomass:

The strains were maintained on agar in petrie dishes

- 5 (9cm) or on slants (see list of Media: PCA and PDA). 44
of the strains were grown in shake flasks under the
following growth conditions: general fungal media as PC,
PD and PB 9 or YPG (see list of media); incubation time
from 3 to 9 days; temperature 26°C; rpm between 150 and
10 175 . Strain No 14 (*F.poae*) was grown on wheat bran for
15 days (26°C; static). Strain No 38 was grown in dilute
salt solution (DS/2), added 1 cm² pieces of autoclaved
filter paper.

15 Activity test:

- Activity was tested on 0.1% AZCL-HE-Cellulose (Megazyme)
plates (14 cm Petrie dishes), made up in 1% agarose (HSB,
Litex Agarose, Medinova). All tests were done in
triplicate, viz. AZCL-HE-Cellulose dissolved in three
20 buffers, adjusted to pH 3, 7 or 9.5 (using various
proportions of the following two ingredients Citric acid
monohydrat, Merck art. No 100244 (21.0 g) dissolved in
water, making a total of 1000 ml; 0.1M tri-Sodium dodeca-
brohydrate, Merck art.no. 6578 (38 g), dissolved in wa-
25 ter, making a total of 1000 ml. The mixing is done
immediatly before use.

Harvesting of Biomass:

- The biomass was harvested by filtering (mesh adjusted to
30 the growth of the fungus, the finest used for fungi which
have highly sporulating mycelium as e.g. *Fusarium* spp.).
The biomass on the filter was scraped into a sterile
plastic bag and immediatly frozen (by submerging into
liquid nitrogen).

5.3 Results

I. Using the PCR screening and amplification techniques described in Materials and Methods the following partial cDNA sequences were obtained:

5

Saccobolus dilutellus (Fuck) Sacc., CBS 275.96: SEQ ID No. 21 (and the deduced amino acid sequence in SEQ ID No. 22);

10 *Thermomyces verrucosus*, CBS 285.96: SEQ ID No. 23 (and the deduced amino acid sequence in SEQ ID No. 24);

Xylaria hypoxylon, CBS 284.96: SEQ ID No. 25 (and the deduced amino acid sequence in SEQ ID No. 26);

15 *Fusarium oxysporum* ssp *lycopersici*, CBS 645.78: SEQ ID No. 27 (and the deduced amino acid sequence in SEQ ID No. 28);

Nectria pinea, CBS 279.96: SEQ ID No. 29 (and the deduced amino acid sequence in SEQ ID No. 30);

Humicola grisea, ATCC 22726: SEQ ID No. 31 (and the deduced amino acid sequence in SEQ ID No. 32);

20 *Humicola nigrescens*, CBS 819.73: SEQ ID No. 33 (and the deduced amino acid sequence in SEQ ID No. 34);

Cladorrhinum foecundissimum, ATCC 62373: SEQ ID No. 35 (and the deduced amino acid sequence in SEQ ID No. 36);

25 *Syspastospora boninensis*, NKBC 1515: SEQ ID No. 37 (and the deduced amino acid sequence in SEQ ID No. 38);

Nigrospora sp., CBS 272.96: SEQ ID No. 39 (and the deduced amino acid sequence in SEQ ID No. 40);

Chaetostylum fresenii: SEQ ID No. 41 (and the deduced amino acid sequence in SEQ ID No. 42);

30 *Exidia glandulosa*, CBS 277.96: SEQ ID No. 43 (and the deduced amino acid sequence in SEQ ID No. 44);

Coniothecium sp.: SEQ ID No. 45 (and the deduced amino acid sequence in SEQ ID No. 46);

35 Deposition No. CBS 271.96: SEQ ID No. 47 (and the deduced amino acid sequence in SEQ ID No. 48);

Deposition No. CBS 270.96: SEQ ID No. 49 (and the deduced amino acid sequence in SEQ ID No. 50);

- Diplodia gossypina, CBS 274.96: SEQ ID No. 51 (and the deduced amino acid sequence in SEQ ID No. 52);
Ulospora bilgramii, NKBC 1444: SEQ ID No. 53 (and the deduced amino acid sequence in SEQ ID No. 54);
5 Penicillium verruculosum, ATCC 62396: SEQ ID No. 55 (and the deduced amino acid sequence in SEQ ID No. 56);
Poronia punctata: SEQ ID No. 57 (and the deduced amino acid sequence in SEQ ID No. 58);
Fusarium anguioides, IFO 4467: SEQ ID No. 59 (and the
10 deduced amino acid sequence in SEQ ID No. 60);
Thielavia thermophila, CBS 174.70: SEQ ID No. 61 (and the deduced amino acid sequence in SEQ ID No. 62);
Chaetomium cuniculorum, CBS 799.83: SEQ ID No. 63 (and the deduced amino acid sequence in SEQ ID No. 64);
15 Chaetomium virescens: SEQ ID No. 65 (and the deduced amino acid sequence in SEQ ID No. 66);
Colletotrichum lagenarium: SEQ ID No. 67 (and the deduced amino acid sequence in SEQ ID No. 68);
Phycomyces nitens: SEQ ID No. 69 (and the deduced amino
20 acid sequence in SEQ ID No. 70); and
Trichothecium roseum: SEQ ID No. 71 (and the deduced amino acid sequence in SEQ ID No. 72);

- II. Using the PCR screening and amplification techniques
25 described in Materials and Methods partial cDNA encoding partially for the enzyme of the invention was obtained and the plasmid was deposited according to the Budapest Treaty:

- Escherichia coli*, DSM 10583, deposition date 13 March,
30 1996;
cDNA from *Trichothecium roseum*;
Escherichia coli, DSM 10584, deposition date 13 March, 1996;
cDNA from *Syspastospora boninensis*;
35 *Escherichia coli*, DSM 10585, deposition date 13 March, 1996;
cDNA from *Cheatomium murorum*

Escherichia coli, DSM 10587, deposition date 13 March, 1996;

cDNA from *Sordaria fimicola*;

5 *Escherichia coli*, DSM 10588, deposition date 13 March, 1996;

cDNA from the unidentified strain CBS 273.96;

Escherichia coli, DSM 10586, deposition date 13 March, 1996;

cDNA from *Spongipellis* sp.

10

Color clarification of crude supernatants

During normal wash the fabric will often fade. However,
15 the fabric appearance is improved and the original colours are much better preserved or maintained if the fabric is washed with a cellulase giving color clarification. Color clarification is measured as removal of surface fibrils and fibers protruding from the yarn of
20 a textile containing cellulosic fibers.

Apparatus	:	Terg-o-tometer
Liquid volume	:	100 ml
Agitation	:	150 movements/min with vertical
25		stirrer
Rinse time	:	5 min in tapwater
Washing temp	:	40°
Washing liquor	:	0.05 M phosphate buffer
pH	:	7.0
30		Washing time : 30 min
Repetitions	:	2
Enzymes	:	Crude supernatants from the strains shown below.
Dosage	:	Two dosages from : 200, 500,
35		1000 or 2500 S-CEVU/l
Textile	:	2 swatches of aged black 100%
cotton	:	5x6 cm (0.9 gram)

Drying : Tumble dry

Evaluation:

The light remission is measured by a Datacolor Elrepho Remission spectrophotometer. Remission is calculated as
5 delta L (Hunter Lab-values). When the surface fibrils and fibers protruding from the yarn are removed by the cellulase, the surface of the black fabric appears darker, and lower L values are obtained.

10 The samples are compared with a blind sample, i.e. washed without enzyme. Below is shown the delta L remission values compared to a blind sample.

15

<u>Strain</u>		ECU/l			
		<u>200</u>	<u>500</u>	<u>1000</u>	<u>2500</u>
13.	Fusarium anguioides	n.t.	-0.71	n.t.	-1.28
15.	Fusarium solani	n.t.	-0.96	n.t.	-1.37
24.	Thielavia thermophila	-0.30	n.t.	-1.25	n.t.
25.	Cladorrhinum foecun.	n.t.	-1.79	n.t.	-2.18
37.	Spongipellis (?)	n.t.	-1.01	n.t.	-1.63
39.	Rhizomucor pusillus	n.t.	-1.90	n.t.	-2.66
41.	Chaetostylum fresenii	n.t.	-0.17	n.t.	-1.33
45.	Acc No.: CBS 273.96	n.t.	-1.31	n.t.	-1.20

The data shows that all strains gives good color clarification under the conditions tested. (n.t. = not tested at this dosage).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: Novo Nordisk A/S
- (B) STREET: Novo Alle
- (C) CITY: DK-2880 Bagsvaerd
- 10 (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): DK-2880
- (G) TELEPHONE: +45 44 44 88 88
- (H) TELEFAX: +45 44 49 32 56

15

(ii) TITLE OF INVENTION: NOVEL ENDOGLUCANASES

(iii) NUMBER OF SEQUENCES: 72

20

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version
- 25 #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1A:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 891 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(B) STRAIN: DSM 9770

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1A:

5 AAAGAAAGGC TCTCTGCTGT CGTCGCTCTC GTCGCTCTCG TCGGCATCCT
CCATCCGTCC 60

GCCTTTGATA ACCCGCTCCC CGACTCAGTC AAGACGACGC ATACTTGGCA
10 CCATGCATCT 120

CTCCGCCACC ACCGGGTTC TCGCCCTCCC GGTCCTGGCC CTGGACCAGC
TCTCGGGCAT 180

15 CGGCCAGACG ACCCGGTACT GGGACTGCTG CAAGCCGAGC TCGCCTGGC
CCGGCAAGGG 240

CCCCTCGTCT CCGGTGCAGG CCTGCGACAA GAACGACAAC CCGCTCAACG
ACGGCGGCTC 300

20 CACCCGGTCC GGCTGCGACG CGGGCGGCAG CGCCTACATG TGCTCCTCCC
AGAGCCCCTG 360

GGCCGTCAGC GACGAGCTGT CGTACGGCTG GCGGCCCGTC AAGCTCGCCG
25 GCAGCTCCGA 420

GTCGCAGTGG TGCTGCGCCT GCTACGAGCT GACCTTCACC AGCGGGCCGG
TCGCGGGCAA 480

30 GAAGATGATT GTGCAGGCGA CCAACACCGG TGGCGACCTG GCGACAACC
ACTTTGACCT 540

GGCCATCCCC GGTGGCGGTG TCGGTATTTT CAACGCCTGC ACCGACCAGT
ACGGCGCTCC 600

35 CCCGAACGGC TGGGGCGACC GCTACGGCGG CATCCATTCC AAGGAAGAGT
GCGAATCCTT 660

CCCGGAGGCC CTCAAGCCCG GCTGCAACTG GCGCTTCGAC TGGTTCCAAA
ACGCCGACAA 720

CCCGTCGGTC ACCTTCCAGG AGGTGGCCTG CCCGTCGGAG CTCACGTCCA
5 AGAGCGGCTG 780

CTCCCGTTAA GAGGGAAGAG AGGGGGCTGG AAGGACCGAA AGATTCAACC
TCTGCTCCTG 840

10 CTGGGGAAGC TCGGGCGCGA GTGTGAAACT GGTGTAAATA TTGTGGCACA
CACAAGCTAC 900

TACAGTCCGT CTCGCCGTCC GGCTAACTAG CCTTGCTGCG GATCTGTCCA
AAAAAAAAAA 960

15

(2) INFORMATION FOR SEQ ID NO: 1B:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 225 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1B:

30 Met His Leu Ser Ala Thr Thr Gly Phe Leu Ala Leu Pro Val Leu Ala
1 5 10 15

35 Leu Asp Gln Leu Ser Gly Ile Gly Gln Thr Thr Arg Tyr Trp Asp Cys
20 25 30

Cys Lys Pro Ser Cys Ala Trp Pro Gly Lys Gly Pro Ser Ser Pro Val

	35	40	45
5	Gln Ala Cys Asp Lys Asn Asp Asn Pro Leu Asn Asp Gly Gly Ser Thr		
	50	55	60
10	Arg Ser Gly Cys Asp Ala Gly Gly Ser Ala Tyr Met Cys Ser Ser Gln		
	65	70	75 80
15	Ser Pro Trp Ala Val Ser Asp Glu Leu Ser Tyr Gly Trp Ala Ala Val		
	85	90	95
20	Lys Leu Ala Gly Ser Ser Glu Ser Gln Trp Cys Cys Ala Cys Tyr Glu		
	100	105	110
25	Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ile Val Gln		
	115	120	125
30	Ala Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp Leu Ala		
	130	135	140
35	Ile Pro Gly Gly Gly Val Gly Ile Phe Asn Ala Cys Thr Asp Gln Tyr		
	145	150	155 160
40	Gly Ala Pro Pro Asn Gly Trp Gly Asp Arg Tyr Gly Gly Ile His Ser		
	165	170	175

Lys Glu Glu Cys Glu Ser Phe Pro Glu Ala Leu Lys Pro Gly Cys Asn
180 185 190

5 Trp Arg Phe Asp Trp Phe Gln Asn Ala Asp Asn Pro Ser Val Thr Phe
195 200 205

10 Gln Glu Val Ala Cys Pro Ser Glu Leu Thr Ser Lys Ser Gly Cys Ser
210 215 220

15 Arg
225

20 (2) INFORMATION FOR SEQ ID NO: 2A:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 894 base pairs
(B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: "Construction 1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2A:

35 ATGCATCTCT CCGCCACCAC CGGGTTCCTC GCCCTCCCGG TCCTGGCCCT GGACCAGCTC
60

TCGGGCATCG GCCAGACGAC CCGGTACTGG GACTGCTGCA AGCCGAGCTG CGCCTGGCCC
120

40 GGCAAGGGCC CTCGTCTCC GGTGCAGGCC TCGACAAGA ACGACAACCC GCTCAACGAC

180

GGCGGCTCCA CCGGTCCGG CTGCGACGG GGGGCAGCG CCTACATGTG CTCCTCCCAG
240

5

AGCCCTGGG CCGTCAGCGA CGAGCTGTG TACGGCTGGG CGGCCGTCAA GCTCGCCGGC
300

10

AGCTCCGAGT CGCAGTGGTG CTGCGCCTGC TACGAGCTGA CCTTCACCAG CGGGCCGGTC
360

GCGGGCAAGA AGATGATTGT GCAGGCGACC AACACCGGTG GCGACCTGGG CGACAACCAC
420

15

TTTGACCTGG CCATCCCCGG TGGCGGTGTC GGTATTTTCA ACGCCTGCAC CGACCAGTAC
480

GGCGCTCCCC CGAACGGCTG GGGCGACCGC TACGGCGGCA TCCATTCCAA GGAAGAGTGC
540

20

GAATCCTTCC CGGAGGCCCT CAAGCCCGGC TGCAACTGGC GCTTCGACTG GTTCCAAAAC
600

25

GCCGACAACC CGTCGGTCAC CTTCCAGGAG GTGGCCTGCC CGTCGGAGCT CACGTCCAAG
660

AGCGGCTGCT CCCGTCCCTC CAGCAGCACC AGCTCTCCGG TCAACCAGCC TACCAGCACC
720

30

AGCACCACGT CCACCTCCAC CACCTCGAGC CGCCAGTCC AGCCTACGAC TCCCAGCGGC
780

TGCACTGCTG AGAGGTGGGC TCAGTGGCGC GGCAATGGCT GGAGCGGCTG CACCACCTGC
840

35

GTCGCTGGCA GCACTTGCAC GAAGATTAAT GACTGGTACC ATCAGTGCCT GTAG
894

40

(2) INFORMATION FOR SEQ ID NO: 2B:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 297 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2B:

Met His Leu Ser Ala Thr Thr Gly Phe Leu Ala Leu Pro Val Leu Ala

15 1 5 10 15

Leu Asp Gln Leu Ser Gly Ile Gly Gln Thr Thr Arg Tyr Trp Asp Cys

20 20 25 30

Cys Lys Pro Ser Cys Ala Trp Pro Gly Lys Gly Pro Ser Ser Pro Val

25 35 40 45

Gln Ala Cys Asp Lys Asn Asp Asn Pro Leu Asn Asp Gly Gly Ser Thr

30 50 55 60

Arg Ser Gly Cys Asp Ala Gly Gly Ser Ala Tyr Met Cys Ser Ser Gln

35 65 70 75 80

Ser Pro Trp Ala Val Ser Asp Glu Leu Ser Tyr Gly Trp Ala Ala Val

40 85 90 95

Lys Leu Ala Gly Ser Ser Glu Ser Gln Trp Cys Cys Ala Cys Tyr Glu

100

105

110

5

Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ile Val Gln

115

120

125

10

Ala Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp Leu Ala

130

135

140

15

Ile Pro Gly Gly Gly Val Gly Ile Phe Asn Ala Cys Thr Asp Gln Tyr

145

150

155

160

20

Gly Ala Pro Pro Asn Gly Trp Gly Asp Arg Tyr Gly Gly Ile His Ser

165

170

175

25

Lys Glu Glu Cys Glu Ser Phe Pro Glu Ala Leu Lys Pro Gly Cys Asn

180

185

190

30

Trp Arg Phe Asp Trp Phe Gln Asn Ala Asp Asn Pro Ser Val Thr Phe

195

200

205

35

Gln Glu Val Ala Cys Pro Ser Glu Leu Thr Ser Lys Ser Gly Cys Ser

210

215

220

40

Arg Pro Ser Ser Ser Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr

225

230

235

240

Ser Thr Thr Ser Thr Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr
245 250 255

5 Thr Pro Ser Gly Cys Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn
260 265 270

10 Gly Trp Ser Gly Cys Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys
275 280 285

15 Ile Asn Asp Trp Tyr His Gln Cys Leu
290 295

20 (2) INFORMATION FOR SEQ ID NO: 3A:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 927 base pairs
(B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (vi) ORIGINAL SOURCE:

(A) ORGANISM: "Construction 2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3A:

35 ATGCATCTCT CCGCCACCAC CGGGTTCTCT GCCCTCCCGG TCCTGGCCCT GGACCAGCTC
60

TCGGGCATCG GCCAGACGAC CCGGTACTGG GACTGCTGCA AGCCGAGCTG CGCCTGGCCC
120

40 GGCAAGGGCC CCTCGTCTCC GGTGCAGGCC TGCACAAGA ACGACAACCC GCTCAACGAC

180

GGGGGCTCCA CCGGGTCCGG CTGCGACGCG GGGGGCAGCG CCTACATGTG CTCCTCCCAG
240

5

AGCCCCCTGGG CCGTCAGCGA CGAGCTGTGG TACGGCTGGG CGGCCGTCAA GCTGGCCGGC
300

10

AGCTCCGAGT CGCAGTGGTG CTGCGCCTGC TACGAGCTGA CCTTCACCAG CGGGCCGGTC
360

GCGGGCAAGA AGATGATTGT GCAGGCGACC AACACCGGTG GCGACCTGGG CGACAACCAC
420

15

TTTGACCTGG CCATCCCOGG TGGCGGTGTC GGTATTTTCA ACGCCTGCAC CGACCAGTAC
480

20

GGCGCTCCCC CGAACGGCTG GGGCGACCGC TACGGCGGCA TCCATTCCAA GGAAGAGTGC
540

GAATCCTTCC CGGAGGCCCT CAAGCCCGGC TGCAACTGGC GCTTCGACTG GTTCCAAAAC
600

25

GCCGACAACC CGTCGGTCAC CTCCAGGAG GTGGCCTGCC CGTCGGAGCT CACGTCCAAG
660

AGCGGCTGCT CCCGTAACGA CGACGGCAAC TTCCCTGCCG TCCAGATCCC CTCCAGCAGC
720

30

ACCAGCTCTC CGGTCAACCA GCCTACCAGC ACCAGCACCA CGTCCACCTC CACCACCTCG
780

35

AGCCCGCCAG TCCAGCCTAC GACTCCCAGC GGCTGCACTG CTGAGAGGTG GGCTCAGTGC
840

GGCGGCAATG GCTGGAGCGG CTGCACCACC TGGCTCGCTG GCAGCACTTG CACGAAGATT
900

40

AATGACTGGT ACCATCAGTG CCTGTAG
927

(2) INFORMATION FOR SEQ ID NO: 3B:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 308 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3B:

15 Met His Leu Ser Ala Thr Thr Gly Phe Leu Ala Leu Pro Val Leu Ala

1 5 10 15

20 Leu Asp Gln Leu Ser Gly Ile Gly Gln Thr Thr Arg Tyr Trp Asp Cys

20 25 30

25 Cys Lys Pro Ser Cys Ala Trp Pro Gly Lys Gly Pro Ser Ser Pro Val

35 40 45

30 Gln Ala Cys Asp Lys Asn Asp Asn Pro Leu Asn Asp Gly Gly Ser Thr

50 55 60

35 Arg Ser Gly Cys Asp Ala Gly Gly Ser Ala Tyr Met Cys Ser Ser Gln

65 70 75 80

40 Ser Pro Trp Ala Val Ser Asp Glu Leu Ser Tyr Gly Trp Ala Ala Val

	85	90	95
5	Lys Leu Ala Gly Ser Ser Glu Ser Gln Trp Cys Cys Ala Cys Tyr Glu		
	100	105	110
10	Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Ile Val Gln		
	115	120	125
15	Ala Thr Asn Thr Gly Gly Asp Leu Gly Asp Asn His Phe Asp Leu Ala		
	130	135	140
20	Ile Pro Gly Gly Gly Val Gly Ile Phe Asn Ala Cys Thr Asp Gln Tyr		
	145	150	155
25	Gly Ala Pro Pro Asn Gly Trp Gly Asp Arg Tyr Gly Gly Ile His Ser		
	165	170	175
30	Lys Glu Glu Cys Glu Ser Phe Pro Glu Ala Leu Lys Pro Gly Cys Asn		
	180	185	190
35	Trp Arg Phe Asp Trp Phe Gln Asn Ala Asp Asn Pro Ser Val Thr Phe		
	195	200	205
40	Gln Glu Val Ala Cys Pro Ser Glu Leu Thr Ser Lys Ser Gly Cys Ser		
	210	215	220
	Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser		

225 230 235 240

5 Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser Thr

245 250 255

10 Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys

260 265 270

15 Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys

275 280 285

20 Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr

290 295 300

25 His Gln Cys Leu

305

(2) INFORMATION FOR SEQ ID NO: 4:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

40

(A) ORGANISM: *Saccharomyces cerevisiae*, DSM

10082

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CCAGTGTGCT GGAAAGCCTT CGTGCTGTCC CCGACGTATC CCTGACCGCC ATGCGTTCCA
60
5
CCAGCATCTT GATCGGCCTT GTTGCCGGCG TCGCTGCTCA GAGCTCTGGC TCTGGCCATA
120
CAACCAGGTA CTGGGACTGC TGCAAGCCCT CATGCGCCTG GGATGAGAAG GCGGCTGTCA
10 180
GCCGGCCGGT CACAACATGC GACAGGAACA ACAGCCCCCT TTCGCCCGGC GCTGTGAGCG
240
15 GCTGCGACCC CAACGGCGTT GCATTCACCT GCAACGACAA CCAGCCTTGG GCCGTAAACA
300
ACAATGTGCG CTACGGTTTT GCGGCTACCG CCTTCCCTGG TGGCAATGAG GCGTCGTGGT
360
20 GCTGTGCCTG CTATGCTCTT CAATTCACAT CCGGCCCGT TGCTGGCAAG ACGATGGTTG
420
TGCAATCCAC CAACACTGGC GGAGATCTCA GCGGCACTCA CTTCGATATC CAGATGCCCCG
25 480
GTGGAGGTCT CGGCATCTTC GACGGGTGCA CCCCAGTTC GGGCTTCACG TTCCCCGGCA
540
30 ACCGCTACGG CGGTACCACG AGCCGACGCC AGTGGCCGA GCTGCCCTCC GTCCTCCGTG
600
ACGGCTGCCA CTGGCGTTAC GACTGGTTCA ACGATGCCGA CAACCCCAAC GTCAACTGGC
660
35 GCCGCTCCG ATGCCCCGGC GCCCTCACGA ACGCTCCGG CTGCGTCCGC AACGACGACA
720
ACAGCTACCC CGTCTTCGAG CCGGCACGG GCACCCCGCC GACCCCAAG ACCACGACTA
40 780
CCAGCTCCCC TCCTCAGCCC ACCAACGGCG GAGGCGGCGG CACTTCTCCT CACTGGGGCC
840

AGTCGGGCGG CCAGGGCTGG TCTGGCCCGA CGGCCTGTGC CGGTGGGTGG ACCTGCAACC
900

TGATCAACCC GTGGTACTCC CAGTGCATTC CCAACTAAGT GATCGGGGCA TTGCGGTGCA
5 960

AAGGGGACCG TTAGTCGACA AGGCCAGCC AGACCTCAGG CAGGTGGCTG CCATGGCAGA
1020

10 TTGTATATAG TCTCCGAGT ACATACTATT GAATGAAAAT AAGAGCGGCT CGGACCATGA
1080

GCAGATGCCA TTGATAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
1140

15 AAAAAAAAAA AAAA
1154

20 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 295 amino acids

(B) TYPE: amino acid

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Arg Ser Thr Ser Ile Leu Ile Gly Leu Val Ala Gly Val Ala Ala

1 5 10 15

35

Gln Ser Ser Gly Ser Gly His Thr Thr Arg Tyr Trp Asp Cys Cys Lys

20 25 30

40

Pro Ser Cys Ala Trp Asp Glu Lys Ala Ala Val Ser Arg Pro Val Thr

35

40

45

5

Thr Cys Asp Arg Asn Asn Ser Pro Leu Ser Pro Gly Ala Val Ser Gly

50

55

60

10

Cys Asp Pro Asn Gly Val Ala Phe Thr Cys Asn Asp Asn Gln Pro Trp

65

70

75

80

15

Ala Val Asn Asn Asn Val Ala Tyr Gly Phe Ala Ala Thr Ala Phe Pro

85

90

95

20

Gly Gly Asn Glu Ala Ser Trp Cys Cys Ala Cys Tyr Ala Leu Gln Phe

100

105

110

25

Thr Ser Gly Pro Val Ala Gly Lys Thr Met Val Val Gln Ser Thr Asn

115

120

125

30

Thr Gly Gly Asp Leu Ser Gly Thr His Phe Asp Ile Gln Met Pro Gly

130

135

140

35

Gly Gly Leu Gly Ile Phe Asp Gly Cys Thr Pro Gln Phe Gly Phe Thr

145

150

155

160

40

Phe Pro Gly Asn Arg Tyr Gly Gly Thr Thr Ser Arg Ser Gln Cys Ala

165

170

175

Glu Leu Pro Ser Val Leu Arg Asp Gly Cys His Trp Arg Tyr Asp Trp
180 185 190

5 Phe Asn Asp Ala Asp Asn Pro Asn Val Asn Trp Arg Arg Val Arg Cys
195 200 205

10 Pro Ala Ala Leu Thr Asn Arg Ser Gly Cys Val Arg Asn Asp Asp Asn
210 215 220

15 Ser Tyr Pro Val Phe Glu Pro Gly Thr Gly Thr Pro Pro Thr Pro Thr
225 230 235 240

20 Thr Thr Thr Thr Ser Ser Pro Pro Gln Pro Thr Asn Gly Gly Gly Gly
245 250 255

25 Gly Thr Ser Pro His Trp Gly Gln Cys Gly Gly Gln Gly Trp Ser Gly
260 265 270

30 Pro Thr Ala Cys Ala Gly Gly Ser Thr Cys Asn Leu Ile Asn Pro Trp
275 280 285

35 Tyr Ser Gln Cys Ile Pro Asn
290 295

40 (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1423 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*, DSM
10080

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AAAGTTCTGG CCGGAACAGA TCTCCGTTGT CGATCTTCGA TTTCCAGAC TCAGTCTGTG
60

15

ACACTCCTTC AATCCACATT CCTTACTTC TTCGTCACTC ATTCACATCA TGATTTCAGC
120

20

TTGGATTCTC CTGGGGCTGG TAGGCGCCGT GCCCTCCTCC GTCATGGCCG CCTCGGGCAA
180

AGGCCACACC ACCCGCTACT GGGATTGCTG CAAGACTTCT TGCGCATGGG AGGGCAAGGC
240

25

ATCCGTCTCC GAGCCTGTCC TGACCTGTAA CAAGCAGGAC AACCCCATCG TCGATGCCAA
300

CGCCAGAAGC GGCTGCGACG GCGGCGGGGC ATTTGCCTGT ACCAACAATT CCCCTTGGGC
360

30

CGTGAGCGAG GACCTGGCCT ACGGATTTCG TGCCACAGCC CTCAGCGGCG GCACTGAGGG
420

35

CAGCTGGTGC TCGCGGTGTT ACGCCATCAC ATTCACGAGT GGCCCTGTGG CTGGCAAGAA
480

GATGGTCGTC CAGTCCACGA ACACGGGAGG CGACCTGTCC AACAAACCACT TTGACCTGAT
540

40

GATTCCCGGT GGAGGCCTCG GCATCTTTGA CGGTTGCTCG GCTCAGTTCG GACAACTTCT
600

TCCCGGCGAG CGTTACGGAG GTGTTTCGTC CCGCTCTCAA TCGATGGCA TGCCCGAGCT
660

CTTGAAAGAC GGTGCCAGT GCGCTTCGA CTGGTTCAAG AACTCAGACA ACCCTGACAT
5 720

CGAGTTCGAG CAGGTCCAGT GTCCCAAAGA GTCATTGCG GTCTCTGGGT GCGTCCGTGA
780

10 CGACGATAGC AGCTTTCCCG TCTTCCAAGG TTCGGGCTCA GGAGATGTCA ACCCACCTCC
840

CAAGCCGACT ACGACTACGA CCTCGTCAAA GCCGAAAACA ACCTCTGCAC CATCCACTCT
900

15 CTGGAACCCA TCCGCCCTC AACAGCCAGG GAACACTGAT AGACCTGCCG AGACAACCAC
960

TACCAAGCTG CCTGCCCTGC CGGCCACGAC GAGCAGCCCT GCTGTCTCAG TTCCTTCGTC
20 1020

CAGCGCTCGC GTGCCTTTGT GGGGGCAATG CGACTCGGAA GCTTCATGGG ACGCACCTAA
1080

25 GAAGTGTGCA AAGGGCACCA AGTGTGTCTA CGTCAACGAC TGGTACTCTC AATGCCAGCC
1140

GAAGAACTCT TGTGCTTGAG AAGCAATGCT CACAGCATGT CCTCTTGTC AACCCTTCTT
1200

30 TCATTCCCAA ACATACTTAC TGTATTATTA TTTCCGATGC TTCATTTCTT GCTTGTTTCT
1260

GTCTTTCCTG CACGCAGCTT TCAACGATAC CCTTCATGCG ATTGCCCTAC GATCAGATGA
35 1320

TGGGCACGAC ATGGAGGATG GTTGGGCAC TCACGCGTTC AGGACGGGAA AATTTATTAG
1380

40 GGCTGAGATC CGTGAATTGA CTTCAATTCG GCGGAATGTC TGC
1423

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 349 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Met Ile Ser Ala Trp Ile Leu Leu Gly Leu Val Gly Ala Val Pro Ser
15 1 5 10 15
Ser Val Met Ala Ala Ser Gly Lys Gly His Thr Thr Arg Tyr Trp Asp
20 20 25 30
Cys Cys Lys Thr Ser Cys Ala Trp Glu Gly Lys Ala Ser Val Ser Glu
25 35 40 45
Pro Val Leu Thr Cys Asn Lys Gln Asp Asn Pro Ile Val Asp Ala Asn
30 50 55 60
Ala Arg Ser Gly Cys Asp Gly Gly Gly Ala Phe Ala Cys Thr Asn Asn
35 65 70 75 80
Ser Pro Trp Ala Val Ser Glu Asp Leu Ala Tyr Gly Phe Ala Ala Thr
40 85 90 95

Ala Leu Ser Gly Gly Thr Glu Gly Ser Trp Cys Cys Ala Cys Tyr Ala
100 105 110

5
Ile Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Val Val Gln
115 120 125

10
Ser Thr Asn Thr Gly Gly Asp Leu Ser Asn Asn His Phe Asp Leu Met
130 135 140

15
Ile Pro Gly Gly Gly Leu Gly Ile Phe Asp Gly Cys Ser Ala Gln Phe
145 150 155 160

20
Gly Gln Leu Leu Pro Gly Glu Arg Tyr Gly Gly Val Ser Ser Arg Ser
165 170 175

25
Gln Cys Asp Gly Met Pro Glu Leu Leu Lys Asp Gly Cys Gln Trp Arg
180 185 190

30
Phe Asp Trp Phe Lys Asn Ser Asp Asn Pro Asp Ile Glu Phe Glu Gln
195 200 205

35
Val Gln Cys Pro Lys Glu Leu Ile Ala Val Ser Gly Cys Val Arg Asp
210 215 220

40
Asp Asp Ser Ser Phe Pro Val Phe Gln Gly Ser Gly Ser Gly Asp Val
225 230 235 240

Asn Pro Pro Pro Lys Pro Thr Thr Thr Thr Thr Ser Ser Lys Pro Lys

245

250

255

5

Thr Thr Ser Ala Pro Ser Thr Leu Ser Asn Pro Ser Ala Pro Gln Gln

260

265

270

10

Pro Gly Asn Thr Asp Arg Pro Ala Glu Thr Thr Thr Thr Lys Leu Pro

275

280

285

15

Ala Leu Pro Ala Thr Thr Ser Ser Pro Ala Val Ser Val Pro Ser Ser

290

295

300

20

Ser Ala Arg Val Pro Leu Trp Gly Gln Cys Asp Ser Glu Ala Ser Trp

305

310

315

320

25

Asp Ala Pro Lys Lys Cys Ala Lys Gly Thr Lys Cys Val Tyr Val Asn

325

330

335

30

Asp Trp Tyr Ser Gln Cys Gln Pro Lys Asn Ser Cys Ala

340

345

35

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1174 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*, DSM

5 10081

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8

10

GAGCAGCACC CCTCAAGCTG TACAGTTTCC ACCCGCTCT CTTTCTTCG GCCCCAGGA
60

15 120

TGCGCTCTAC TCCCGTTCTT CGCACAACCC TGGCGCTGC ACTTCCTCTG GTCGCCTCCG

CGGCCAGTGG CAGTGGCCAG TCCACGAGAT ACTGGGACTG CTGCAAGCCG TCGTGGCTT
180

20

GGCCCGGGAA GGCCGCCGTC AGCCAACCGG TCTACGGTG CGATGCCAAC TTCCAGCGCC
240

TGTCCGACTT CAATGTCCAG TCGGGCTGCA ACGGCGGCTC GGCCTACTCC TCGCGCGACC
300

25

AGACTCCCTG GCGGGTGAAC GACAATCTCG CCTACGGCTT CGCCGCGACG AGCATCGCCG
360

30 420

GCGGGTCCGA ATCCTCGTGG TGCTGCGCCT GCTACGGCT CACCTTCACT TCGGTCCCG

TCGCCGGCAA GACAATGGTG GTGCAGTCAA CGAGCACTGG CGGCGACCTG GGAAGTAACC
480

35

AGTTCGATAT CGCCATGCCC GGCGGCGGCG TGGGCATCTT CAACGGCTGC AGCTCGCAGT
540

TCGGCGGCCT CCCCGGCGCT CAATACGGCG GCATTCGTC GCGCGACCAG TCGGATTCCT
600

40

TCCCCGCGCC GCTCAAGCCC GGCTGCCAGT GGCGGTTTGA CTGGTTCCAG AACGCCGACA
660

ACCGACGTT CACGTTCCAG CAGGTGCAGT GCGCGCGA GATCGTTGCC CGCTCGGCT
720

GCAAGCGCAA CGACGACTCC AGCTTCCCCG TCTTACCCC CCCAAGCGGT GGCAACGGTG
5 780

GCACGGGGAC GCGCACGTCG ACTGCGCCTG GGTGGGGCCA GACGTCTCCC GCGGGCGGCA
840

GTGGCTGCAC GTCTCAGAAG TGGGCTCAGT GCGGTGGCAT CGGCTTCAGC GGATGCACCA
10 900

CCTGTGTCTC TGGCACCACC TGCCAGAAGT TGAACGACTA CTACTCGCAG TGCCTCTAAA
960

CAGCTTTTCG CACGAGGTGG CCGGACGGAG CAAGGAGACC GTCAACTTCG TCATGCATAT
15 1020

TTTTTGAGCG CTC AATACAT ACATAACCTT CGATTCTTGT ACATAGCAGC CGGTACACA
20 1080

TCTCACACCG ACTTTGGGGG CGGAATCAGG CCCGTTTAA AAAAAAAAAA AAAAAAAAAA
1140

AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAA
25 1174

(2) INFORMATION FOR SEQ ID NO: 9:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 299 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

40 Met Arg Ser Thr Pro Val Leu Arg Thr Thr Leu Ala Ala Ala Leu Pro

1

5

10

15

Leu Val Ala Ser Ala Ala Ser Gly Ser Gly Gln Ser Thr Arg Tyr Trp
5 20 25 30

Asp Cys Cys Lys Pro Ser Cys Ala Trp Pro Gly Lys Ala Ala Val Ser
10 35 40 45

Gln Pro Val Tyr Ala Cys Asp Ala Asn Phe Gln Arg Leu Ser Asp Phe
15 50 55 60

Asn Val Gln Ser Gly Cys Asn Gly Gly Ser Ala Tyr Ser Cys Ala Asp
20 65 70 75 80

Gln Thr Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala
25 85 90 95

Thr Ser Ile Ala Gly Gly Ser Glu Ser Ser Trp Cys Cys Ala Cys Tyr
30 100 105 110

Ala Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Thr Met Val Val
35 115 120 125

Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn Gln Phe Asp Ile
40 130 135 140

Ala Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Ser Gln

145 150 155 160

5 Phe Gly Gly Leu Pro Gly Ala Gln Tyr Gly Gly Ile Ser Ser Arg Asp

165 170 175

10 Gln Cys Asp Ser Phe Pro Ala Pro Leu Lys Pro Gly Cys Gln Trp Arg

180 185 190

15 Phe Asp Trp Phe Gln Asn Ala Asp Asn Pro Thr Phe Thr Phe Gln Gln

195 200 205

20 Val Gln Cys Pro Ala Glu Ile Val Ala Arg Ser Gly Cys Lys Arg Asn

210 215 220

25 Asp Asp Ser Ser Phe Pro Val Phe Thr Pro Pro Ser Gly Gly Asn Gly

225 230 235 240

30 Gly Thr Gly Thr Pro Thr Ser Thr Ala Pro Gly Ser Gly Gln Thr Ser

245 250 255

35 Pro Gly Gly Gly Ser Gly Cys Thr Ser Gln Lys Trp Ala Gln Cys Gly

260 265 270

40 Gly Ile Gly Phe Ser Gly Cys Thr Thr Cys Val Ser Gly Thr Thr Cys

275 280 285

Gln Lys Leu Asn Asp Tyr Tyr Ser Gln Cys Leu

290 295

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 913 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Escherichia coli*, DSM 10512

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

15

GCCTATTCT CAGCTCCATT CTCCTTGAA GTAATTCACC ATGTTCTCTC CGCTCTGGGC
60

20

CCTGTGGGCT CTGCTCCTAT TTCCTGCCAC TGAAGCCACT AGCGGCGTGA CAACCAGGTA
120

CTGGGACTGC TGCAAGCCGT CTTGTGCTTG GACGGGCAAA GCATCCGTCT CCAAGCCCGT
180

25

CGGAACCTGC GACATCAACG ACAACGCCCA GACGCCGAGC GATCTGCTCA AGTCGTCTCTG
240

TGATGGCGGC AGCGCCTACT ACTGCAGCAA CCAGGGCCCA TGGGCGGTGA ACGACAGCCT
300

30

TTCCTACGGC TTCGCTGCCG CCAAGCTGTC CGGAAAGCAG GAGACTGATT GGTGCTGTGG
360

35

CTGCTACAAG CTCACATTCA CCTCCACCGC CGTTCCGGC AAGCAAATGA TCGTGCAAAT
420

CACGAACACG GCGGGGACG TCGGCAACAA CCACTTCGAC ATCGCCATGC CGGGCGGCGG
480

40

CGTCGGCATC TTCAACGGGT GCTCCAAGCA ATGGAACGGC ATCAATCTGG GCAACCAGTA
540

TGGCGGCTTC ACTGACCGCT CGCAATGTGC GACGCTCCCG TCCAAGTGGC AGGCCAGCTG
600

CAACTGGCGC TTCGACTGGT TCGAGAATGC CGACAACCCC ACCGTCGATT GGGAGCCTGT
5 660

CACTTGCCCA CAGGAATTGG TCGCCCGGAC TGGCTGTTCC CGTACCTAAG TGGGGGTGGA
720

ACCTCCATGT GAATTGGTGT ATATAGCTCC TGCCTGAGCA TCCACCAGTT CGCATGTGTT
10 780

GATCAGGAGT TGTGTTGCCT TGCTAGGAAA GACTTTGTTG GAAACTTGC G TTTTATTCC
840

15 AATTGAATAA CCCTGTATAG ACCGGTCACA TTTTCTCTG AAAAAAAAAA AAAAAAAAAA
900

AAAAAAAAAA AAA
20 913

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 222 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Met Phe Ser Pro Leu Trp Ala Leu Ser Ala Leu Leu Leu Phe Pro Ala
35 1 5 10 15

Thr Glu Ala Thr Ser Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys
40 20 25 30

Pro Ser Cys Ala Trp Thr Gly Lys Ala Ser Val Ser Lys Pro Val Gly
35 40 45

5 Thr Cys Asp Ile Asn Asp Asn Ala Gln Thr Pro Ser Asp Leu Leu Lys
50 55 60

10 Ser Ser Cys Asp Gly Gly Ser Ala Tyr Tyr Cys Ser Asn Gln Gly Pro
65 70 75 80

15 Trp Ala Val Asn Asp Ser Leu Ser Tyr Gly Phe Ala Ala Ala Lys Leu
85 90 95

20 Ser Gly Lys Gln Glu Thr Asp Trp Cys Cys Gly Cys Tyr Lys Leu Thr
100 105 110

25 Phe Thr Ser Thr Ala Val Ser Gly Lys Gln Met Ile Val Gln Ile Thr
115 120 125

30 Asn Thr Gly Gly Asp Leu Gly Asn Asn His Phe Asp Ile Ala Met Pro
130 135 140

35 Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Lys Gln Trp Asn Gly
145 150 155 160

40 Ile Asn Leu Gly Asn Gln Tyr Gly Gly Phe Thr Asp Arg Ser Gln Cys
165 170 175

Ala Thr Leu Pro Ser Lys Trp Gln Ala Ser Cys Asn Trp Arg Phe Asp

180

185

190

5

Trp Phe Glu Asn Ala Asp Asn Pro Thr Val Asp Trp Glu Pro Val Thr

195

200

205

10

Cys Pro Gln Glu Leu Val Ala Arg Thr Gly Cys Ser Arg Thr

210

215

220

15 2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 808 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Escherichia coli, DSM 10511

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

30 CCGCTGCTGG GATATAATG CTCAGACTTG GAACCAATGG TCCATCCAAA CATGCTTAAA
60

ACGCTCGCTC CATTGATCAT CTTGGCGGCC TCGGTCACAG CGCAAACAGC AGGAGTTACG
120

35 ACCCGCTACT GGGACTGCTG CAAGCCAAGC TGTGGATGGA GTGGAAAGGC TTCTGTTTCT
180

GCTCCAGTCA GAACTTGCGA TCGTAATGGA AATACACTTG GCCCAGACGT GAAAAGCCGA
40 240

TGTGATAGCG GTGGAACGTC ATTCACTTGC GCGAACAATG GTCCATTTCG GATTGACAAT
300

AACACTGCAT ATGGTTTTGC TGCAGCCAC TTAGCGGGCT CTAGCGAAGC AGCCTGGTGT
5 360

TGCCAGTGCT ACGAATTGAC GTTACGAGT GGACCCGTAG TTGGGAAGAA ACTGACCGTT
420

10 CAAGTCACAA ACACGGGAGG TGACCTCGGA AATAATCACT TTGACCTGAT GATCCCCGGT
480

GGAGGTGTTG GCCTCTTCAC ACAAGGATGT CCTGCTCAGT TTGGGAGCTG GAACGGGGGT
540

15 GCTCAATACG GGGGTGTGTC CAGCCGTGAC CAATGCTCCC AACTTCCAGC AGCTGTGCAA
600

GCTGGATGTC AATTCCGTTT CGACTGGATG GGTGGCGCGG ATAACCCCAA CGTCACCTTC
20 660

CGACCTGTGA CCTGCCCAGC GCAGCTCACT AATATCTCGG GCTGTGTTTG TAAATGATTC
720

25 ACGAATATGT AGTGTCGAAT ATGTACATGT GTATGTACTA TAGCTTCAA GATGGAGGGT
780

CTGTTTAAAA AAAAAAAAAA AAAAAAAAAA
808

30

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 226 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

	Met	Val	His	Pro	Asn	Met	Leu	Lys	Thr	Leu	Ala	Pro	Leu	Ile	Ile	Leu
5	1				5					10					15	
	Ala	Ala	Ser	Val	Thr	Ala	Gln	Thr	Ala	Gly	Val	Thr	Thr	Arg	Tyr	Trp
10					20					25					30	
	Asp	Cys	Cys	Lys	Pro	Ser	Cys	Gly	Trp	Ser	Gly	Lys	Ala	Ser	Val	Ser
15				35					40					45		
	Ala	Pro	Val	Arg	Thr	Cys	Asp	Arg	Asn	Gly	Asn	Thr	Leu	Gly	Pro	Asp
20			50					55					60			
	Val	Lys	Ser	Gly	Cys	Asp	Ser	Gly	Gly	Thr	Ser	Phe	Thr	Cys	Ala	Asn
25		65				70					75				80	
	Asn	Gly	Pro	Phe	Ala	Ile	Asp	Asn	Asn	Thr	Ala	Tyr	Gly	Phe	Ala	Ala
30					85						90				95	
	Ala	His	Leu	Ala	Gly	Ser	Ser	Glu	Ala	Ala	Trp	Cys	Cys	Gln	Cys	Tyr
35					100					105					110	
	Glu	Leu	Thr	Phe	Thr	Ser	Gly	Pro	Val	Val	Gly	Lys	Lys	Leu	Thr	Val
40					115					120					125	
	Gln	Val	Thr	Asn	Thr	Gly	Gly	Asp	Leu	Gly	Asn	Asn	His	Phe	Asp	Leu

170

130

135

140

5

Met Ile Pro Gly Gly Gly Val Gly Leu Phe Thr Gln Gly Cys Pro Ala

145

150

155

160

10

Gln Phe Gly Ser Trp Asn Gly Gly Ala Gln Tyr Gly Gly Val Ser Ser

165

170

175

15

Arg Asp Gln Cys Ser Gln Leu Pro Ala Ala Val Gln Ala Gly Cys Gln

180

185

190

20

Phe Arg Phe Asp Trp Met Gly Gly Ala Asp Asn Pro Asn Val Thr Phe

195

200

205

25

Arg Pro Val Thr Cys Pro Ala Gln Leu Thr Asn Ile Ser Gly Cys Val

210

215

220

30

Arg Lys

225

(2) INFORMATION FOR SEQ ID NO: 14-A:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1048 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14-A:

GACTTGGAAAC CAATGGTCCA TCCAAACATG CTTAAAACGC TCGCTCCATT GATCATCTTG
60
5 GCGCGCTCGG TCACAGCGCA AACAGCAGGA GTTACGACCC GCTACTGGGA CTGCTGCAAG
120
CCAAGCTGTG GATGGAGTGG AAAGGCTTCT GTTCTGCTC CAGTCAGAAC TTGCGATCGT
10 180
AATGGAAATA CACTTGGCCC AGACGTGAAA AGCGGATGTG ATAGCGGTGG AACGTCATTC
240
15 ACTTGCGCGA ACAATGGTCC ATTTGCGATT GACAATAACA CTGCATATGG TTTTGCTGCA
300
GCCCACTTAG CGGGCTCTAG CGAAGCAGCC TGGTGTGCGC AGTGCTACGA ATTGACGTTT
360
20 ACGAGTGGAC CCGTAGTTGG GAAGAACTG ACCGTTCAAG TCACAAACAC GGGAGGTGAC
420
CTCGGAAATA ATCACTTTGA CCTGATGATC CCCGCTGGAG GTGTTGGCCT CTTACACAA
25 480
GGATGTCCTG CTCAGTTTGG GAGCTGGAAC GGGGGTGCTC AATACGGGGG TGTGTCCAGC
540
30 CGTGACCAAT GCTCCCAACT TCCAGCAGCT GTGCAAGCTG GATGTCAATT CCGTTTCGAC
600
TGGATGGGTG GCGCGGATAA CCCCAACGTC ACCTTCGAC CTGTGACCTG CCCAGCGCAG
660
35 CTCACTAATA TCTCGGGCTG TGTTTCGTAAA CCCTCCAGCA GCACCAGCTC TCCGGTCAAC
720
CAGCCTACCA GCACCAGCAC CACGTCCACC TCCACCACCT CGAGCCCGCC AGTCCAGCCT
40 780
ACGACTCCCA GCGGCTGCAC TGCTGAGAGG TGGGCTCAGT GCGGCGGCAA TGGCTGGAGC
840

GGCTGCACCA CCTGCGTCGC TGGCAGCACT TGCACGAAGA TTAATGACTG GTACCATCAG
900

TGCCTGTAGA CGCAGGGCAG CTTGAGGGCC TTACTGGTGG CGCAACGAAA TGACACTCCC
5 960

AATCACTGTA TTAGTTCTTG TACATAATTT CGTCATCCCT CCAGGGATTG TCACATAAAT
1020

GCAATGAGGA ACAATGAGTA CAGAATTC
1048

(2) INFORMATION FOR SEQ ID NO: 14-B:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 298 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14-B:

25 Met Val His Pro Asn Met Leu Lys Thr Leu Ala Pro Leu Ile Ile Leu
1 5 10 15

30 Ala Ala Ser Val Thr Ala Gln Thr Ala Gly Val Thr Thr Arg Tyr Trp
20 25 30

35 Asp Cys Cys Lys Pro Ser Cys Gly Trp Ser Gly Lys Ala Ser Val Ser
35 40 45

40 Ala Pro Val Arg Thr Cys Asp Arg Asn Gly Asn Thr Leu Gly Pro Asp
50 55 60

Val Lys Ser Gly Cys Asp Ser Gly Gly Thr Ser Phe Thr Cys Ala Asn
5 65 70 75 80

Asn Gly Pro Phe Ala Ile Asp Asn Asn Thr Ala Tyr Gly Phe Ala Ala
10 85 90 95

Ala His Leu Ala Gly Ser Ser Glu Ala Ala Trp Cys Cys Gln Cys Tyr
15 100 105 110

Glu Leu Thr Phe Thr Ser Gly Pro Val Val Gly Lys Lys Leu Thr Val
20 115 120 125

Gln Val Thr Asn Thr Gly Gly Asp Leu Gly Asn Asn His Phe Asp Leu
25 130 135 140

Met Ile Pro Gly Gly Gly Val Gly Leu Phe Thr Gln Gly Cys Pro Ala
30 145 150 155 160

Gln Phe Gly Ser Trp Asn Gly Gly Ala Gln Tyr Gly Gly Val Ser Ser
35 165 170 175

Arg Asp Gln Cys Ser Gln Leu Pro Ala Ala Val Gln Ala Gly Cys Gln
40 180 185 190

Phe Arg Phe Asp Trp Met Gly Gly Ala Asp Asn Pro Asn Val Thr Phe

	195	200	205
	Arg Pro Val Thr Cys Pro Ala Gln Leu Thr Asn Ile Ser Gly Cys Val		
5	210	215	220
	Arg Lys Pro Ser Ser Ser Thr Ser Ser Pro Val Asn Gln Pro Thr Ser		
10	225	230	235 240
	Thr Ser Thr Thr Ser Thr Ser Thr Thr Ser Ser Pro Pro Val Gln Pro		
15	245	250	255
	Thr Thr Pro Ser Gly Cys Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly		
20	260	265	270
	Asn Gly Trp Ser Gly Cys Thr Thr Cys Val Ala Gly Ser Thr Cys Thr		
25	275	280	285
	Lys Ile Asn Asp Trp Tyr His Gln Cys Leu		
30	290	295	

(2) INFORMATION FOR SEQ ID NO: 15-A:

- (i) SEQUENCE CHARACTERISTICS:
- 35 (A) LENGTH: 1031 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 40 (ii) MOLECULE TYPE: cDNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 15-A:

CCATCCAAAC ATGCTTAAAA CGCTGCTCC ATTGATCATC TTGGCCGCCT CGGTCACAGC
60
5
GCAAACAGCA GGAGTTACGA CCCGCTACTG GGAATGCTGC AAGCCAAGCT GTGGATGGAG
120
TGGAAAGGCT TCTGTTTCTG CTCCAGTCAG AACTTGGGAT CGTAATGGAA ATACACTTGG
10 180
CCCAGACGTG AAAAGCGGAT GTGATAGCGG TGAACGTCA TTCACTTGGC CGAACAATGG
240
15 TCCATTGCG ATTGACAATA AACTGCGATA TGGTTTGCT GCAGCCCACT TAGCGGGCTC
300
TAGCGAAGCA GCCTGGTGTT GCCAGTGCTA CGAATTGACG TTTACGAGTG GACCCGTAGT
360
20 TGGGAAGAAA CTGACCGTTC AAGTCACAAA CACGGGAGGT GACCTCGGAA ATAATCACTT
420
TGACCTGATG ATCCCCGGTG GAGGTGTTGG CCTCTTCACA CAAGGATGTC CTGCTCAGTT
25 480
TGGGAGCTGG AACGGGGGTG CTCAATACGG GGGTGTGTCC AGCCGTGACC AATGCTCCCA
540
30 ACTTCCAGCA GCTGTGCAAG CTGGATGTCA ATTCCGTTTC GACTGGATGG GTGGCGCGGA
600
TAACCCCAAC GTCACCTTCC GACCTGTGAC CTGCCCAGCG CAGCTCACTA ATATCTCGGG
660
35 CTGTGTTTGT AAACCTTCCA GCAGCACCAG CTCTCCGGTC AACCAGCCTA CCAGCACCAG
720
CACCACGTCC ACCTCCACCA CCTCGAGCCC GCCAGTCCAG CCTACGACTC CCAGCGGCTG
40 780
CACTGCTGAG AGGTGGGCTC AGTGGGGCGG CAATGGCTGG AGCGGCTGCA CCACCTGCGT
840

CGCTGGCAGC ACTTGACGA AGATTAAATGA CTGGTACCAT CAGTGCCTGT AGACGCAGGG
900

CAGCTTGAGG GCCTTACTGG TGGCGCAACG AAATGACACT CCCAATCACT GTATTAGTTC
5 960

TTGTACATAA TTTCGTCATC CCTCCAGGGA TTGTCACATA AATGCAATGA GGAACAATGA
1020

10 GTACAGAATT C
1031

(2) INFORMATION FOR SEQ ID NO: 15-B:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 293 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15-B:

25 Met Leu Lys Thr Leu Ala Pro Leu Ile Ile Leu Ala Ala Ser Val Thr
1 5 10 15

30 Ala Gln Thr Ala Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys Pro
20 25 30

35 Ser Cys Gly Trp Ser Gly Lys Ala Ser Val Ser Ala Pro Val Arg Thr
35 40 45

40 Cys Asp Arg Asn Gly Asn Thr Leu Gly Pro Asp Val Lys Ser Gly Cys
50 55 60

Asp Ser Gly Gly Thr Ser Phe Thr Cys Ala Asn Asn Gly Pro Phe Ala
5 65 70 75 80

Ile Asp Asn Asn Thr Ala Tyr Gly Phe Ala Ala Ala His Leu Ala Gly
10 85 90 95

Ser Ser Glu Ala Ala Trp Cys Cys Gln Cys Tyr Glu Leu Thr Phe Thr
15 100 105 110

Ser Gly Pro Val Val Gly Lys Lys Leu Thr Val Gln Val Thr Asn Thr
20 115 120 125

Gly Gly Asp Leu Gly Asn Asn His Phe Asp Leu Met Ile Pro Gly Gly
25 130 135 140

Gly Val Gly Leu Phe Thr Gln Gly Cys Pro Ala Gln Phe Gly Ser Trp
30 145 150 155 160

Asn Gly Gly Ala Gln Tyr Gly Gly Val Ser Ser Arg Asp Gln Cys Ser
35 165 170 175

Gln Leu Pro Ala Ala Val Gln Ala Gly Cys Gln Phe Arg Phe Asp Trp
40 180 185 190

Met Gly Gly Ala Asp Asn Pro Asn Val Thr Phe Arg Pro Val Thr Cys

195 200 205

5 Pro Ala Gln Leu Thr Asn Ile Ser Gly Cys Val Arg Lys Pro Ser Ser
210 215 220

10 Ser Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr Ser
225 230 235 240

15 Thr Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly
245 250 255

20 Cys Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly
260 265 270

25 Cys Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp
275 280 285

30 Tyr His Gln Cys Leu
290

(2) INFORMATION FOR SEQ ID NO: 16:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1132 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

40

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Escherichia coli*, DSM 10571

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

5
CAACAGTTCA AACACCTACA AGGTCCCGTG CCCTGTAGAC CATGCGTTCC TCTGCAGTCC
60

10
TCATCGGCCT CGTGGCCCGT GTGGCCGCCC AGTCCTCTGG CACCGGCCGC ACCACCAGAT
120

15
ACTGGGACTG CTGCAAGCCG TCCTGCCGGT GGGACGAAA GGCCTCCGTC AGCCAGCCCG
180

20
TCAAGACGTG CGATAGGAAC AACAAACCCTC TCGCGTCCAC GGCCAGGAGC GGCTGCGATT
240

25
CCAACGGCGT CGCCTACACG TGCAACGATA ACCAGCCGTG GGCTGTCAAC GATAACCTGG
300

35
CCTATGGTTT TGCTGCCACG GCTTTCAGTG GTGGATCGGA GGCCAGCTGG TGCTGTGCCT
360

40
GCTATGCCCT TCAGTTCACC TCCGGCCCTG TTGCGGGAAA GACCATGGTC GTCCAGTCGA
420

45
CAAACACCGG CGGCGACCTC AGCGGCAACC ACTTTGACAT CCTCATGCCC GGCGGCGGCC
480

50
TGGGCATCTT CGACGGCTGC ACCCCGCAAT GGGGCGTCAG CTCCCCGGA AACCCTACG
540

55
GCGGCACCAC CAGCCGCAGC CAGTGCTCCC AAATCCCCTC GGCCCTGCAG CCGGCTGCA
600

60
ACTGGCGGTA CGACTGGTTC AACGACGCCG ACAACCCCGA CGTCTCGTGG CGCCGCGTCC
660

65
AGTGCCCCGC CGCACTCACC GACCGCACCG GCTGCCGCCG CTCCGATGAC GGGAACTATC
720

70
CGTCTTCCA GCCCGGTCCG CCCCCGCCA CGACGATCAG GACATCGACT ACCATCACAG
780

CCTCATCGTC GTCTTCGTCT TCGTCGTCTG CGACTACGGC TGGTAGCCCG CCTGTGCCGA
840

CTGGTGGTGG TAGTGGGCCA ACGTCGCCTG TCTGGGGACA GTCGGGCGGT CAGGGATGGA
5 900

GTGGTCCTAC GCGTTGTGTT GCTGGGTCGA CATGCAGTGT GGTCAACCCG TGGTACTCGC
960

10 AGTGTTTTCC TTAAGGAGCC TCTGGCTGAG CAGATCCTTT CGAAGAGGAG GGTCTCTCTG
1020

CTCTTTCAGT CTGTTCAGGG AACGGCCGTC TCGGCTACAT TGTACATATC CCACCTCGTA
1080

15 TATAGCTAGC TCATCTACAC TTGTGATCTC CAAAAAAAAA AAAAAAAAAA AA
1132

(2) INFORMATION FOR SEQ ID NO: 17:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 310 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

30

Met Arg Ser Ser Ala Val Leu Ile Gly Leu Val Ala Gly Val Ala Ala

1 5 10 15

35

Gln Ser Ser Gly Thr Gly Arg Thr Thr Arg Tyr Trp Asp Cys Cys Lys

20 25 30

40

Pro Ser Cys Gly Trp Asp Glu Lys Ala Ser Val Ser Gln Pro Val Lys

	35	40	45
5	Thr Cys Asp Arg Asn Asn Asn Pro Leu Ala Ser Thr Ala Arg Ser Gly		
	50	55	60
10	Cys Asp Ser Asn Gly Val Ala Tyr Thr Cys Asn Asp Asn Gln Pro Trp		
	65	70	75 80
15	Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Thr Ala Phe Ser		
	85	90	95
20	Gly Gly Ser Glu Ala Ser Trp Cys Cys Ala Cys Tyr Ala Leu Gln Phe		
	100	105	110
25	Thr Ser Gly Pro Val Ala Gly Lys Thr Met Val Val Gln Ser Thr Asn		
	115	120	125
30	Thr Gly Gly Asp Leu Ser Gly Asn His Phe Asp Ile Leu Met Pro Gly		
	130	135	140
35	Gly Gly Leu Gly Ile Phe Asp Gly Cys Thr Pro Gln Trp Gly Val Ser		
	145	150	155 160
40	Phe Pro Gly Asn Arg Tyr Gly Gly Thr Thr Ser Arg Ser Gln Cys Ser		
	165	170	175
	Gln Ile Pro Ser Ala Leu Gln Pro Gly Cys Asn Trp Arg Tyr Asp Trp		

	180	185	190
5	Phe Asn Asp Ala Asp Asn Pro Asp Val Ser Trp Arg Arg Val Gln Cys		
	195	200	205
10	Pro Ala Ala Leu Thr Asp Arg Thr Gly Cys Arg Arg Ser Asp Asp Gly		
	210	215	220
15	Asn Tyr Pro Val Phe Gln Pro Gly Pro Pro Pro Ala Thr Thr Ile Arg		
	225	230	235 240
20	Thr Ser Thr Thr Ile Thr Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser		
	245	250	255
25	Ser Thr Thr Ala Gly Ser Pro Pro Val Pro Thr Gly Gly Gly Ser Gly		
	260	265	270
30	Pro Thr Ser Pro Val Trp Gly Gln Cys Gly Gly Gln Gly Trp Ser Gly		
	275	280	285
35	Pro Thr Arg Cys Val Ala Gly Ser Thr Cys Ser Val Val Asn Pro Trp		
	290	295	300
40	Tyr Ser Gln Cys Phe Pro		
	305	310	

(2) INFORMATION FOR SEQ ID NO: 18-A:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 885 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(vi) ORIGINAL SOURCE:

"Construction from Macrophomina"

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
(B) LOCATION: 1..885

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18-A:

20 ATG TTC TCT CCG CTC TGG GCC CTG TCG GCT CTG CTC CTA TTT CCT GCC
48
Met Phe Ser Pro Leu Trp Ala Leu Ser Ala Leu Leu Leu Phe Pro Ala
145 150 155

25 ACT GAA GCC ACT AGC GGC GTG ACA ACC AGG TAC TGG GAC TGC TGC AAG
96
Thr Glu Ala Thr Ser Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys
160 165 170

30 CCG TCT TGT GCT TGG ACG GGC AAA GCA TCC GTC TCC AAG CCC GTC GGA
144
Pro Ser Cys Ala Trp Thr Gly Lys Ala Ser Val Ser Lys Pro Val Gly
175 180 185

35 ACC TGC GAC ATC AAC GAC AAC GCC CAG ACG CCG AGC GAT CTG CTC AAG
192
Thr Cys Asp Ile Asn Asp Asn Ala Gln Thr Pro Ser Asp Leu Leu Lys
190 195 200 205

40 TCG TCC TGT GAT GGC GGC AGC GCC TAC TAC TGC AGC AAC CAG GGC CCA

240
 Ser Ser Cys Asp Gly Gly Ser Ala Tyr Tyr Cys Ser Asn Gln Gly Pro
 210 215 220

5 TGG GCC GTG AAC GAC AGC CTT TCC TAC GGC TTC GCT GCC GCC AAG CTG
 288
 Trp Ala Val Asn Asp Ser Leu Ser Tyr Gly Phe Ala Ala Ala Lys Leu
 225 230 235

10 TCC GGA AAG CAG GAG ACT GAT TGG TGC TGT GGC TGC TAC AAG CTC ACA
 336
 Ser Gly Lys Gln Glu Thr Asp Trp Cys Cys Gly Cys Tyr Lys Leu Thr
 240 245 250

15 TTC ACC TCC ACC GCC GTT TCC GGC AAG CAA ATG ATC GTG CAA ATC ACG
 384
 Phe Thr Ser Thr Ala Val Ser Gly Lys Gln Met Ile Val Gln Ile Thr
 255 260 265

20 AAC ACG GGC GGC GAC CTC GGC AAC AAC CAC TTC GAC ATC GCC ATG CCG
 432
 Asn Thr Gly Gly Asp Leu Gly Asn Asn His Phe Asp Ile Ala Met Pro
 270 275 280 285

25 GGC GGC GGC GTC GGC ATC TTC AAC GGG TGC TCC AAG CAA TGG AAC GGC
 480
 Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Lys Gln Trp Asn Gly
 290 295 300

30 ATC AAT CTG GGC AAC CAG TAT GGC GGC TTC ACT GAC CGC TCG CAA TGT
 528
 Ile Asn Leu Gly Asn Gln Tyr Gly Gly Phe Thr Asp Arg Ser Gln Cys
 305 310 315

35 GCG ACG CTC CCG TCC AAG TGG CAG GCC AGC TGC AAC TGG CGC TTC GAC
 576
 Ala Thr Leu Pro Ser Lys Trp Gln Ala Ser Cys Asn Trp Arg Phe Asp
 320 325 330

40 TGG TTC GAG AAT GCC GAC AAC CCC ACC GTC GAT TGG GAG CCT GTC ACT
 624
 Trp Phe Glu Asn Ala Asp Asn Pro Thr Val Asp Trp Glu Pro Val Thr
 335 340 345

TGC CCA CAG GAA TTG GTC GCC CGG ACT GGC TGT TCC CGT ACC CCC TCC
 672
 Cys Pro Gln Glu Leu Val Ala Arg Thr Gly Cys Ser Arg Thr Pro Ser
 350 355 360 365
 5
 AGC AGC ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC AGC
 720
 Ser Ser Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Thr
 370 375 380
 10
 TCC ACC TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC
 768
 Ser Thr Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser
 385 390 395
 15
 GGC TGC ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC
 816
 Gly Cys Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser
 400 405 410
 20
 GGC TGC ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC
 864
 Gly Cys Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp
 415 420 425
 25
 TGG TAC CAT CAG TGC CTG TAG
 885
 Trp Tyr His Gln Cys Leu *
 430 435
 30

(2) INFORMATION FOR SEQ ID NO: 18-B:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 295 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18-B:

Met Phe Ser Pro Leu Trp Ala Leu Ser Ala Leu Leu Leu Phe Pro Ala

	1		5		10		15									
	Thr	Glu	Ala	Thr	Ser	Gly	Val	Thr	Thr	Arg	Tyr	Trp	Asp	Cys	Cys	Lys
				20				25						30		
5	Pro	Ser	Cys	Ala	Trp	Thr	Gly	Lys	Ala	Ser	Val	Ser	Lys	Pro	Val	Gly
			35					40					45			
	Thr	Cys	Asp	Ile	Asn	Asp	Asn	Ala	Gln	Thr	Pro	Ser	Asp	Leu	Leu	Lys
10		50					55					60				
	Ser	Ser	Cys	Asp	Gly	Gly	Ser	Ala	Tyr	Tyr	Cys	Ser	Asn	Gln	Gly	Pro
	65					70					75				80	
15	Trp	Ala	Val	Asn	Asp	Ser	Leu	Ser	Tyr	Gly	Phe	Ala	Ala	Ala	Lys	Leu
					85					90					95	
	Ser	Gly	Lys	Gln	Glu	Thr	Asp	Trp	Cys	Cys	Gly	Cys	Tyr	Lys	Leu	Thr
				100					105					110		
20	Phe	Thr	Ser	Thr	Ala	Val	Ser	Gly	Lys	Gln	Met	Ile	Val	Gln	Ile	Thr
				115					120					125		
	Asn	Thr	Gly	Gly	Asp	Leu	Gly	Asn	Asn	His	Phe	Asp	Ile	Ala	Met	Pro
25		130					135					140				
	Gly	Gly	Gly	Val	Gly	Ile	Phe	Asn	Gly	Cys	Ser	Lys	Gln	Trp	Asn	Gly
	145					150					155				160	
30	Ile	Asn	Leu	Gly	Asn	Gln	Tyr	Gly	Gly	Phe	Thr	Asp	Arg	Ser	Gln	Cys
					165					170					175	
	Ala	Thr	Leu	Pro	Ser	Lys	Trp	Gln	Ala	Ser	Cys	Asn	Trp	Arg	Phe	Asp
				180					185					190		
35	Trp	Phe	Glu	Asn	Ala	Asp	Asn	Pro	Thr	Val	Asp	Trp	Glu	Pro	Val	Thr
				195				200					205			
	Cys	Pro	Gln	Glu	Leu	Val	Ala	Arg	Thr	Gly	Cys	Ser	Arg	Thr	Pro	Ser
40		210					215					220				
	Ser	Ser	Thr	Ser	Ser	Pro	Val	Asn	Gln	Pro	Thr	Ser	Thr	Ser	Thr	Thr
	225					230					235				240	

Ser Thr Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser
245 250 255

5 Gly Cys Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser
260 265 270

Gly Cys Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp
275 280 285

10 Trp Tyr His Gln Cys Leu *
290 295

(2) INFORMATION FOR SEQ ID NO: 19:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 425 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

25

(A) ORGANISM: Escherichia coli, DSM 10576

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..425

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CAAGATACAA TATGCGTTCC TCCACTATTT TGCAAACCGG CCTGGTGGCC GTTCTCCCCT
60

35

TCGCCGTCCA GGCCGCCTCA GGATCCGGCA AGTCCACCAG ATATTGGGAC TGCTGCAAAC
120

40

CATCTTGTGC CTGCTCCGGC AAGGCTTCTG TCAACCGCCC TGTCTCGCC TGCAACGCAA
180

ACAACAACCC GCTGAACGAC GCCAACGTCA AGTCAGGATG TGATGGCGGT TCTGCATACA
240

5 CCTGTGCCAA CAACTCTCCC TGGGCACTGA ATGACAATCT GGCCTACGGC TTCGCGGCCA
300

CAAACTCAG CCGGGGGACC GAGTCATCTT GGTGCTGCGC CTGTTATGCC CTCACATTCA
360

10 CATCGGGTCC TGTTCCTGGC AAAACCTTGG TTGTCCAGTC TACCAGTACC GGTGGTGATC
420

TTGGC
425

15

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 141 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Arg Ser Ser Thr Ile Leu Gln Thr Gly Leu Val Ala Val Leu Pro

30 1 5 10 15

Phe Ala Val Gln Ala Ala Ser Gly Ser Gly Lys Ser Thr Arg Tyr Trp

35 20 25 30

Asp Cys Cys Lys Pro Ser Cys Ala Trp Ser Gly Lys Ala Ser Val Asn

40 35 40 45

Arg Pro Val Leu Ala Cys Asn Ala Asn Asn Asn Pro Leu Asn Asp Ala

50 55 60

5 Asn Val Lys Ser Gly Cys Asp Gly Gly Ser Ala Tyr Thr Cys Ala Asn
65 70 75 80

10 Asn Ser Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala
85 90 95

15 Thr Lys Leu Ser Gly Gly Thr Glu Ser Ser Trp Cys Cys Ala Cys Tyr
100 105 110

20 Ala Leu Thr Phe Thr Ser Gly Pro Val Ser Gly Lys Thr Leu Val Val
115 120 125

25 Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly
130 135

(2) INFORMATION FOR SEQ ID NO: 21:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

40

(A) ORGANISM: *Saccobolus dilutellus*

(B) STRAIN: CBS 275.96

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..108

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TCG GCT TGC GAT AAC GGT GGT GGC ACT GCA TAC ATG TGT GCC AGC CAG
Ser Ala Cys Asp Asn Gly Gly Gly Thr Ala Tyr Met Cys Ala Ser Gln
10 1 5 10 15
GAG CCG TGG GCA GTG AGC TCC AAC GTC GCG TAC GGC TTT GCT GCA GTT
Glu Pro Trp Ala Val Ser Ser Asn Val Ala Tyr Gly Phe Ala Ala Val
15 20 25 30
AGA ATC AGC GGA
Arg Ile Ser Gly
20 35

(2) INFORMATION FOR SEQ ID NO: 22:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Ser Ala Cys Asp Asn Gly Gly Gly Thr Ala Tyr Met Cys Ala Ser Gln
1 5 10 15
35 Glu Pro Trp Ala Val Ser Ser Asn Val Ala Tyr Gly Phe Ala Ala Val
20 25 30
Arg Ile Ser Gly
40 35

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 99 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Thermomyces verrucosus*
(B) STRAIN: CBS 285.96

15 (ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..99

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GCC TGC AAC GCA AAC TTC CAG CGC ATC AGT GAC CCC AAC GCC AAG TCG
Ala Cys Asn Ala Asn Phe Gln Arg Ile Ser Asp Pro Asn Ala Lys Ser

25

GGC TGC GAT GGT GGC TCG GCC TTC TCT TGC GCC AAA CAA ACC CCT TGG
Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Lys Gln Thr Pro Trp

30 GCC
Ala

(2) INFORMATION FOR SEQ ID NO: 24:

35

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

5

Ala Cys Asn Ala Asn Phe Gln Arg Ile Ser Asp Pro Asn Ala Lys Ser
1 5 10 15

10 Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Lys Gln Thr Pro Trp
20 25 30

Ala

15 (2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 225 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Xylaria hypoxylon

(B) STRAIN: CBS 284.96

(ix) FEATURE:

30 (A) NAME/KEY: CDS

(B) LOCATION:1..225

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

35

GAC CAG CCG CTC GGC GGA CAA CGG ACG CGA CCA AGG AGC GCG TGC GAC
48

Asp Gln Pro Leu Gly Gly Gln Arg Thr Arg Pro Arg Ser Ala Cys Asp
35 40 45

AAT GGC GGC TCT GCA TAC ATG TGC AGC AAC CAG AGC CCG TGG GCC GTC
 96
 Asn Gly Gly Ser Ala Tyr Met Cys Ser Asn Gln Ser Pro Trp Ala Val
 50 55 60 65
 5
 GAC GAT TCT CTC AGT TAC GGA TGG GCT GCC GTT AGG ATC TAT GGA CAT
 144
 Asp Asp Ser Leu Ser Tyr Gly Trp Ala Ala Val Arg Ile Tyr Gly His
 70 75 80
 10
 ACC GAA ACT ACT TGG TGC TGC GCT TGC TAC GAG TTG ACT TTT ACC AGC
 192
 Thr Glu Thr Thr Trp Cys Cys Ala Cys Tyr Glu Leu Thr Phe Thr Ser
 85 90 95
 15
 GGT CCG GTT AGC GGC AAG AAG ATG ATT GTT CAG
 225
 Gly Pro Val Ser Gly Lys Lys Met Ile Val Gln
 100 105
 20

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 75 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Asp Gln Pro Leu Gly Gly Gln Arg Thr Arg Pro Arg Ser Ala Cys Asp
 1 5 10 15
 35 Asn Gly Gly Ser Ala Tyr Met Cys Ser Asn Gln Ser Pro Trp Ala Val
 20 25 30
 Asp Asp Ser Leu Ser Tyr Gly Trp Ala Ala Val Arg Ile Tyr Gly His
 35 40 45
 40
 Thr Glu Thr Thr Trp Cys Cys Ala Cys Tyr Glu Leu Thr Phe Thr Ser
 50 55 60

Gly Pro Val Ser Gly Lys Lys Met Ile Val Gln
 65 70 75

5 (2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
 (B) TYPE: nucleic acid
 10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Fusarium oxysporum* ssp
lycopersici
 (B) STRAIN: CBS 645.78

20 (ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..177

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

AGA AAC GAC AAC CCC ATC TCC AAC ACC AAC GCT GTC AAC GGT TGT GAG
 48
 Arg Asn Asp Asn Pro Ile Ser Asn Thr Asn Ala Val Asn Gly Cys Glu
 30 30 35 40 45
 GGT GGT GGT TCT GCT TAT GCT TGC ACC AAC TAC TCT CCC TGG GCT GTC
 96
 Gly Gly Gly Ser Ala Tyr Ala Cys Thr Asn Tyr Ser Pro Trp Ala Val
 35 50 55 60
 AAC GAT GAG CTT GCC TAC GGT TTC GCT GCT ACC AAG ATC TCC GGT GGC
 144
 Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala Thr Lys Ile Ser Gly Gly

65

70

75

TCC GAG GCC AGC TGG TGC TGT GCC TGC TAT CTA
177

5 Ser Glu Ala Ser Trp Cys Cys Ala Cys Tyr Leu
80 85

(2) INFORMATION FOR SEQ ID NO: 28:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Arg Asn Asp Asn Pro Ile Ser Asn Thr Asn Ala Val Asn Gly
20 Cys Glu

1

5

10

15

Gly Gly Gly Ser Ala Tyr Ala Cys Thr Asn Tyr Ser Pro Trp
25 Ala Val

20

25

30

Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala Thr Lys Ile Ser
30 Gly Gly

35

40

45

Ser Glu Ala Ser Trp Cys Cys Ala Cys Tyr Leu
35 50 55

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 63 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- 10 (A) ORGANISM: Nectria pinea
(B) STRAIN: CBS 279.96

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
(B) LOCATION: 1..63

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

20 AGC GGC TGT GAC GGT GGT TCT GCC TAC GCC TGT GCA AAC AAC
TCC CCT 48
Ser Gly Cys Asp Gly Gly Ser Ala Tyr Ala Cys Ala Asn Asn
Ser Pro
60 65 70
25 75
TGG GCT GTC AAC GAT
63
Trp Ala Val Asn Asp
30 80

(2) INFORMATION FOR SEQ ID NO: 30:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

5

Ser Gly Cys Asp Gly Gly Ser Ala Tyr Ala Cys Ala Asn Asn
Ser Pro

1 5 10

15

10

Trp Ala Val Asn Asp

20

(2) INFORMATION FOR SEQ ID NO: 31:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 177 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

25

(A) ORGANISM: Humicola grisea Traeen

(B) STRAIN: ATCC 22726

(ix) FEATURE:

(A) NAME/KEY: CDS

30

(B) LOCATION:1..177

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

35 AAC CAG CCT GTC TTC ACT TGC GAC GCC AAA TTC CAG CGC ATC
ACC GAC 48

Asn Gln Pr Val Phe Thr Cys Asp Ala Lys Phe Gln Arg Ile

Thr Asp

25

30

35

5 CCC AAT ACC AAG TCG GGC TGC GAT GGC GGC TCG GCC TTT TCG
TGT GCT 96

Pro Asn Thr Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser
Cys Ala

40

45

50

10

GAC CAA ACC CCC TGG GCT CTG AAC GAC GAT TTC GCC TAT GGC
TTC GCT 144

Asp Gln Thr Pro Trp Ala Leu Asn Asp Asp Phe Ala Tyr Gly

15 Phe Ala

55

60

65

GCC ACG GCT ATT TCG GGT GGA TCG GAA GCC TCG

20

177

Ala Thr Ala Ile Ser Gly Gly Ser Glu Ala Ser

70

75

80

25 (2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids

(B) TYPE: amino acid

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

35 Asn Gln Pro Val Phe Thr Cys Asp Ala Lys Phe Gln Arg Ile
Thr Asp

1

5

10

15

Pro Asn Thr Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser
Cys Ala

5

20

25

30

Asp Gln Thr Pro Trp Ala Leu Asn Asp Asp Phe Ala Tyr Gly
Phe Ala

10

35

40

45

Ala Thr Ala Ile Ser Gly Gly Ser Glu Ala Ser

50

55

15

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 153 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Humicola nigrescens* Omvik

(B) STRAIN: CBS 819.73

30

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..153

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GTC TAC GCC TGC AAC GCA AAC TTC CAG CGC ATC ACC GAC GCC

AAC GCC 48
Val Tyr Ala Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp Ala
Asn Ala
60 65 70
5 75

AAG TCC GGC TGC GAT GGC GGC TCC GCC TTC TCG TGC GCC AAC
CAG ACC 96
Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asn
10 Gln Thr
80 85
90

CCG TGG GCC GTG AGC GAC GAC TTT GCC TAC GGT TTC GCG GCT
15 ACG GCG 144
Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala
Thr Ala
95 100 105

20
CTC GCC GGC
153
Leu Ala Gly
110
25

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 51 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Val Tyr Ala Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp Ala

Asn Ala
1 5 10
15
5 Lys Ser Gly Cys Asp Gly Gly Ser Ala Phe Ser Cys Ala Asn
Gln Thr
20 25 30
10 Pro Trp Ala Val Ser Asp Asp Phe Ala Tyr Gly Phe Ala Ala
Thr Ala
35 40 45
15 Leu Ala Gly
50

(2) INFORMATION FOR SEQ ID NO: 35:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 181 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
25
(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Cladorrhinum foecundissimum
30 (B) STRAIN: ATCC 62373

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..181
35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GTC AAC CGC CCT GTC CTC GCC TGC GAC GCA AAC AAC AAC CCT
CTG ACC 48
Val Asn Arg Pro Val Leu Ala Cys Asp Ala Asn Asn Asn Pro
Leu Thr
5 1 5 10
15
GAC GCC GGC GTC AAG TCC GGA TGT GAT GGC GGT TCT GCA TAC
ACC TGT 96
10 Asp Ala Gly Val Lys Ser Gly Cys Asp Gly Gly Ser Ala Tyr
Thr Cys
20 25 30
15 GCC AAC AAC TCC CCA TGG GCA GTG AAC GAC CAG CTC GCC TAC
GGC TTT 144
Ala Asn Asn Ser Pro Trp Ala Val Asn Asp Gln Leu Ala Tyr
Gly Phe
35 40 45
20
GCC GCC ACC AAA CTG AGC GGC GGA ACT GAG TCG TCA
180
Ala Ala Thr Lys Leu Ser Gly Gly Thr Glu Ser Ser
25 50 55 60

(2) INFORMATION FOR SEQ ID NO: 36:

- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Val Asn Arg Pro Val Leu Ala Cys Asp Ala Asn Asn Asn Pro
Leu Thr

1 5 10
15

5

Asp Ala Gly Val Lys Ser Gly Cys Asp Gly Gly Ser Ala Tyr
Thr Cys

20 25 30

10

Ala Asn Asn Ser Pro Trp Ala Val Asn Asp Gln Leu Ala Tyr
Gly Phe

35 40 45

15

Ala Ala Thr Lys Leu Ser Gly Gly Thr Glu Ser Ser

50 55 60

20 (2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 base pairs

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (vi) ORIGINAL SOURCE:

(A) ORGANISM: *Syspastospora boninensis*

(B) STRAIN: NKBC 1515

(ix) FEATURE:

35 (A) NAME/KEY: CDS

(B) LOCATION: 1..64

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GGC TGC GAC GGC GGC AGC GCC TTC ACC TGC TCC AAC AAC TCT
CCA TGG 48

5 Gly Cys Asp Gly Gly Ser Ala Phe Thr Cys Ser Asn Asn Ser
Pro Trp

GCT GTG AAC GAA GAT

10 63
Ala Val Asn Glu Asp

15

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids
20 (B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

25

Gly Cys Asp Gly Gly Ser Ala Phe Thr Cys Ser Asn Asn Ser
Pro Trp

30 Ala Val Asn Glu Asp

(2) INFORMATION FOR SEQ ID NO: 39:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Nigrospora sp

(B) STRAIN: CBS 272.96

10

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..153

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

ACA AGA AAC GAC GGG CCC CTG TCC AGC CCC GAT GCC GCC TCC
GGC TGT 48

20 Thr Arg Asn Asp Gly Pro Leu Ser Ser Pro Asp Ala Ala Ser
Gly Cys

25

30

35

25 GAT GGC GGC GAA GCC TTT GCC TGT TCT AAT ACC TCG CCT TGG
GCC GTC 96

Asp Gly Gly Glu Ala Phe Ala Cys Ser Asn Thr Ser Pro Trp
Ala Val

40

45

50

30

AGC GAC CAG CTC GCG TAC GGA TAC GTC GCC ACG TCC ATC TCC
GGC GGC 144

Ser Asp Gln Leu Ala Tyr Gly Tyr Val Ala Thr Ser Ile Ser

35 Gly Gly

55

60

65

ACC GAG TCA

153

Thr Glu Ser

70

5

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 51 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Thr Arg Asn Asp Gly Pro Leu Ser Ser Pro Asp Ala Ala Ser

Gly Cys

1

5

10

20 15

Asp Gly Gly Glu Ala Phe Ala Cys Ser Asn Thr Ser Pro Trp

Ala Val

20

25

30

25

Ser Asp Gln Leu Ala Tyr Gly Tyr Val Ala Thr Ser Ile Ser

Gly Gly

35

40

45

30

Thr Glu Ser

50

35 (2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Chaetostylum fresenii*

10

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..159

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GTC CGA ACG TGT AGT GCC AAC GAC TCG CCC TTG TCC GAC CCA
AAT GCC 48

20 Val Arg Thr Cys Ser Ala Asn Asp Ser Pro Leu Ser Asp Pro
Asn Ala

55

60

65

25 CCA AGT GGG TGT GAC GGT GGT AGC GCC TTC ACT TGT TCC AAC
AAC TCC 96

Pro Ser Gly Cys Asp Gly Gly Ser Ala Phe Thr Cys Ser Asn
Asn Ser

70

75

80

30

CCG TGG GCA GTC GAT GAC CAG ACA GCT TAT GGC TTT GCG GCA
ACA GCC 144

Pro Trp Ala Val Asp Asp Gln Thr Ala Tyr Gly Phe Ala Ala
35 Thr Ala

85

90

95

ATC AGT GGC CAG TCC

159

Ile Ser Gly Gln Ser

100

5

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 53 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Val Arg Thr Cys Ser Ala Asn Asp Ser Pro Leu Ser Asp Pro
Asn Ala

1 5 10

20 15

Pro Ser Gly Cys Asp Gly Gly Ser Ala Phe Thr Cys Ser Asn
Asn Ser

20 25 30

25

Pro Trp Ala Val Asp Asp Gln Thr Ala Tyr Gly Phe Ala Ala
Thr Ala

35 40 45

30

Ile Ser Gly Gln Ser

50

- 35 (2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Exidia glandulosa*
(B) STRAIN: CBS 277.96

10

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..153

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

TGT GAG AAG AAC GAC AAC CCC TTA GCT GAC TTC AGC ACG AAA
20 TCC GGG 48
Cys Glu Lys Asn Asp Asn Pro Leu Ala Asp Phe Ser Thr Lys
Ser Gly

55 60 65

25

TGT GAA AGC GGA GGT TCG GCT TAT ACG TGT AAC AAC CAA TCA
CCA TGG 96
Cys Glu Ser Gly Gly Ser Ala Tyr Thr Cys Asn Asn Gln Ser
Pro Trp

30 70 75 80
85

GCC GTC AAT GAC TTG GTG TCG TAT GGC TTC GCC GCC ACA GCG
ATC AAT 144

35 Ala Val Asn Asp Leu Val Ser Tyr Gly Phe Ala Ala Thr Ala
Ile Asn

90

95

100

GGT GGC AAT

153

5 Gly Gly Asn

(2) INFORMATION FOR SEQ ID NO: 44:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Cys Glu Lys Asn Asp Asn Pro Leu Ala Asp Phe Ser Thr Lys

20 Ser Gly

1

5

10

15

Cys Glu Ser Gly Gly Ser Ala Tyr Thr Cys Asn Asn Gln Ser

25 Pro Trp

20

25

30

Ala Val Asn Asp Leu Val Ser Tyr Gly Phe Ala Ala Thr Ala

30 Ile Asn

35

40

45

Gly Gly Asn

35

50

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 171 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Coniothecium sp

10

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..171

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

AGC CGC CCC GTC GGA ACC TGC AAG AGG AAC GAC AAC CCC CTC
20 TCC GAC 48
Ser Arg Pro Val Gly Thr Cys Lys Arg Asn Asp Asn Pro Leu
Ser Asp

55

60

65

25

CCC GAT GCC AAG TCC GGC TGC GAC GGC GGC GGC GCC TTC ATG
TGC TCC 96
Pro Asp Ala Lys Ser Gly Cys Asp Gly Gly Gly Ala Phe Met
Cys Ser

30

70

75

80

ACC CAG CAG CCG TGG GCC GTC AAC GAC AAT CTG GCA TAT GGC
TTC GCC 144
35 Thr Gln Gln Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly
Phe Ala

85

90

95

GCC ACG GCC ATC AGC GGC GGC AAC GAG

171

5 Ala Thr Ala Ile Ser Gly Gly Asn Glu
100 105

(2) INFORMATION FOR SEQ ID NO: 46:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Ser Arg Pro Val Gly Thr Cys Lys Arg Asn Asp Asn Pro Leu
20 Ser Asp
1 5 10
15

Pro Asp Ala Lys Ser Gly Cys Asp Gly Gly Gly Ala Phe Met
25 Cys Ser
20 25 30

Thr Gln Gln Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly
30 Phe Ala
35 40 45

Ala Thr Ala Ile Ser Gly Gly Asn Glu
35 50 55

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

10 (B) STRAIN: CBS 271.96

(ix) FEATURE:

(A) NAME/KEY: CDS

15 (B) LOCATION: 1..159

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

20 ACT TGC AAC AAG AAC GAC GGG CCC CTG TCC AGC CCC GAT GCC
GCC TCC 48Thr Cys Asn Lys Asn Asp Gly Pro Leu Ser Ser Pro Asp Ala
Ala Ser

60

65

70

25

GGC TGT GAT GGC GGC GAA GCC TTT GCC TGT TCT AAT ACC TCG
CCT TGG 96Gly Cys Asp Gly Gly Glu Ala Phe Ala Cys Ser Asn Thr Ser
Pro Trp

30

75

80

85

GCC GTC AGC GAC CAG CTC GCG TAC GGA TAC CTC GCC ACG TCC
ATC TCC 14435 Ala Val Ser Asp Gln Leu Ala Tyr Gly Tyr Leu Ala Thr Ser
Ile Ser

90

95

100

105

GGC GGC ACC GAG TCG

159

5 Gly Gly Thr Glu Ser

110

(2) INFORMATION FOR SEQ ID NO: 48:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Thr Cys Asn Lys Asn Asp Gly Pro Leu Ser Ser Pro Asp Ala

20 Ala Ser

1

5

10

15

Gly Cys Asp Gly Gly Glu Ala Phe Ala Cys Ser Asn Thr Ser

25 Pro Trp

20

25

30

Ala Val Ser Asp Gln Leu Ala Tyr Gly Tyr Leu Ala Thr Ser

30 Ile Ser

35

40

45

Gly Gly Thr Glu Ser

35

50

(2) INFORMATION FOR SEQ ID NO: 49:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

10 (B) STRAIN: CBS 270.96

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..84

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

CCA GTT TTC TCC TGT GAC AAG TAC GAC AAC CCT CTA CCT GAC
20 GCC AAT 48
Pro Val Phe Ser Cys Asp Lys Tyr Asp Asn Pro Leu Pro Asp
Ala Asn

55

60

65

25

GCT GTG TCC GGG TGT GAC CCC GGA GGT ACT GCC TTC
84

Ala Val Ser Gly Cys Asp Pro Gly Gly Thr Ala Phe

70

75

80

30

(2) INFORMATION FOR SEQ ID NO: 50:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Pro Val Phe Ser Cys Asp Lys Tyr Asp Asn Pro Leu Pro Asp
5 Ala Asn
1 5 10
15
Ala Val Ser Gly Cys Asp Pro Gly Gly Thr Ala Phe
10 20 25

(2) INFORMATION FOR SEQ ID NO: 51:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 147 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

25

(B) STRAIN: *Diplodia gossypina*, CBS 274.96

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

30 ACCTGCGACG CCTGCGACAG CCCCTCAGC GACTACGACG CCAAGTCCGG
CTGCGACGGC 60
GGTAGCGCAT ACACCTGCAC CTACTCTACC CCCTGGGCCG TCGACGACAA
CCTCTCCTAC 120
35 GGTTTCGCCG CCGCCAAGCT GAGCGGA
147

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 49 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

15 Thr Cys Asp Ala Cys Asp Ser Pro Leu Ser Asp Tyr Asp
Ala Lys Ser

1 5 10
15

20 Gly Cys Asp Gly Gly Ser Ala Tyr Thr Cys Thr Tyr Ser
Thr Pro Trp

20 25
30

25 Ala Val Asp Asp Asn Leu Ser Tyr Gly Phe Ala Ala Ala
Lys Leu Ser

35 40 45

30 Gly

(2) INFORMATION FOR SEQ ID NO: 53:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 135 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(vi) ORIGINAL SOURCE:

(B) STRAIN: Ulospora bilgramii, NKBC 1444

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

CCACTAGCAG ATTTACACCGG TGGAACCGGC TGTAATGGCG GTTCGACATT
CTCATGCTCA 60

15 AACCAACAAC CATGGGCGGT CAACGACACA TTCTCGTACG GCTTTGCGGG
CATCTTTATC 120

ACAGGCCATG TCGAG
135

20

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

25

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

35 Pro Leu Ala Asp Phe Thr Gly Gly Thr Gly Cys Asn Gly
Gly Ser Thr

1

5

10

15

Phe Ser Cys Ser Asn Gln Gln Pro Trp Ala Val Asn Asp
Thr Phe Ser

5

20

25

30

Tyr Gly Phe Ala Gly Ile Phe Ile Thr Gly His Val Glu
35 40 45

10

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 114 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Penicillium verruculosum*, ATCC

62396

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GCCAAATCTG GATGTGATGC TGGTGGAGGT CAAGCCTACA TGTGCTCCAA
CCAACAACCT 60

30

TGGGTAGTCA ACGACAACCT CGCCTACGGT TTCGCCGCAG TCAACATTGC
CGGC 114

(2) INFORMATION FOR SEQ ID NO: 56:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

10

Ala Lys Ser Gly Cys Asp Ala Gly Gly Gly Gln Ala Tyr
Met Cys Ser

1 5 10

15

15

Asn Gln Gln Pro Trp Val Val Asn Asp Asn Leu Ala Tyr
Gly Phe Ala

20 25

30

20

Ala Val Asn Ile Ala Gly

35

(2) INFORMATION FOR SEQ ID NO: 57:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 113 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

35

(B) STRAIN: Poronia punctata

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

TTCGACGTCC GGGTGGCACA ATGGCGGCAG CGCCTTCATG TGCTCTAACC
AAAGCCCCTG 60

5

GGCCGTCAAC GACGATCTGG CCTACGGCTG GGCCGCCGTC TCAATCGCGG
GCC 113

(2) INFORMATION FOR SEQ ID NO: 58:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

Ser Thr Ser Gly Cys Asp Asn Gly Gly Ser Ala Phe Met
Cys Ser Asn

25

1

5

10

15

Gln Ser Pro Trp Ala Val Asn Asp Asp Leu Ala Tyr Gly
Trp Ala Ala

30

20

25

30

Val Ser Ile Ala Gly

35

35

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 177 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- 10 (B) STRAIN: *Fusarium anguioides*, IFO 4467

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

15 TCAACACCGG TGCAGACGTG CGACCGCAAC GACAACCCGC TCTACGACGG
CGGGTCGACG 60

CGGTCCGGCT GCGACGCCGG CGGCGGCGCC TACATGTGCT CGTCGCACAG
CCCGTGGGCC 120

20 GTCAGCGACA GCCTCTCGTA CGGCTGGGCG GCCGTCCGCA TCGCCGGCCA
GTCCGAG 177

(2) INFORMATION FOR SEQ ID NO: 60:

25

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

Ser Thr Pro Val Gln Thr Cys Asp Arg Asn Asp Asn Pro
Leu Tyr Asp

1 5 10

15

5

Gly Gly Ser Thr Arg Ser Gly Cys Asp Ala Gly Gly Gly
Ala Tyr Met

20 25

30

10

Cys Ser Ser His Ser Pro Trp Ala Val Ser Asp Ser Leu
Ser Tyr Gly

35 40 45

15

Trp Ala Ala Val Arg Ile Ala Gly Gln Ser Glu

50 55

20

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: cDNA

30

(vi) ORIGINAL SOURCE:

(B) STRAIN: Thielavia thermophila, CBS 174.70

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

AACGACAACC CCATCTCCAA CACCAACGCT GTCAACGGTT GTGAGGGTGG

TGGTTCTGCT 60

TACGCTTGCT CCAACTACTC TCCCTGGGCT GTCAACGATG ACCTTGCCTA
CGGTTTCGCT 120

5

GTTACCAAGA TCTCCGGTGG CTCCGAGGCC
150

(2) INFORMATION FOR SEQ ID NO: 62:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Asn Asp Asn Pro Ile Ser Asn Thr Asn Ala Val Asn Gly
Cys Glu Gly

25

1

5

10

15

Gly Gly Ser Ala Tyr Ala Cys Ser Asn Tyr Ser Pro Trp
Ala Val Asn

30

20

25

30

Asp Asp Leu Ala Tyr Gly Phe Ala Val Thr Lys Ile Ser
Gly Gly Ser

35

35

40

45

Glu Ala

50

(2) INFORMATION FOR SEQ ID NO: 63:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 180 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

15 (A) ORGANISM: Chaetomium cuniculorum, CBS

799.83

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

20

GTCAATCAGC CCATCCGAAC GTGTAGTGCC AACGACTCGC CCTTGTCCGA
CCCAAATACC 60CCAAGTGGCT GTGACGGTGG TAGCGCCTTC ACTTGTTCCA ACAACTCCCC
25 GTGGGCAGTC 120GATGACCAGA CAGCTTATGG CTTGCGGCA ACAGCCATCA GTGGCCAGTC
CGAGAGCAGC 180

30

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 amino acids

35 (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

Val Asn Gln Pro Ile Arg Thr Cys Ser Ala Asn Asp Ser
Pro Leu Ser

1 5 10
10 15

Asp Pro Asn Thr Pro Ser Gly Cys Asp Gly Gly Ser Ala
Phe Thr Cys

20 25
15 30

Ser Asn Asn Ser Pro Trp Ala Val Asp Asp Gln Thr Ala
Tyr Gly Phe

35 40 45
20

Ala Ala Thr Ala Ile Ser Gly Gln Ser Glu Ser Ser
50 55 60

25 (2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 base pairs
(B) TYPE: nucleic acid
30 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35 (iv) ORIGINAL SOURCE: Chaetomium virescens, CBS
547.75

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

ACCTGCGACA AGAAGGACAA CCCCATCTCT GATGCCAACG CCAAGAGCGG
CTGTGATGGC 60
5
GGTTCTGCTT TCGCCTGCAC CAACTACTCT CCCTTCGCCG TCAACGACAA
CCTCGCCTAC 120
GGTTTCGCTG CCACCAAGCT TGCTGGAGGC TCCGAGGCT
10 159

(2) INFORMATION FOR SEQ ID NO: 66:

- (i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 53 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

25 Thr Cys Asp Lys Lys Asp Asn Pro Ile Ser Asp Ala Asn
Ala Lys Ser
1 5 10
15
30 Gly Cys Asp Gly Gly Ser Ala Phe Ala Cys Thr Asn Tyr
Ser Pro Phe
20 25
30
35 Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Thr
Lys Leu Ala

35

40

45

Gly Gly Ser Glu Ala

5

50

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 81 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: Colletotrichum lagenarium

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

ACCTGCTACG CCAATGACCA GCGCATCGCC GACCGCAGCA CCAAGTCCGG

CTGCGACGGC 60

25

GGCTCGGCCT ACTCCTGTTC T

81

(2) INFORMATION FOR SEQ ID NO: 68:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

5 Thr Cys Tyr Ala Asn Asp Gln Arg Ile Ala Asp Arg Ser
Thr Lys Ser
 1 5 10
 15

10 Gly Cys Asp Gly Gly Ser Ala Tyr Ser Cys Ser
 20 25

(2) INFORMATION FOR SEQ ID NO: 69:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 160 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: cDNA

 (vi) ORIGINAL SOURCE:
 (B) STRAIN: *Phycomyces nitens*

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

ACCTGTGACA AGAAGGACAA CCCCATCTCA AACTTGAACG CTGTCAACGG
30 TTGTGAGGGT 60

GGTGGTTCTG CCTTCGCCTG CACCAACTAC TCTCCTTGGG CGGTCAATGA
CAACCTTGCC 120

35 TACGGCTTCG CTGCAACCAA GCTTGCCGGT GGCTCCGAGG
 160

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 53 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

15 Thr Cys Asp Lys Lys Asp Asn Pro Ile Ser Asn Leu Asn
Ala Val Asn

1 5 10
15

20 Gly Cys Glu Gly Gly Gly Ser Ala Phe Ala Cys Thr Asn
Tyr Ser Pro

20 25
30

25 Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala
Thr Lys Leu

35 40 45

30 Ala Gly Gly Ser Glu

50

(2) INFORMATION FOR SEQ ID NO: 71:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 165 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(iv) ORIGINAL SOURCE: *Trichothecium roseum*, IFO

5372

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

10

CCAGTAGGCA CCTGCGACGC CGGCAACAGC CCCCTCGGCG ACCCCCTGGC
CAAGTCTGGC 60

15

TGCGAGGGCG GCCCGTCGTA CACGTGCGCC AACTACCAGC CGTGGGCGGT
CAACGACCAG 120

CTGGCCTACG GCTTCGCGGC CACGGCCATC AACGGCGGCA CCGAG
165

20 (2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 55 amino acids

(B) TYPE: amino acid

25

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

Pro Val Gly Thr Cys Asp Ala Gly Asn Ser Pro Leu Gly

35 Asp Pro Leu

1

5

10

15

Ala Lys Ser Gly Cys Glu Gly Gly Pro Ser Tyr Thr Cys
Ala Asn Tyr

20

25

30

5

Gln Pro Trp Ala Val Asn Asp Gln Leu Ala Tyr Gly Phe
Ala Ala Thr

35

40

45

10

Ala Ile Asn Gly Gly Thr Glu

50

55

REFERENCES

Background of the invention:

- 5 GB-A-1368599
- EP-A-0 307 564
- EP-A-0 435 876
- 10 WO 91/17243
- WO 91/10732
- 15 WO 91/17244
- WO 95/24471
- WO 95/26398
- 20 Methods in Enzymology, 1988, Vol. 160, p. 200-391 (edited by Wood, W.A. and Kellogg, S.T.).
- Béguin, P., "Molecular Biology of Cellulose Degradation",
- 25 Annu. Rev. Microbiol. (1990), Vol. 44, pp. 219-248.
- Henrissat, B., "Cellulases and their interaction with cellulose", Cellulose (1994), Vol. 1, pp. 169-196.
- 30 T.-M. Enveri, "Microbial Cellulases" in W.M. Fogarty, Microbial Enzymes and Biotechnology, Applied Science Publishers, 183-224 (1983).
- Béguin, P. and Aubert, J-P., "The biological degradation
- 35 of cellulose", FEMS Microbiology Reviews 11 (1994) 25-58.
- Shppard, P.O., et al., "The use of conserved cellulase

family-specific sequences to clone Cellulase homologue cDNAs from *Fusarium oxysporum*, *Gene*, (1994), Vol. 15, pp. 163-167.

5 Saloheimo, A., et al., "A novel, small endoglucanase gene, *egI5*, from *Trichoderma reesei* isolated by expression in yeast", *Molecular Microbiology* (1994), Vol. 13(2), pp. 219-228.

10 van Arsdell, J.W. et al, (1987) Cloning, characterization, and expression in *Saccharomyces cerevisiae* of endoglucanase I from *Trichoderma reesei*, *Bio/Technology* 5: 60-64.

15 Penttilä, M. et al, (1986) Homology between cellulase genes of *Trichoderma reesei*: complete nucleotide sequence of the endoglucanase I gene. *Gene* 45:253-263.

Saloheimo, M. et al, (1988) EGIII, a new endoglucanase
20 from *Trichoderma reesei*: the characterization of both gene and enzyme. *Gene* 63:11-21.

González, R., et al., "Cloning, sequence analysis and yeast expression of the *egl1* gene from *Trichoderma*
25 *longibrachiatum*", *Appl. Microbiol. Biotechnol.* (1992), Vol. 38, pp. 370-375.

Ooi, T. et al. "Cloning and sequence analysis of a cDNA for cellulase (FI-CMCase) from *Aspergillus aculeatus*"
30 *Curr. Genet.* (1990), Vol. 18, pp. 217-222.

Ooi, T. et al, "Complete nucleotide sequence of a gene coding for *Aspergillus aculeatus* cellulase (FI-CMCase)"
35 *Nucleic Acids Research* (1990), Vol. 18, No. 19, p. 5884.

Xue, G. et al., "Cloning and expression of multiple cellulase cDNAs from the anaerobic rumen fungus

Neocallimastix patriciarum in *E. coli*, J. Gen. Microbiol. (1992), Vol. 138, pp. 1413-1420.

5 Xue, G. et al., "A novel polysaccharide hydrolase cDNA (*celD*) from *Neocallimastix patriciarum* encoding three multi-functional catalytical domains with high endoglucanase, cellobiohydrolase and xylanase activities", J. Gen. Microbiol. (1992), Vol. 138, pp. 2397-2403.

10

Zhou, L. et al., "Intronless *celB* from the anaerobic fungus *Neocallimastix patriciarum* encodes a modular family A endoglucanase", Biochem. J. (1994), Vol. 297, pp. 359-364.

15

Dalbøge, H. and Heldt-Hansen, H.P., "A novel method for efficient expression cloning of fungal enzyme genes", Mol. Gen. Genet. (1994), Vol. 243, pp. 253-260.

20 Ali, B.R.S. et al., "Cellulases and hemicellulases of the anaerobic fungus *Piromyces* constitute a multiprotein cellulose-binding complex and are encoded by multigene families", FEMS Microbiol. Lett. (1995), Vol. 125, No. 1, pp. 15-21.

25

DNA Data Bank of Japan (DDBJ).

30 Wang, H.Y. and Jones, R.W.: "Cloning, characterization and functional expression of an endoglucanase-encoding gene from the phytopathogenic fungus *Macrophomina phaseolina*", Gene, 158:125-128, 1995.

35 Wang, H.Y. and Jones, R.W.: "A unique endoglucanase-encoding gene cloned from the phytopathogenic fungus *Macrophomina phaseolina*", Appl. and Environm. Microbiology, 61:2004-2006, 1995.

B. Henrissat: Biochem. J., 280:309-316, 1991.

Schauwecker, F., Wanner, G., Kahmann, R.: "Filament-specific expression of a cellulase gene in the dimorphic
5 fungus *Ustilago maydis*", 1995, Biological Chemistry
Hoppe-Seyler, 376:617-625.

WO 93/20193

10 WO 94/21801

WO 94/26880

WO 95/02043

15

The Drawings:

Feng and Doolittle, 1987, J. Mol. Evol. 25: 351-360.

20 NIH Data Base (Entrez, version spring 1996) available on
World Wide Web: (<http://www3.ncbi.nlm.nih.gov/htbin/ef/entrezTAX>).

Eriksson, O.E. & Hawksworth, D.L.: Systema Ascomycetum
25 vol 12 (1993).

Jülich, W.: Higher Taxa of Basidiomycetes, Bibliotheca
Mycologia 85, 485pp (1981).

30 O'Donnell, K.: Zygomycetes in culture, University of
Georgia, US, 257pp (1979).

Hawksworth, D.L., Kirk, P.M., Sutton, B.C. and Pegler,
D.N.: Dictionary of the fungi, International Mycological
35 Institute, 616pp (1995);

Von Arx, J.A.: The genera of fungi sporulating in

culture, 424pp (1981).

Detailed Description:

- 5 Ford et al., Protein Expression and Purification 2: 95-107, 1991.

Cunningham and Wells, Science 244, 1081-1085, 1989.

- 10 de Vos et al., Science 255: 306-312, 1992.

Smith et al., J. Mol. Biol. 224: 899-904, 1992.

Wlodaver et al., FEBS Lett. 309: 59-64, 1992.

15

Tomme, P. et al. "Cellulose-Binding Domains: Classification and Properties" in "Enzymatic Degradation of Insoluble Carbohydrates", John N. Saddler and Michael H. Penner (Eds.), ACS Symposium Series, No. 618, 1996.

20

WO 90/00609

WO 95/16782

25

Needleman, S.B. and Wunsch, C.D., *Journal of Molecular Biology*, 48: 443-453, 1970.

WO 94/14953

30

Sambrook, J., Fritsch, E. F. & Maniatis, T. 1989. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Lab., Cold Spring Harbor, NY.

- 35 Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869.

Matthes et al., EMBO Journal 3 (1984), 801 - 805.

US 4,683,202

5 Saiki et al., Science 239 (1988), 487 - 491.

Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080.

10 Alber and Kawasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434).

Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New
15 York, 1982).

US 4,599,311

Russell et al., Nature 304 (1983), 652 - 654.

20

McKnight et al., The EMBO J. 4 (1985), 2093 - 2099

P.R. Russell, Gene 40, 1985, pp. 125-130.

25 US 4,870,008

O. Hagenbuchle et al., Nature 289, 1981, pp. 643-646.

L.A. Valls et al., Cell 48, 1987, pp. 887-897.

30

WO 87/02670

M. Egel-Mitani et al., Yeast 6, 1990, pp. 127-137.

35 US 4,546,082

EP 16 201

EP 123 294

EP 123 544

5 EP 163 529

WO 89/02463

WO 92/11378

10

US 4,599,311

US 4,931,373

15 US 4,870,008

US 5,037,743

US 4,845,075

20

US 4,931,373

Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465.

25

US 4,882,279

EP 272 277

30

EP 230 023

Malardier et al., 1989, Gene 78: 147-156.

35 WO 93/11249.

WO 94/14953.

WO 95/02043.

Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and
Pease, L. R. (1989) *Gene* 77, 61-68

5

Dalbøge, H., and Heldt-Hansen, H. (1994) *Mol. Gen. Genet.*
243, 253-260

Christensen, T., Wøldike, H., Boel, E., Mortensen, S. B.,
10 Hjortshøj, K., Thim, L., and Hansen, M. T. (1988)
Bio/Technology 6, 1419-1422

Sanger, F., Nicklen, S., and Coulson, A. R. (1977) *Proc.*
Natl. Acad. Sci. U. S. A. 74, 5463-5467

15

Devereux, J., Haeberli, P., and Smithies, O. (1984)
Nucleic Acids Res. 12, 387-395

Becker, D. M. & Guarante, L. 1991. *Methods Enzymol.* 194:
20 182-187.

Gubler, U. & Hoffman, B. J. 1983. *Gene* 25: 263-269.

R. Higuchi, B. Krummel, and R.K. Saiki (1988). A general
25 method of in vitro preparation and specific mutagenesis
of DNA fragments: study of protein and DNA interactions.
Nucl. Acids Res. 16: 7351-7367.

Sanger, F., Nicklen, S. & Coulson, A. R. 1977. *Proc.*
30 *Natl. Acad. Sci. U. S. A.* 74: 5463-5467.

N. Axelsen et al., A Manual of Quantitative
Immunoelectrophoresis, Blackwell Scientific Publications,
1973, Chapters 2,3,4 and 23.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>20</u> , line <u>6</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 270.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div>For receiving Office use only</div> <div><input checked="" type="checkbox"/> This sheet was received with the international application</div> <div>Authorized officer <u>C. S. Henningsen</u></div>	<div>For International Bureau use only</div> <div><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div>Authorized officer</div>

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>20</u> , line <u>6</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 271.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>S. Henningson</u>	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>19</u> , line <u>28</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 272.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>A. S. Henriksen</u>	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>20</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 273.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/> During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) 	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") 	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer C. S. Hewitson	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on. Authorized office:

245

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>18</u> , line <u>35</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 274.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized office: <u>A. S. Henderson</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized office:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>18</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 275.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>C. S. Henriksen</u>	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>70</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 276.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u>C. S. Heijmans</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on. Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>9</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 277.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>C. S. Henderson</i>	Authorized officer


INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>19</u> , line <u>27</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 278.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u>[Signature]</u> ARVID GUNDEL HENRIKSSON Head of the	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer


INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>20</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 279.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input type="checkbox"/> This sheet was received with the international application Authorized officer:  J. S. J. van der Sluis Head of Office	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>10</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 280.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer 	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>18</u> , line <u>36</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 281.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on
Authorized officer <u>Antoon G. J. M. de Vries</u> Antoon G. J. M. de Vries	Authorized officer:


INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>34</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 282.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>[Signature]</u>	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>17</u> , line <u>11</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 283.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>19</u> , line <u>28</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 284.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer: <u>[Signature]</u>	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>19</u> , line <u>2</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 12 March 1996	Accession Number CBS 285.96
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: <u>[Signature]</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer: _____

257

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>21</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, the Netherlands	
Date of deposit 28. September, 1994	Accession Number CBS 478.94
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: <u>[Signature]</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on Authorized officer: _____

A. The indications made below relate to the microorganism referred to in the description on page <u>22</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT <div style="text-align: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 24 February 1995	Accession Number DSM 9770
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div style="text-align: center;">For receiving Office use only</div> <input checked="" type="checkbox"/> This sheet was received with the international application	<div style="text-align: center;">For International Bureau use only</div> <input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>[Signature]</u> 	Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>22</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 30 June 1995	Accession Number DSM 10080
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 0 10px;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input checked="" type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer </div>	<div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 0 10px;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">Authorized officer</div>

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)


A. The indications made below relate to the microorganism referred to in the description on page <u>22</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 30 June 1995	Accession Number DSM 10081
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: <u>[Signature]</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>22</u> , line <u>37</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 30 June 1995	Accession Number DSM 10082
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
<div>For receiving Office use only</div> <div><input checked="" type="checkbox"/> This sheet was received with the international application</div> <div>Authorized officer <u>C. S. J. E.</u></div>	<div>For International Bureau use only</div> <div><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div>Authorized officer</div>

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>23</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 2 February 1996	Accession Number DSM 10511
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u></u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer _____

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>23</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 6 March 1996	Accession Number DSM 10571
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: <u>[Signature]</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

A. The indications made below relate to the microorganism referred to in the description on page <u>23</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL-KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Republic of Germany	
Date of deposit 2 February 1996	Accession Number DSM 10512
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/> During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") 	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u>[Signature]</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer _____


INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>23</u> , line <u>1</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 12 March 1996	Accession Number DSM 10576
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: <u>CA. S. H.</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>24</u> , line <u>24</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 13 March 1996	Accession Number DSM 10583
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: 	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)


A. The indications made below relate to the microorganism referred to in the description on page <u>24</u> , line <u>29</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 13 March 1996	Accession Number DSM 10584
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u>af. S. de</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM


(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>24</u> , line <u>39</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 13 March 1996	Accession Number DSM 10585
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer:  APPROVED FOR DEPOSIT	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:
---	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>25</u> , line <u>7</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 13 March 1996	Accession Number DSM 10586
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer: 	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer:

(PCT Rule 13bis)

Form PCT/RO/134 (July 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>25</u> , line <u>21</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELL- KULTUREN GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1b, D-38124 Braunschweig, Federal Re- public of Germany	
Date of deposit 13 March 1996	Accession Number DSM 10588
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
During the pendency of the patent application a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. e.g. Rule 28(4) EPC / Regulation 3.25 of Australia Statutory Rules 1991 No 71) in those designated states providing for such "expert solution".	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u> </u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer <u> </u>

CLAIMS

1. An enzyme preparation consisting essentially of an enzyme which has cellulytic activity and comprises a first amino acid sequence consisting of 14 amino acid residues having the following sequence

Thr	Arg	Xaa	Xaa	Asp	Cys	Cys	Xaa	Xaa	Xaa	Cys	Xaa	Trp	Xaa
1	2	3	4	5	6	7	8	9	10	11	12	13	14

10

and a second amino acid sequence consisting of 5 amino acid residues having the following sequence

Trp	Cys	Cys	Xaa	Cys
1	2	3	4	5

15

wherein,

- in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;
- in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;
- in position 8 of the first sequence, the amino acid is Arg, Lys or His;
- in position 9, 10, 12 and 14, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues with the provisos that, in the first amino acid sequence, (i) when the amino residue in position 12 is Ser, then the amino acid residue in position 14 is not Ser, and (ii) when the amino residue in position 12 is Gly, then the amino acid residue in position 14 is not Ala.
2. The enzyme preparation according to claim 1, wherein the amino acid residue in position 9 of the first sequence is selected from the group consisting of

proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of proline and threonine.

5

3. The enzyme preparation according to claim 1 or 2, wherein the amino acid residue in position 10 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably serine.

4. The enzyme preparation according to any of the claims 1-3, wherein the amino acid residue in position 12 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of alanine and glycine.

5. The enzyme preparation according to any of the claims 1-4, wherein the amino acid residue in position 14 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine, tryptophan, glutamic acid and aspartic acid, preferably from the group consisting of proline, threonine, serine, alanine, glutamic acid and aspartic acid.

6. The enzyme preparation according to any of the claims 1-5, wherein the amino acid residue in position 4 of the second sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine, glycine, cysteine, asparagine, glutamine, tyrosine, serine, methi nine, tryptophan, glutamic acid

and aspartic acid, preferably from the group consisting of alanine, glycine, and glutamine.

7. The enzyme preparation according to any of the claims 1-6, wherein, in the first sequence, the amino acid residue in position 3 is tyrosine; or the amino acid residue in position 4 is tryptophan; or the amino acid residue in position 8 is lysine.

8. The enzyme preparation according to any of the claims 1-7, wherein the first sequence comprises an amino acid sequence selected from the group consisting of the sequences

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ;

Thr Arg Tyr Trp Asp Cys Cys Lys Thr Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ; and

20

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 .

9. The enzyme preparation according to any of the claims 1-8 which is of microbial origin, preferably fungal origin.

10. A DNA construct encoding for the enzyme according to any of the claims 1-9.

30

11. An enzyme preparation consisting essentially of an enzyme having cellulytic activity and being obtainable from a strain belonging to *Hymenomycetes* (*Basidiomycota*) which enzyme comprises an amino acid sequence selected from the group consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa

1 2 3 4 5 6 7 ;

Xaa Thr Arg Xaa Tyr Asp Xaa

1 2 3 4 5 6 7 ; and

5

Xaa Thr Arg Xaa Trp Asp Xaa

1 2 3 4 5 6 7

wherein,

10 in position 4, Xaa is Trp, Tyr or Phe; and
in position 1 and 7, Xaa is any of the 20 naturally
occurring amino acid residues.

12. The enzyme preparation according to claim 11, wherein
15 the amino acid residue in position 7 is cysteine (Cys).

13. The enzyme preparation according to claim 11, wherein
the amino acid residue in position 1 is selected from the
group consisting of aspartic acid (Asp), threonine (Thr)
20 and alanine (Ala).

14. The enzyme preparation according to any of the claims
11-13, wherein the enzyme comprises a first peptide
consisting of 13 amino acid residues having the following
25 sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp

1 2 3 4 5 6 7 8 9 10 11 12 13

30 and a second peptide consisting of 5 amino acid residues
having the following sequence

Trp Cys Cys Xaa Cys

1 2 3 4 5

35

wherein,

- in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;
in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;
5 in position 8 of the first sequence, the amino acid is Arg, Lys or His;
in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino
10 acid residues.
15. The enzyme preparation according to any of the claims 11-14 wherein the enzyme is obtainable from a strain belonging to the group consisting of the orders *Agaricales*, *Aphyllphorales*, and *Auriculariales*.
15
16. The enzyme preparation according to claim 15 wherein the enzyme is obtainable from a strain belonging to the group consisting of the families *Exidiaceae*,
20 *Tricholomataceae*, *Coprinaceae*, *Schizophyllaceae*, *Bjerkanderaceae* and *Polyporaceae*, preferably belonging to the group consisting of the genera *Exidia*, *Crinipellis*, *Fomes*, *Panaeolus*, *Trametes*, *Schizophyllum*, and *Spongipellis*.
25
17. The enzyme preparation according to claim 16 wherein the enzyme is obtainable from a strain belonging to the group consisting of the species *Exidia glandulosa*, *Crinipellis scabella*, *Fomes fomentarius*, and *Spongipellis*
30 *sp.*, preferably from *Exidia glandulosa*, CBS 277.96, *Crinipellis scabella*, CBS 280.96, *Fomes fomentarius*, CBS 276.96, and *Spongipellis sp.*, CBS 283.96.
18. An enzyme preparation consisting essentially of an
35 enzyme having cellulytic activity and being obtainable from a strain belonging to *Chytridiomycota* which enzyme comprises an amino acid sequence selected from the group

consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
1 2 3 4 5 6 7 ;

5

Xaa Thr Arg Xaa Tyr Asp Xaa
1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa
10 1 2 3 4 5 6 7

wherein,

in position 4, Xaa is Trp, Tyr or Phe; and

15 in position 1 and 7, Xaa is any of the 20 naturally
occurring amino acid residues.

19. The enzyme preparation according to claim 18, wherein
the amino acid residue in position 7 is cysteine (Cys).

20 20. The enzyme preparation according to claim 18, wherein
the amino acid residue in position 1 is selected from the
group consisting of aspartic acid (Asp), threonine (Thr)
and alanine (Ala).

25 21. The enzyme preparation according to any of the claims
18-20, wherein the enzyme comprises a first peptide
consisting of 13 amino acid residues having the following
sequence

30 Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp
1 2 3 4 5 6 7 8 9 10 11 12 13

and a second peptide consisting of 5 amino acid residues
having the following sequence

35

Trp Cys Cys Xaa Cys
1 2 3 4 5

wherein, .

in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;

5 in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;

in position 8 of the first sequence, the amino acid is Arg, Lys or His;

10 in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues.

22. The enzyme preparation according to any of the claims
15 18-21 wherein the enzyme is obtainable from a strain belonging to the class of *Chytridiomycetes*, preferably belonging to the group consisting of the orders *Chytridiales*, *Spizellomycetales*, *Harpochytriales*, and *Blastocladales*.

20

23. The enzyme preparation according to claim 22 wherein the enzyme is obtainable from a strain belonging the family *Spizellomycetaceae*, preferably belonging to the genus *Rhizophlyctis*, preferably belonging to the species
25 *Rhizophlyctis rosea*, especially *R.. rosea.*, CBS 282.96.

24. An enzyme preparation consisting essentially of an enzyme having cellulytic activity and being obtainable from a strain belonging to *Zygomycota* which enzyme comprises an amino acid sequence selected from the group
30 consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
1 2 3 4 5 6 7 ;

35

Xaa Thr Arg Xaa Tyr Asp Xaa
1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa
1 2 3 4 5 6 7

wherein,

- 5 in position 4, Xaa is Trp, Tyr or Phe; and
in position 1 and 7, Xaa is any of the 20 naturally
occurring amino acid residues.

25. The enzyme preparation according to claim 24, wherein
10 the amino acid residue in position 7 is cysteine (Cys).

26. The enzyme preparation according to claim 24, wherein
the amino acid residue in position 1 is selected from the
group consisting of aspartic acid (Asp), threonine (Thr)
15 and alanine (Ala).

27. The enzyme preparation according to any of the claims
24-26, wherein the enzyme comprises a first peptide
consisting of 13 amino acid residues having the following
20 sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp
1 2 3 4 5 6 7 8 9 10 11 12 13

- 25 and a second peptide consisting of 5 amino acid residues
having the following sequence

Trp Cys Cys Xaa Cys
1 2 3 4 5

30

wherein,

- in position 3 of the first sequence, the amino acid is
Trp, Tyr or Phe;
35 in position 4 of the first sequence, the amino acid is
Trp, Tyr or Phe;
in position 8 of the first sequence, the amino acid is

Arg, Lys or His;
in position 9, 10, and 12, respectively, of the first
sequence, and in position 4 of the second sequence, the
amino acid is any of the 20 naturally occurring amino
5 acid residues.

28. The enzyme according to any of the claims 24-27 which
enzyme is obtainable from a strain belonging to the class
Zygomycetes, preferably to the order *Mucorales*.

10

29. The enzyme according to claim 28 which enzyme is
obtainable from a strain belonging to the group
consisting of the families *Mucoracea* and *Thamnidaceae*,
preferably belonging to the group consisting of the ge-
15 nera *Rhizomucor*, *Phycomyces* and *Chaetostylum*.

30. The enzyme according to claim 29 which enzyme is
obtainable from a strain belonging the group consisting
of the species *Rhizomucor pusillus*, *Phycomyces nitens*,
20 *Chaetostylum fresenii*, preferably *Rhizomucor pusillus*,
IFO 4578, *Phycomyces nitens*, IFO 4814, and *Chaetostylum*
fresenii, NRRL 2305.

31. An enzyme preparation consisting essentially of an
25 enzyme having cellulytic activity and being obtainable
from a strain belonging to the group consisting of *Ar-*
chaeascomycetes, *Discomycetes*, *Hermiascomycetes*, *Loculoa-*
scomycetes, and *Plectomycetes* which enzyme comprises an
amino acid sequence selected from the group consisting of
30 the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
1 2 3 4 5 6 7 ;

35 Xaa Thr Arg Xaa Tyr Asp Xaa
1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa
1 2 3 4 5 6 7

wherein,

- 5 in position 4, Xaa is Trp, Tyr or Phe; and
in position 1 and 7, Xaa is any of the 20 naturally
occurring amino acid residues.

32. The enzyme preparation according to claim 31, wherein
10 the amino acid residue in position 7 is cysteine (Cys).

33. The enzyme preparation according to claim 31, wherein
the amino acid residue in position 1 is selected from the
group consisting of aspartic acid (Asp), threonine (Thr)
15 and alanine (Ala).

34. The enzyme preparation according to any of the claims
31-33, wherein the enzyme comprises a first peptide
consisting of 13 amino acid residues having the following
20 sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp
1 2 3 4 5 6 7 8 9 10 11 12 13

- 25 and a second peptide consisting of 5 amino acid residues
having the following sequence

Trp Cys Cys Xaa Cys
1 2 3 4 5

30

wherein,

- in position 3 of the first sequence, the amino acid is
Trp, Tyr or Phe;
35 in position 4 of the first sequence, the amino acid is
Trp, Tyr or Phe;
in position 8 of the first sequence, the amino acid is

Arg, Lys or His;
in position 9, 10, and 12, respectively, of the first
sequence, and in position 4 of the second sequence, the
amino acid is any of the 20 naturally occurring amino
5 acid residues.

35. The enzyme preparation according to any of the claims
31-34 wherein the enzyme is obtainable from a strain
belonging to the group consisting of the orders
10 *Pezizales*, *Phytismatales*, *Dothideales*, and *Eurotiales*.

36. The enzyme preparation according to claim 35 wherein
the enzyme is obtainable from a strain belonging the the
group consisting of the families *Cucurbitariaceae*,
15 *Rhytismataceae*, *Ascobolaceae*, and *Trichocomaceae*, pre-
ferably belonging the the group consisting of the genera
Diplodia, *Microsphaeropsis*, *Ulospora*, *Macrophomina*,
Ascobolus, *Saccobolus*, *Penicillium*, and *Thermomyces*.

20 37. The enzyme preparation according to claim 36 wherein
the enzyme is obtainable from a strain belonging the the
group consisting of the species *Diplodia gossypina*,
Microsphaeropsis sp., *Ulospora bilgramii*, *Macrophomina*
phaseolina, *Ascobolus stictoides*, *Saccobolus dilutellus*,
25 *Penicillium verruculosum*, *Penicillium chrysogenum*, and
Thermomyces verrucosus; preferably *Diplodia gossypina*,
CBS 274.96, *Ulospora bilgramii*, NKBC 1444, *Macrophomina*
phaseolina, CBS 281.96, *Saccobolus dilutellus*, CBS
275.96, *Penicillium verruculosum*, ATCC 62396, *Penicillium*
30 *chrysogenum*, ATCC 9480, and *Thermomyces verrucosus*, CBS
285.96.

38. An enzyme preparation consisting essentially of an
enzyme having cellulytic activity and being obtainable
35 from a strain belonging to the group consisting of the
orders *Diaportales*, *Xylariales*, *Trichoaphaeriales* and
Phyllachorales which enzyme comprises an amino acid

sequence selected from the group consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
5 1 2 3 4 5 6 7 ;

Xaa Thr Arg Xaa Tyr Asp Xaa
1 2 3 4 5 6 7 ; and

10 Xaa Thr Arg Xaa Trp Asp Xaa
1 2 3 4 5 6 7

wherein,

in position 4, Xaa is Trp, Tyr or Phe; and

15 in position 1 and 7, Xaa is any of the 20 naturally occurring amino acid residues.

39. The enzyme preparation according to claim 38, wherein the amino acid residue in position 7 is cysteine (Cys).

20

40. The enzyme preparation according to claim 38, wherein the amino acid residue in position 1 is selected from the group consisting of aspartic acid (Asp), threonine (Thr) and alanine (Ala).

25

41. The enzyme preparation according to any of the claims 38-40, wherein the enzyme comprises a first peptide consisting of 13 amino acid residues having the following sequence

30

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp
1 2 3 4 5 6 7 8 9 10 11 12 13

and a second peptide consisting of 5 amino acid residues having the following sequence

35

Trp Cys Cys Xaa Cys
1 2 3 4 5

wherein,
in position 3 of the first sequence, the amino acid is
Trp, Tyr or Phe;
in position 4 of the first sequence, the amino acid is
5 Trp, Tyr or Phe;
in position 8 of the first sequence, the amino acid is
Arg, Lys or His;
in position 9, 10, and 12, respectively, of the first
sequence, and in position 4 of the second sequence, the
10 amino acid is any of the 20 naturally occurring amino
acid residues.

42. The enzyme preparation according to any of the claims
38-41 wherein the enzyme is obtainable from a strain
15 belonging to the group consisting of the families
Xylariaceae, *Valsaceae*, and *Phyllachoraceae*, preferably
belonging to the genera *Diaporthe*, *Colletotrichum*,
Nigrospora, *Xylaria*, *Nodulisporum* and *Poronia*.

20 43. The enzyme according to claim 42 which enzyme is ob-
tainable from a strain belonging to the group consisting
of the species *Diaporthe syngenesia*, *Colletotrichum*
lagenarium, *Nigrospora* sp., *Xylaria hypoxylon*,
Nodulisporum sp., and *Poronia punctata*, preferably *Dia-*
25 *porthe syngenesia*, CBS 278.96, *Colletotrichum lagenarium*,
ATCC 52609, *Nigrospora* sp., CBS 272.96, *Xylaria*
hypoxylon, CBS 284.96

44. An enzyme preparation consisting essentially of an
30 enzyme having cellulytic activity and being obtainable
from a strain belonging to the group consisting of the
families *Nectriaceae*, *Sordariaceae*, *Chaetomiaceae*,
Ceratostomaceae, *Lasiosphaeriaceae* and the genera
Acremonium, *Gliocladium*, *Scytalidium*, *Cylindrocarpon* and
35 *Volutella* which enzyme comprises an amino acid sequence
selected from the group consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
1 2 3 4 5 6 7 ;

Xaa Thr Arg Xaa Tyr Asp Xaa
5 1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa
1 2 3 4 5 6 7

10 wherein,

in position 4, Xaa is Trp, Tyr or Phe; and
in position 1 and 7, Xaa is any of the 20 naturally
occurring amino acid residues.

15 45. The enzyme preparation according to claim 44, wherein
the amino acid residue in position 7 is cysteine (Cys).

46. The enzyme preparation according to claim 44, wherein
the amino acid residue in position 1 is selected from the
20 group consisting of aspartic acid (Asp), threonine (Thr)
and alanine (Ala).

47. The enzyme preparation according to any of the claims
44-46, wherein the enzyme comprises a first peptide
25 consisting of 13 amino acid residues having the following
sequence

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp
1 2 3 4 5 6 7 8 9 10 11 12 13

30

and a second peptide consisting of 5 amino acid residues
having the following sequence

Trp Cys Cys Xaa Cys

35 1 2 3 4 5

wherein,

in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;

in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;

5 in position 8 of the first sequence, the amino acid is Arg, Lys or His;

in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino

10 acid residues.

48. The enzyme preparation according to any of the claims 44-47 wherein the enzyme is obtainable from a strain belonging to the group consisting of the genera *Cylindro-*
15 *carpon*, *Nectria*, *Volutella*, *Sordaria*, *Thielavia*, *Sypasto-*
spora, *Chaetomium*, *Myceliophthora*, *Scytalidium*,
Cladorrhinum, *Gliocladium*, *Acremonium*.

49. The enzyme according to claim 48 which enzyme is ob-
20 tainable from a strain belonging to the group consisting
of the species *Cylindrocarpon* sp., *Nectria pinea*, *Volu-*
tella colletotrichoides, *Sordaria fimicola*, *Sordaria*
macrospora, *Thielavia terrestris*, *Thielavia thermophila*,
Syspastospora boninensis, *Cladorrhinum foecundissimum*,
25 *Chaetomium murorum*, *Chaetomium virescens*, *Chaetomium*
brasiliensis, *Chaetomium cunicolorum*, *Myceliophthora*
thermophila, *Gliocladium catenulatum*, *Scytalidium*
thermophila, and *Acremonium* sp., preferably from
Gliocladium catenulatum, ATCC 10523 & CBS 227.48, *Nectria*
30 *pinea*, CBS 279.96, *Volutella colletotrichoides*, CBS
400.58, *Sordaria fimicola*, ATCC 52644, *Sordaria*
macrospora, ATCC 60255, *Thielavia terrestris*, NRRL 8126,
Thielavia thermophila, CCBS 174.70, *Chaetomium murorum*,
CBS 163.52, *Chaetomium virescens*, CBS 547.75, *Chaetomium*
35 *brasiliensis*, CBS 122.65, *Chaetomium cunicolorum*, CBS
799.83, *Syspastospora boninensis*, NKBC 1515, *Cladorrhinum*
foecundissimum, ATCC 62373, *Myceliophthora thermophila*,

CBS 117.65, *Scytalidium thermophila*, ATCC 28085, and *Acremonium* sp., CBS 478.94

50. An enzyme preparation consisting essentially of an
5 enzyme having cellulytic activity and being obtainable
from a strain belonging to the group consisting of the
species *Fusarium lycopersici*, *Fusarium passiflora*,
Fusarium solani, *Fusarium anguioides*, *Fusarium poae*,
Humicola nigrescens and *Humicola grisea* which enzyme com-
10 prises an amino acid sequence selected from the group
consisting of the sequences

Xaa Thr Arg Xaa Phe Asp Xaa
1 2 3 4 5 6 7 ;

15

Xaa Thr Arg Xaa Tyr Asp Xaa
1 2 3 4 5 6 7 ; and

Xaa Thr Arg Xaa Trp Asp Xaa
20 1 2 3 4 5 6 7

wherein,
in position 4, Xaa is Trp, Tyr or Phe; and
in position 1 and 7, Xaa is any of the 20 naturally
25 occurring amino acid residues.

51. The enzyme preparation according to claim 50, wherein
the amino acid residue in position 7 is cysteine (Cys).

30 52. The enzyme preparation according to claim 50, wherein
the amino acid residue in position 1 is selected from the
group consisting of aspartic acid (Asp), threonine (Thr)
and alanine (Ala).

35 53. The enzyme preparation according to any of the claims
50-52, wherein the enzyme comprises a first peptide
c nsisting f 13 amino acid residues having the following

sequence

Thr	Arg	Xaa	Xaa	Asp	Cys	Cys	Xaa	Xaa	Xaa	Cys	Xaa	Trp
1	2	3	4	5	6	7	8	9	10	11	12	13

5

and a second peptide consisting of 5 amino acid residues having the following sequence

Trp	Cys	Cys	Xaa	Cys
-----	-----	-----	-----	-----

10	1	2	3	4	5
----	---	---	---	---	---

wherein,

in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe;

15 in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe;

in position 8 of the first sequence, the amino acid is Arg, Lys or His;

20 in position 9, 10, and 12, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues.

54. The enzyme preparation according to claim 53 wherein
25 the enzyme is obtainable from a strain belonging to the group consisting of the strains *Fusarium oxysporum ssp lycopersici*, CBS 645.78, *Fusarium oxysporum ssp passiflora*, CBS 744.79, *Fusarium solani*, IMI 107.511, *Fusarium anguioides*, IFO 4467, *Fusarium poae*, ATCC 60883,
30 *Humicola nigrescens*, CBS 819.73 and *Humicola grisea*, ATCC 22726.

55. The enzyme according to any of the claims 14-17, 21-23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein the
35 amino acid residue in position 9 of the first sequence is selected from the group consisting of proline, threonine, valine, alanine, leucine, isoleucine, phenylalanine,

glycine, cysteine, asparagine, glutamine, tyrosine, serine, methionine and tryptophan, preferably from the group consisting of proline and threonine.

5 56. The enzyme according to any of the claims 14-17, 21-
23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein the
amino acid residue in position 10 of the first sequence
is selected from the group consisting of proline,
threonine, valine, alanine, leucine, isoleucine,
10 phenylalanine, glycine, cysteine, asparagine, glutamine,
tyrosine, serine, methionine and tryptophan, preferably
serine.

57. The enzyme according to any of the claims 14-17, 21-
15 23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein the
amino acid residue in position 12 of the first sequence
is selected from the group consisting of proline,
threonine, valine, alanine, leucine, isoleucine,
phenylalanine, glycine, cysteine, asparagine, glutamine,
20 tyrosine, serine, methionine and tryptophan, preferably
from the group consisting of alanine and glycine.

58. The enzyme according to any of the claims 14-17, 21-
23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein the
25 amino acid residue in position 4 of the second sequence
is selected from the group consisting of proline,
threonine, valine, alanine, leucine, isoleucine,
phenylalanine, glycine, cysteine, asparagine, glutamine,
tyrosine, serine, methionine, tryptophan, glutamic acid
30 and aspartic acid, preferably from the group consisting
of alanine, glycine, and glutamine.

59. The enzyme according to any of the claims 14-17, 21-
23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein, in
35 the first sequence, the amino acid residue in position 3
is tyrosine; or the amino acid residue in position 4 is
tryptophan; or the amino acid residue in position 8 is

lysine.

60. A DNA construct encoding for the enzyme according to any of the claims 11-59.

5

61. The enzyme preparation according to any of the claims 14-17, 21-23, 27-30, 34-37, 41-43, 47-49, 53 and 54, wherein the first sequence comprises an amino acid sequence selected from the group consisting of the sequences

10

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ;

15 Thr Arg Tyr Trp Asp Cys Cys Lys Thr Ser Cys Ala Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 ; and

Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp
1 2 3 4 5 6 7 8 9 10 11 12 13 .

20

62. A method for providing a microbial strain comprising a gene encoding for the enzyme present in the enzyme preparation according to any of the claims 1-9, 11-59, and 61 which method comprises hybridization, e.g. PCR amplification, under standard conditions with an oligonucleotide derived from any of the conserved regions illustrated in Fig.1.

25

63. The method according to claims 62, wherein the oligonucleotide comprises a nucleotide sequence encoding at least a pentapeptide comprised in a peptide selected from the group consisting of
a.

30

Thr Arg Xaa Xaa Asp Cys Cys Xaa Xaa Xaa Cys Xaa Trp Xaa
35 1 2 3 4 5 6 7 8 9 10 11 12 13 14
the amino acid in position 3 or 4 being Trp, Tyr or Phe;
the amino acid in position 8 being Arg, Lys or His;

the amino acid in position 9, 10, 12 and 14, respectively, being any of the 20 naturally occurring amino acid residues ; and

b.

5 Trp Cys Cys Xaa Cys Tyr

1 2 3 4 5 6

the amino acid in position 4 being any of the 20 naturally occurring amino acid residues ; and

c.

10 Xaa Pro Gly Gly Gly Xaa Gly Xaa Phe

1 2 3 4 5 6 7 8 9

the amino acid in position 1 being Met or Ile;

the amino acid in position 6 and 8, respectively, being Leu, Ile or Val; and

15 d.

Gly Cys Xaa Xaa Arg Xaa Asp Trp Xaa

1 2 3 4 5 6 7 8 9

the amino acid in position 3 being any of the 20 naturally occurring amino acid residues;

20 the amino acid in position 4 and 6, respectively, being Trp, Tyr or Phe; and

the amino acid in position 9 being Phe or Met;

64. The method according to claim 62, wherein the
25 oligonucleotide comprises a nucleotide sequence complementary to the sequences of claim 63.

65. The method according to claim 63, wherein the
30 oligonucleotide corresponds to a PCR primer selected from the group consisting of the PCR primers

sense,

5'-CCCCAAGCTTACI^A/C^GITAC^C/T^TG^GGA^C/T^TG^C/T^TG^C/T^TAA^A/O^A/C-3'

antisense 1,

35 5'- CTAGTCTAGATA^A/O^OCAIGC^A/O^OCA^A/O^OCACC -3';

antisense 2,

5'- CTAGTCTAGAAAIA^A/O^O/T^TIC^CCA^A/C^C/O^OIC^CIC^CIC^CIGG -3'; and

antisense 3,

5'- CTAGTCTAGAIAACCA^A/_oTCA^A/_o^A/_TAIC^G/_TCC -3.

66. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting cellulytic activity, which DNA sequence comprises

- a) the DNA sequence shown in SEQ ID No. 1, and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, or
- 10 b) an analogue of the DNA sequence shown in SEQ ID No. 1 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770, which
 - i) 15 is homologous, preferably at least 70% homologous, with the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770,
 - ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770,
 - 20 iii) encodes a polypeptide which is homologous preferably at least 65% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 1 and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 9770,
 - 25 iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID No 1 or obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 9770.
- 30

35 67. The DNA construct according to claim 66, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family

Chaetomiaceae, preferably to the genus *Myceliophthora*, in particular a strain of *M. thermophila*, especially *M. thermophila*, CBS 117.65.

- 5 68. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises
- a) the DNA sequence shown in SEQ ID No. 4, and/or the DNA sequence obtainable from the plasmid in *Saccharomyces*
- 10 *cerevisiae* DSM 10082, or
- b) an analogue of the DNA sequence shown in SEQ ID No. 4 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10082, which
- i) 15 is homologous, preferably at least 70% homologous, with the DNA sequence shown in SEQ ID No. 4 and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10082,
- ii) 20 hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 4 and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10082,
- iii) 25 encodes a polypeptide which is homologous preferably at least 60% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. and/or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10085,
- iv) 30 encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID No 4 or obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 10082.
- 35 69. The DNA construct according to claim 68, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family

Hypocreaceae, preferably to the genus *Acremonium*, in particular *Acremonium sp.*, CBS 478.94.

70. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises

- a) the DNA sequence shown in SEQ ID No. 6, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10080, or
- 10 b) an analogue of the DNA sequence shown in SEQ ID No. 6 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10080, which
 - i) is homologous, preferably 65% homologous, with the DNA sequence shown in SEQ ID No. 6 or the DNA
 - 15 sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10080,
 - ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 6 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10080,
 - 20 iii) encodes a polypeptide which is homologous, preferably at least 70%, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 6 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10080,
 - 25 iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID No 6 /or obtainable from the
 - 30 plasmid in *Saccharomyces cerevisiae*, DSM 10080.

71. The DNA construct according to claim 70, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family *Chaetomiceae*, preferably to the genus *Acremonium*, in par-

ticular *Acremonium* sp., CBS 478.94.

72. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA
- 5 sequence comprises
- a) the DNA sequence shown in SEQ ID No. 8, or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10081, or
- b) an analogue of the DNA sequence shown in SEQ ID No. 8
- 10 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10081, which
- i) is homologous, preferably at least 75% homologous, with the DNA sequence shown in SEQ ID No. 8 or the DNA sequence obtainable from the plasmid in *Sac-*
- 15 *charomyces cerevisiae* DSM 10081,
- ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 8 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae*
- 20 DSM 10081,
- iii) encodes a polypeptide which is homologous, preferably at least 70% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 8 or the DNA
- 25 sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10081,
- iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence
- 30 shown in SEQ ID No 8 or obtainable from the plasmid in *Saccharomyces cerevisiae*, DSM 10081.

73. The DNA construct according to claim 72, in which the DNA sequence is isolated from or produced on the basis of
- 35 a DNA library of a strain belonging to the family *Chaetomiaceae*, preferably to the genus *Thielavia*, in particular a strain of *Thielavia terrestris*, especially

Thielavia terrestris, NRRL 8126.

74. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA

5 sequence comprises

a) the DNA sequence shown in SEQ ID No. 10, or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10512, or

b) an analogue of the DNA sequence shown in SEQ ID No. 10 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10512, which

i) is homologous, preferably at least 65% homologous, with the DNA sequence shown in SEQ ID No. 10 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10512,

ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 10 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10512,

iii) encodes a polypeptide which is homologous, preferably at least 55% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 10 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10512,

iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID No 10 or obtainable from the plasmid in *Escherichia coli*, DSM 10512.

75. The DNA construct according to claim 74, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family

Rhytismataceae, preferably to the genus *Macrophomina*, in particular *Macrophomina phaseolina*, especially *M. phaseolicola*, CBS 281.96.

- 5 76. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises
- 10 a) the DNA sequence shown in SEQ ID No. 12, or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10511, or
- b) an analogue of the DNA sequence shown in SEQ ID No. 12 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10511, which
- 15 i) is homologous, preferably at least 60% homologous, with the DNA sequence shown in SEQ ID No. 12 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10511,
- 20 ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 12 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10511,
- 25 iii) encodes a polypeptide which is homologous, preferably at least 60% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 12 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10511,
- 30 iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID No 12 or obtainable from the plasmid in
- 35 *Escherichia coli*, DSM 10511.

77. The DNA construct according to claim 76, in which the

DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family Tricholomataceae, preferably to the genus *Crinipellis*, in particular *Crinipellis scabella*, especially *C.scabella*,
5 CBS 280.96.

78. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises

- 10 a) the DNA sequence shown in SEQ ID No. 16, or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10571, or
- b) an analogue of the DNA sequence shown in SEQ ID No. 16 or the DNA sequence obtainable from the plasmid in
15 *Escherichia coli*, DSM 10571, which
 - i) is homologous, preferably at least 70 % homologous, with the DNA sequence shown in
20 SEQ ID No. 16 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10571,
 - ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 16 or the DNA sequence obtainable from the plasmid in
25 *Escherichia coli*, DSM 10571,
 - iii) encodes a polypeptide which is homologous, preferably at least 60% homologous, with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID
30 No. 16 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10571,
 - iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID
35 No 16 or obtainable from the plasmid in *Escherichia coli*, DSM 10571.

79. The DNA construct according to claim 78, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain of *Volutella*, in particular *Volutella colletotrichoides*, especially *V.*

5 *colletotrichoides*, CBS 400.58.

80. A DNA construct comprising a DNA sequence encoding an enzyme exhibiting endoglucanase activity, which DNA sequence comprises

- 10 a) the DNA sequence shown in SEQ ID No. 19, or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10576, or
- b) an analogue of the DNA sequence shown in SEQ ID No. 19 or the DNA sequence obtainable from the plasmid in
- 15 *Escherichia coli*, DSM 10576, which
- i) is homologous with the DNA sequence shown in SEQ ID No. 19 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10576,
- 20 ii) hybridizes under the conditions described herein with the same nucleotide probe as the DNA sequence shown in SEQ ID No. 19 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10576,
- 25 iii) encodes a polypeptide which is homologous with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 19 or the DNA sequence obtainable from the plasmid in *Escherichia coli*, DSM 10576,
- 30 iv) encodes a polypeptide which is immunologically reactive with an antibody raised against the purified endoglucanase encoded by the DNA sequence shown in SEQ ID
- 35 No 19 or obtainable from the plasmid in *Escherichia coli*, DSM 10576.

81. The DNA construct according to claim 80, in which the DNA sequence is isolated from or produced on the basis of a DNA library of a strain belonging to the family of *Sordariaceae*, preferably to the genus *Sordaria*, in particular *Sordaria fimicola*, especially *S. fimicola*, ATCC 52644.

82. The DNA construct according to any of the claims 66-81 which further comprises a DNA sequence encoding a cellulose-binding domain.

83. The DNA construct according to claim 82 which further comprises a DNA sequence encoding a cellulose-binding domain (CBD), the cellulose-binding domain and enzyme core (catalytically active domain) of the enzyme encoded by the DNA sequence of the DNA construct being operably linked.

84. A recombinant expression vector comprising a DNA construct according to any of claims 62-83.

85. A cell comprising a DNA construct according to any of claims 66-83 or a recombinant expression vector according to claim 84.

86. A cell according to claim 85, which is a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, or an endogenous cell from which the gene originates.

87. A cell according to claim 86, wherein the cell belongs to a strain of *Aspergillus*, *Fusarium*, or *Trichoderma*, in particular a strain of *Fusarium graminearum*, *Aspergillus niger* or *Aspergillus oryzae*.

88. A method of producing an enzyme exhibiting endoglucanase activity, the method comprising culturing a

cell according to any of claims 85-87 under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

- 5 89. An enzyme exhibiting endoglucanase activity, which enzyme
- a) is encoded by a DNA construct according to any of claims 66-83,
- b) produced by the method according to claim 88, or
- 10 c) is immunologically reactive with an antibody raised against a purified endoglucanase encoded by the DNA sequence shown in any of the sequence listings SEQ ID No 1, 4, 6, 8, 10, 12, 16, 19.
- 15 90. A method of providing colour clarification of laundry, which method comprising treating the laundry with a soaking, washing or rinsing liquor comprising an enzyme preparation according to any of the claims 1-9, 11-61 and 89.
- 20 91. The method according to claim 90, wherein the laundry is treated in a washing machine.
92. The method according to claim 90 or 91, wherein the
- 25 endoglucanase is present in the soaking, washing, or rinsing liquor in an effective amount of between 1 and 1000 S-CEVU, preferably between 5 and 200 S-CEVU, per liter of liquor during machine cycle use conditions.
- 30 93. The method according to any of the claim 90-92, wherein the pH of the soaking, washing, or rinsing liquor is between 4 and 11, preferably between 6 and 10.5.
94. The method according to any of the claims 90-93,
- 35 whrein the temperature is between 15°C and 60°C.
95. The method according to any of the claims 90-94,

wherein the soaking, washing or rinsing liquor further comprises one or more enzymes selected from the group consisting of proteases, cellulases, xylanases, amylases, lipases, peroxidases and laccases.

5

96. A laundry composition comprising the enzyme preparation according to any of the claims 1-9, 11-61 and 89, and a compound selected from the group consisting of a surfactant, a builder compound, and a fabric softening agent.

10

97. The laundry composition according to claim 96, which further comprises one or more enzymes selected from the group consisting of proteases, amylases, lipases, cellulases, xylanases, peroxidases and laccases.

15

98. The composition according to claim 97, wherein the surfactant is a nonionic, anionic, cationic, zwitterionic, ampholytic or amphoteric surfactant.

20

99. The composition according to claim 98, wherein the fabric softening agent is a cationic or nonionic softening agent, preferably a quaternary ammonium compound, and which optionally further comprises one or more compounds selected from a surfactant, an electrolyte, a buffer, an antioxidant and a liquid carrier.

25

100. Use of the enzyme according to any of the claims 1-9, 11-61 and 89 for degradation or modification of plant material, e.g. cell walls.

30

101. Use of the enzyme according to any of the claims 1-9, 11-61 and 89 for treatment of fabric or textile, preferably for preventing backstaining, for bio-polishing or for "stone-washing" cellulosic fabric.

35

102. Use of the enzyme according to any of the claims 1-9, 11-61 and 89 in the treatment of paper pulp, preferably for debarking, defibration, fibre modification, enzymatic de-inking or drainage improvement.

5

103. An enzyme preparation which is enriched in an enzyme exhibiting cellulytic activity according to any of the claims 1-9, 11-61 and 89.

10 104. The preparation according to claim 103, which additionally comprises one or more enzymes selected from the group consisting of galactanases, xylanases, arabinanases, pectin acetyl esterases, polygalacturonases, rhamnogalacturonases, pectin lyases,
15 pectate lyases, endoglucanases, pectin methylesterases, proteases, lipases, amylases, cutinases, peroxidases, laccases, cellobiohydrolases and transglutaminases.

1/8

Acremonium I	1	-	-	-	-	M	R	S	T	S	I	L	I	G	L	V	A	G	V	A	A	-	-	Q	S	S	G	S	G	H	23				
V. colletotrichoides	1	-	-	-	-	M	R	S	S	A	V	L	I	G	L	V	A	G	V	A	A	-	-	Q	S	S	G	T	G	R	23				
C. scabella	1	M	V	H	P	N	M	L	K	T	L	A	P	L	I	L	A	A	S	V	T	A	-	-	Q	T	A	G	V	-	27				
Acremonium II	1	-	-	-	-	M	I	S	A	W	I	L	L	G	L	V	G	A	V	P	S	S	V	M	A	A	S	G	K	G	H	26			
T. terrestris	1	-	-	-	-	M	R	S	T	P	V	L	R	T	T	L	A	A	L	P	L	V	A	S	-	A	A	S	G	S	G	Q	27		
M. thermophila	1	-	-	-	-	M	H	L	S	A	T	T	G	E	L	A	L	P	V	L	A	L	D	Q	L	S	G	I	G	Q	25				
M. phaseolina	1	-	-	-	-	M	F	S	P	L	W	A	L	S	A	L	L	F	P	A	T	-	-	-	E	A	T	S	G	V	23				
Acremonium I	24	T	T	R	Y	W	D	C	C	K	P	S	C	A	W	D	E	K	A	A	V	S	R	P	V	I	T	C	D	R	N	S	55		
V. colletotrichoides	24	T	T	R	Y	W	D	C	C	K	P	S	C	G	W	D	E	K	A	S	V	S	Q	P	V	K	T	C	D	R	N	N	55		
C. scabella	28	T	T	R	Y	W	D	C	C	K	P	S	C	G	W	S	G	K	A	S	V	S	A	P	V	R	T	C	D	R	N	G	N	59	
Acremonium II	27	T	T	R	Y	W	D	C	C	K	T	S	C	A	W	E	G	K	A	S	V	S	E	P	V	L	T	C	N	K	Q	D	N	58	
T. terrestris	28	S	T	R	Y	W	D	C	C	K	P	S	C	A	W	P	G	K	A	A	V	S	Q	P	V	Y	A	C	D	A	N	F	Q	59	
M. thermophila	26	T	T	R	Y	W	D	C	C	K	P	S	C	A	W	P	G	K	G	P	-	S	S	P	V	Q	A	C	D	K	N	D	N	56	
M. phaseolina	24	T	T	R	Y	W	D	C	C	K	P	S	C	A	W	T	G	K	A	S	V	S	K	P	V	G	T	C	D	I	N	D	N	55	
Acremonium I	56	P	-	L	S	P	G	-	A	V	S	G	C	D	P	N	G	V	A	F	T	C	N	D	N	Q	P	W	A	V	N	N	85		
V. colletotrichoides	56	P	-	L	A	S	T	-	A	R	S	G	C	D	S	N	G	V	A	Y	T	T	C	N	D	N	Q	P	W	A	V	N	D	N	85
C. scabella	60	I	-	L	G	P	D	-	V	K	S	G	C	D	S	G	G	T	S	F	T	C	A	N	N	G	P	F	A	L	D	N	N	89	
Acremonium II	59	P	I	V	D	A	N	-	A	R	S	G	C	D	G	G	-	A	F	A	C	T	N	N	S	P	W	A	V	S	E	D	88		
T. terrestris	60	R	L	S	D	F	N	-	V	Q	S	G	C	N	-	G	G	S	A	Y	S	C	A	D	Q	T	P	W	A	V	N	D	N	89	
M. thermophila	57	P	L	N	D	G	G	S	T	R	S	G	C	D	A	G	G	S	A	Y	M	C	S	S	Q	S	P	W	A	V	S	D	E	88	
M. phaseolina	56	A	Q	T	P	S	D	L	L	K	S	S	C	D	-	G	G	S	A	Y	Y	C	S	N	Q	G	P	W	A	V	N	D	S	86	
Acremonium I	86	V	A	Y	G	F	A	A	T	A	F	P	G	G	N	E	A	S	W	C	C	A	C	Y	A	L	Q	F	T	S	G	P	V	117	
V. colletotrichoides	86	L	A	Y	G	F	A	A	T	A	F	S	G	G	S	E	A	S	W	C	C	A	C	Y	A	L	Q	F	T	S	G	P	V	117	
C. scabella	90	T	A	Y	G	F	A	A	A	H	L	A	G	S	S	E	A	A	W	C	C	Q	C	Y	E	L	T	F	T	S	G	P	V	121	
Acremonium II	89	L	A	Y	G	F	A	A	T	A	L	S	G	T	E	G	S	W	C	C	A	C	Y	A	L	T	F	T	S	G	P	V	120		
T. terrestris	90	L	A	Y	G	F	A	A	T	S	I	A	G	S	E	S	S	W	C	C	A	C	Y	A	L	T	F	T	S	G	P	V	121		
M. thermophila	89	L	S	Y	G	W	A	A	V	K	L	A	G	S	S	E	S	Q	W	C	C	A	C	Y	E	L	T	F	T	S	G	P	V	120	
M. phaseolina	87	L	S	Y	G	F	A	A	K	L	S	G	K	Q	E	T	D	W	C	C	G	C	Y	K	L	I	F	T	S	T	A	V	118		

Fig. 1A

2/8

Acremonium I	118	AGKTMVVQSTNTGGDL	SGTHFDIQ	MPGGGLGI	149															
V. colletotrichoides	118	AGKTMVVQSTNTGGDL	SGNHFDIL	MPGGGLGI	149															
C. scabella	122	VGKKLT	VQVITNTGGDL	GNHFDLM	IPGGGVGL	153														
Acremonium II	121	AGKKM	VVQSTNTGGDL	SNHFDLM	IPGGGLGI	152														
T. terrestris	122	AGKTM	VVQSTNTGGDL	SNHFDLM	IPGGGVGI	153														
M. thermophila	121	AGKKM	I	VQAITNTGGDL	GNHFDLA	IPGGGVGI	152													
M. phaseolina	119	SGKQM	I	VQIITNTGGDL	GNHFDIA	MPGGGVGI	150													
Acremonium I	150	F-DGCTPQ	FGFTFP	-GNRYGGTT	SRSQCAEL	178														
V. colletotrichoides	150	F-DGCTPQ	WGVVFP	-GNRYGGTT	SRSQCSQI	178														
C. scabella	154	FTQGC	PAQFGSWNG	-GAQYGGVSS	RQCSQL	183														
Acremonium II	153	F-DGCS	AAQFGQLLP	-GERYGGVSS	SRSQCDGM	181														
T. terrestris	154	F-NGCS	SQFGGLP	-GAQYGGI	SSRDQCDSF	181														
M. thermophila	153	F-NACT	DQYGA	PPNGWGD	RYGGIH	SKEECESF	183													
M. phaseolina	151	F-NGCS	KQWNGI	-NLGNQYGGFT	DRSQCATL	179														
Acremonium I	179	PSVL	RDCGCHWRY	DWFNDADNP	NVNWRRVRC	210														
V. colletotrichoides	179	PSAL	QPGCNWRY	DWFNDADNP	DVSVWRRVQC	210														
C. scabella	184	PAAV	QAGCQFR	FDWMGGADNP	NVTFRPVTC	215														
Acremonium II	182	PEL	LKDGCQWR	FDWFKNS	DNPDIEFEQVQC	213														
T. terrestris	182	PAPL	KPGCQWR	FDWFKQ	NADNPTE	TFQQVQC	213													
M. thermophila	184	PEAL	KPGCNWRF	DFWFKQ	NADNPST	VEQEVAC	215													
M. phaseolina	180	PSKWQ	A	SCNWRFDWFE	NADNP	TVDWEPT	VC	211												
Acremonium I	211	ALTNR	SGCVR	RNDNSY	YPV	VFEPGT	GTPPT	TT	241											
V. colletotrichoides	211	ALTDR	TGCR	RSDD	GNYP	VFQPGPP	ATT	I	RTS	242										
C. scabella	216	QLTN	ISGCV	RK	-	-	-	-	-	226										
Acremonium II	214	ELIA	VS	SGCVR	RDD	SSFP	VFQSGS	G	DV	NPP	PK	245								
T. terrestris	214	ELIA	RS	SGCVR	R	DD	SSFP	-	V	F	T	PP	SG	G	N	G	G	T	GT	244
M. thermophila	216	ELTS	KS	SGCSR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	225
M. phaseolina	212	ELVA	RT	TGCSR	RT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	222

Fig. 1B

[illegible]

Fig. 1C

4/8




Fig. 2A

5/8




Fig. 2B

6/8




Fig. 2C

7/8

H. nigrescens	1	-	-	V	Y	A	C	N	A	N	F	Q	R	I	T	D	A	N	-	A	K	S	G	C	D	G	G	S	-	A	F	S	C	28			
T. verrucosus	1	-	-	-	-	-	-	A	C	N	A	N	F	Q	R	I	S	D	P	N	-	A	K	S	G	C	D	G	G	S	-	-	A	F	S	C	26
H. grisea	1	-	N	Q	P	V	F	T	C	D	A	K	F	Q	R	I	T	D	P	N	-	T	K	S	G	C	D	G	G	S	-	-	A	F	S	C	31
C. lagenarium	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26		
P. punctata	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14		
X. hypoxylon	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24		
Coniothecium sp.	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31		
P. verruculosum	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15		
F. anguloides	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33		
S. dilutellus	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13		
F. oxy. ssp. lycop.	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24		
T. thermophila	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23		
P. nitens	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27		
C. virescens	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26		
Nigrospora sp.	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24		
CBS 271.96	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26		
C. foecundissimum	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32		
N. pinea	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11		
C. cuniculorum	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32		
C. fresenii	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28		
S. boninensis	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10		
T. roseum	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29		
D. gossypina	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26		
E. glandulosa	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26		
U. bilgramii	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19		
CBS 270.96	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28		

Fig. 3A




Fig. 3B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00105

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 9/42, C11D 3/386, D06M 16/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, EMBL/GENBANK/DBJ/SWISSPROT (STRAND)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9407998 A1 (NOVO NORDISK A/S), 14 April 1994 (14.04.94), see fig 1A --	1-104
A	EP 0508358 A1 (THE PROCTER & GAMBLE COMPANY), 14 October 1992 (14.10.92) --	1-104
A	EP 0495257 A1 (THE PROCTER & GAMBLE COMPANY), 22 July 1992 (22.07.92) --	1-104
A	WO 9117243 A1 (NOVO NORDISK A/S), 14 November 1991 (14.11.91) --	1-104



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

25 June 1996

Date of mailing of the international search report

02-07-1996

Name and mailing address of the ISA/

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00105

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9320193 A1 (NOVO NORDISK A/S), 14 October 1993 (14.10.93) --	1-104
A	WO 9502043 A1 (NOVO NORDISK A/S), 19 January 1995 (19.01.95) --	1-104
A	Eur. J. Biochem., Volume 146, 1985, Gerrit Beldman et al, "The cellulase of Trichoderma viride" page 301 - page 308 -- -----	1-104

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/96

International application No.

PCT/DK 96/00105

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9407998	14/04/94	NONE	
EP-A1- 0508358	14/10/92	AU-B- 663084	28/09/95
		AU-B- 665193	21/12/95
		AU-A- 1757992	17/11/92
		AU-A- 1798692	17/11/92
		BR-A- 9205889	05/07/94
		BR-A- 9205891	27/09/94
		CA-A- 2108164	13/10/92
		CA-A- 2108165	13/10/92
		CN-A- 1066878	09/12/92
		CN-A- 1067917	13/01/93
		DE-D- 69117490	00/00/00
		EP-A, A, B 0508034	14/10/92
		ES-T- 2083560	16/04/96
		HU-D- 9302871	00/00/00
		JP-T- 6506497	21/07/94
		JP-T- 6506721	28/07/94
		NO-A- 933603	10/12/93
		NO-A- 933644	02/12/93
		NZ-A- 242314	24/02/95
		NZ-A- 242315	26/05/95
		SK-A- 110493	06/07/94
		TR-A- 26786	15/05/95
		WO-A, A- 9218597	29/10/92
		WO-A, A- 9218598	29/10/92
EP-A1- 0495257	22/07/92	AU-B- 661672	03/08/95
		AU-B- 662736	14/09/95
		AU-A- 1230592	27/08/92
		AU-A- 1542092	27/08/92
		BR-A- 9205427	15/03/94
		BR-A- 9205428	05/04/94
		BR-A- 9205451	15/03/94
		CA-A- 2099508	17/07/92
		CA-A- 2100097	17/07/92
		CA-A- 2100554	17/07/92
		CN-A- 1064309	09/09/92
		CZ-A- 9301410	16/03/94
		EP-A, A- 0495258	22/07/92
		EP-A- 0495344	22/07/92
		EP-A, A- 0495554	22/07/92
		EP-A- 0646165	05/04/95
		HU-A- 65221	02/05/94
		JP-T- 6504311	19/05/94
		JP-T- 6505049	09/06/94
		JP-T- 6509122	13/10/94
		NZ-A- 241308	26/07/94
		SK-A- 72493	12/01/94
		US-A- 5443750	22/08/95
		WO-A, A, A 9213053	06/08/92
		WO-A, A- 9213054	06/08/92
		WO-A, A- 9213057	06/08/92

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/96

International application No.

PCT/DK 96/00105

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9117243	14/11/91	AT-T- 118545 AU-B- 639570 AU-A- 7887491 CA-A- 2082279 DE-D,T- 69107455 EP-A,A,B 0531372 ES-T- 2068586 JP-T- 5509223	15/03/95 29/07/93 27/11/91 10/11/91 12/10/95 17/03/93 16/04/95 22/12/93
WO-A1- 9320193	14/10/93	NONE	
WO-A1- 9502043	19/01/95	NONE	